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High-throughput technologies are widely used for understanding biological processes. Gene set analysis is
a well-established computational approach for providing a concise biological interpretation of high-throughput
gene expression data. Gene set analysis utilizes the available knowledge about the groups of genes involved
in cellular processes or functions. Large collections of such groups of genes, referred to as gene set databases,
are available through online repositories to facilitate gene set analysis. There are a large number of gene
set analysis methods available, and current recommendations and guidelines about the method of choice for
a given experiment are often inconsistent and contradictory. It has also been reported that some gene set
analysis methods suffer from a lack of specificity. Furthermore, the sheer size of gene set databases makes it
difficult to study these databases and their effect on gene set analysis.
In this thesis, we propose quantitative approaches for the study of reproducibility, sensitivity, and speci-
ficity of gene set analysis methods; characterize gene set databases; and offer guidelines for choosing an
appropriate gene set database for a given experiment. We review commonly used gene set analysis methods;
classify these methods based on their components; describe the underlying requirements and assumptions for
each class; suggest the appropriate method to be used for a given experiment; and explain the challenges and
pitfalls in interpreting results for each class of methods. We propose a methodology and use it for evaluating
the effect of sample size on the results of thirteen gene set analysis methods utilizing real datasets. Further,
to investigate the effect of method choice on the results of gene set analysis, we develop a quantitative ap-
proach and use it to evaluate ten commonly used gene set analysis methods. We also quantify and visualize
gene set overlap and study its effect on the specificity of over-representation analysis. We propose Silver,
a quantitative framework for simulating gene expression datasets and evaluating gene set analysis methods
without relying on oversimplifying assumptions commonly made when evaluating gene set analysis methods.
Finally, we propose a systematic approach to select appropriate gene set databases for conducting gene set
analysis for a given experiment. Using this approach, we highlight the drawbacks of meta-databases such as
MSigDB, a well-established gene set database made by extracting gene sets from several sources including
GO, KEGG, Reactome, and BioCarta.
Our findings suggest that the results of most gene set analysis methods are not reproducible for small
sample sizes. In addition, the results of gene set analysis significantly vary depending on the method used,
with little to no commonality between the 20 most significant results. We show that there is a significant
negative correlation between gene set overlap and the specificity of over-representation analysis. This sug-
gests that gene set overlap should be taken into account when developing and evaluating gene set analysis
methods. We show that the datasets synthesized using Silver preserve complex gene-gene correlations and
the distribution of expression values. Using Silver provides unbiased insight about how gene set analysis
methods behave when applied on real datasets and real gene set databases. Our quantitative study of several
well-established gene set databases reveals that commonly used gene set databases fall short in representing
ii
some phenotypes.
The proposed methodologies and achieved results in this research reveal the main challenges facing gene
set analysis. We identify key factors that contribute to the lack of specificity and reproducibility of gene
set analysis methods, establishing the direction for future research. Also, the quantitative methodologies
proposed in this thesis facilitate the design and development of gene set analysis methods as well as gene set
databases and benefit a wide range of researchers utilizing high-throughput technologies.
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1 Introduction
High-throughput technologies are widely used for understanding the biology of an organism. The primary
challenge facing the deployment of these technologies is gaining insight from the data generated. Gene
expression is often studied using high-throughput technologies. A common approach in gene expression
analysis is comparing the gene expression levels for treatment(s) versus control(s) for each gene to find genes
with different expression patterns across control and case samples. For each gene, a p-value—which is the
probability of obtaining a random gene expression difference as extreme as the observed difference, assuming
that the gene is not differentially expressed—is calculated. Then, in order to reduce the number of false
positives resulting from multiple comparisons, an adjustment is made. Finally, genes with an adjusted p-
value smaller than a given threshold value α are predicted as differentially expressed. This approach is also
known as single gene analysis. The main shortcomings of this approach are as follows:
• High-throughput technologies make monitoring a large number of genes in a single experiment possible
but introduces the “curse of dimensionality”. In a typical gene expression study, the differential ex-
pression of thousands of genes are tested; therefore, the adjustment for multiple comparisons are made
for a large number of comparisons. This may result in false negatives [14, 16, 11].
• Selecting a cutoff value in single gene analysis is often challenging. It has been shown that the biological
interpretation of gene expression experiments may change depending of the cutoff value being used [13].
Conservative cutoff values might lead to false negatives and relaxed cutoff values might result in false
positives [4, 3].
• Cellular processes and functions are often the result of groups of genes working in concert. Single
gene analysis ignores this fact and leaves all interpretation to the researcher. The information about
genes that correspond to some biological functions or processes is known and available through public
knowledge bases such as GO [7], KEGG [9], and OMIM [1]. Single gene analysis does not use such
information even though incorporating this information might facilitate gaining biological insight.
• There are many factors that may confound the data resulting from a high-throughput study [17]. These
errors may affect the observed change in expression of a single gene and therefore confound the results
of single gene analysis. Expression patterns of a set of genes, rather than a single gene, are more robust
in the presence of such noise [10, 6].
Gene set analysis, also known as enrichment analysis, is an alternative approach that can alleviate the
shortcomings of single gene analysis [11, 15]. In gene set analysis the difference in expression patterns of a
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group of genes that share a common biological attribute are tested. Such groups of genes are referred to as
gene sets and a collection of such gene sets are referred to as a gene set database.
Although gene set analysis aims at alleviating the shortcomings of single gene analysis, it is not a panacea
to solve all challenges in high-throughput data analysis, and it comes with its own complications and limita-
tions. In this thesis, we study the shortcomings and limitations of gene set analysis and offer guidelines for
choosing a proper gene set analysis method for a given experiment. In addition, we propose a quantitative
approach for choosing a sample size for achieving reproducible results for a given gene set analysis method.
Further, we develop a quantitative framework for the evaluation of gene set analysis methods using real
expression datasets. Our findings establish a direction for further research on developing gene set analysis
methods.
This thesis is composed of several papers each tailored to focus on one research goal. Chapter 2 reviews the
literature on gene set analysis, lays out the main shortcomings of commonly used gene set analysis methods
and sets the direction for future research. Chapter 3 proposes a quantitative methodology to study the
effect of sample size on the reproducibility of gene set analysis. Using the proposed method, we investigate
the impact of sample size on the reproducibility of thirteen widely used gene set analysis methods. In
Chapter 4, we propose an approach for evaluating gene set analysis methods using real expression datasets
and compare ten well-established gene set analysis methods. We quantify and visualize gene set overlap in
several gene set databases, which are specifically designed for gene set analysis methods, in Chapter 5. We
also assess the hypothesis that there is a negative correlation between gene set overlap and the specificity
of over-representation analysis. In Chapter 6, we discuss that the main reason behind the lack of consensus
in the research community about the gene set analysis method to be used for a given experiment is the
absence of gold standard datasets, i.e. expression datasets with their list of differentially enriched gene sets
known a priori. We propose Silver, a framework for synthesizing expression datasets without relying on
oversimplifying assumptions commonly used when evaluating gene set analysis methods. Silver also provides
a methodology for evaluating a gene set analysis method using quantitative measures such as sensitivity,
specificity, and accuracy. Gene set databases are a crucial component of gene set analysis. In Chapter 7,
we propose a systematic approach to select appropriate gene set databases for conducting gene set analysis
for a given experiment. Using this approach, we study well-established gene set databases such as Gene
Ontology [2], KEGG [8], Reactome [5], and BioCarta [12]. Finally, Chapter 8 contains a summary and
suggestions for future research. Each chapter of this thesis consists of a journal or conference paper. Some of
these papers have been published (Chapters 3, 4, and 5), and some are in the final stages of preparation for
submission (Chapters 2, 6, and 7). For the chapters consisting of published papers, there is an introductory
section added linking the paper to the bulk of the thesis. Appendix F describes the copyright licensing for the
papers and includes the corresponding documents. Also for some of the published papers, page limitations
meant that there were more research results than could be described in the paper. Those additional research
results appear as appendices to the thesis, and are described in the relevant chapter.
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2 Background
Gene set analysis methods differ in their various components such as gene score, gene set score, the null
hypothesis, and the method of significance assessment. This chapter reviews and classifies gene set analysis
methods based on their components. We discuss the strengths and shortcomings of each class of gene set
analysis methods and establish the direction for further research in gene set analysis. An extended version
of this chapter will be submitted to Frontiers in Genetics.
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Abstract
Gene set analysis methods are widely used to provide insight into high-throughput gene expression data.
These methods rely on various assumptions and have different requirements, strengths and weaknesses. In this
paper, we classify gene set analysis methods based on their components, describe the underlying requirements
and assumptions for each class, suggest the appropriate method to be used for a given experiment, and
describe the challenges and pitfalls in interpreting results for each class of method.
2.1 Introduction
High-throughput technologies such as DNA microarrays and RNA-Seq are widely used to monitor the ac-
tivity of thousands of genes in a single experiment. The primary challenge facing the deployment of these
technologies is to gain biological insight from the generated data.
The early approach for analysing gene expression data is single gene analysis, where expression measures
of each gene for case and control samples are compared using a statistical test such as t-test or Wilcoxon
rank-sum test and a p-value is calculated. Then, in order to reduce the number of false positives resulting
from multiple comparisons, an adjustment for multiple comparisons is made. Next, genes with an adjusted
p-value smaller than a given threshold are predicted as being differentially expressed. Finally, a biological
interpretation is attempted using these genes.
Single gene analysis suffers from several shortcomings. In a high-throughput gene expression study, many
single-gene tests are typically performed. Consequently, adjustment for multiple comparisons is performed
for a large number of genes. Such adjustments may lead to many false negatives by detecting very few or even
no gene as being differentially expressed [45, 55, 41]. This issue is more pronounced when using conservative
methods, such as Bonferroni and Sˇ´ıda´k for multiple comparisons adjustment [11].
In the single-gene approach often researchers use arbitrary cutoff values to choose a reasonable number of
genes for further study and interpretation. Different choices of threshold value may lead to different biological
interpretations [43]. Conservative threshold values may cause false negatives and relaxed thresholds may cause
false positives [8, 6].
Further, cellular processes are often associated with changes in the expression patterns of groups of genes
that share common biological functions or attributes. A meaningful change in a group of these genes is more
biologically reliable and interpretable than a change in a single gene. A priori knowledge about some of these
sets of genes is available through public online databases such as GO [9], KEGG [28], and OMIM [3]. The
single-gene approach simply disregards this information. Incorporating this information in the data analysis
may provide valuable insight about underlying biological processes or functions.
Although high-throughput technologies make the monitoring of expression of thousands of genes in a
single experiment possible, they introduce a challenge of dealing with high dimensional data, often referred
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to as the “curse of dimensionality” [7]. To deal with high dimensional data dimensionality reduction methods
are used for downstream analysis and visualization. Relying on sets of biologically related genes is the most
intuitive and biologically relevant approach to dimensionality reduction in high-throughput gene expression
studies.
When differences in measured values for a single gene across treatments are subtle, the single-gene ap-
proach makes it difficult to differentiate the true difference in gene expression from the difference due to
biological variability of samples [41, 46]. Gene set analysis, on the other hand, might be able to detect such
subtle but concordant changes in expression patterns of genes within a gene set.
Further, the single-gene approach may report several hundred to a few thousand genes as being differ-
entially expressed. Interpreting a long list of differentially expressed genes is a cumbersome task prone to
investigator bias toward a hypothesis of interest.
Gene set analysis, also known as enrichment analysis, is an attempt to resolve these shortcomings and to
gain insight from gene expression data. The primary aim of gene set analysis is to identify enrichment or
depletion of expression levels of a given set of genes of interest, referred to as a gene set.
There are a large number of gene set analysis methods available [21]. These methods differ in their
various components such as their underlying assumptions, notion of differential enrichment, null hypothesis,
and their significance assessment procedure. Study of gene set analysis methods based on their components
helps to understand the strengths and weaknesses of each category of methods, select an appropriate method
for a given experiment, facilitate the interpretation of the outcomes of gene set analysis, and develop new
methods with higher sensitivity and specificity.
In this paper, we review gene set analysis methods based on their various components, classify different
approaches based on their components, characterize the strengths and shortcomings of each approach, and
describe the underlying requirements and assumptions for each class of methods. We also suggest the ap-
propriate method to be used for a given experiment, and describe the challenges and pitfalls in interpreting
results for each class of gene set analysis methods. In addition, we set direction for further research in gene
set analysis.
2.2 Gene set analysis
Data from a high-throughput case-control experiment can be organised in an expression matrix. This matrix
is generated by joining the corresponding expression values for all samples in the experiment. Each column
of the matrix corresponds to the expression measures for one sample and each row of the matrix corresponds
to the expression measures for one gene across all samples. This expression matrix is the base for expression
analysis including single gene and gene set analysis. Figure 2.1 shows an expression matrix with ‖C‖ control
samples and ‖T‖ case samples.
There are many gene set analysis methods available. Over-representation analysis (ORA), functional scor-
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Figure 2.1: Expression matrix for a pairwise comparison where A(c1), . . . , A(c‖C‖) columns represent
control samples and A(t1), . . . , A(t‖T‖) columns represent case samples. ci represents the index of a
sample in the control group, and tj represents the index of a sample in the case/treatment group.
ing (FCS), and pathway topology-based methods are three main categories of gene set analysis methods [31].
In this paper, we focus on ORA and FCS methods that comprise the main body of gene set analysis methods
used by researchers. For a review and a comparison of topology-based methods refer to Mitrea et al. [40] and
Ihnatova et al. [25].
2.2.1 Over-representation analysis
ORA is the natural extension of single gene analysis and one of the most widely used gene set analysis
methods. Due to its simplicity, well-established underlying statistical model, and ease of implementation,
ORA is available through many bioinformatics toolkits. Huang et al. listed 68 gene set analysis methods and
tools of which 40 are ORA-based. These tools differ in their various components such as gene set databases,
data visualization, and user interfaces [21]. ORA uses a list L of genes predicted as being differentially
expressed by a single gene analysis method.
Given L and a gene set Gi that has n
′
i genes in common with L, ORA considers Gi as being differentially
enriched if the occurrence of n′i differentially expressed genes in Gi is unlikely to be due to chance. Table 2.1
illustrates the contingency table representation for the over-representation of differentially expressed genes in
Gi given L and U . The set of n genes under study is called the reference set or background set and depicted
by U , and Gi is the complement of Gi with respect to U .
Under the null hypothesis that there is no association between differential expression and membership in
Gi, we can assume that Gi is the result of a simple random sampling of ‖Gi‖ genes from U ; therefore, the
probability of having n′i differentially expressed genes within Gi can be calculated using the hypergeometric
distribution as follows [11]:








Table 2.1: Representation of ORA as a contingency table. Each cell contains a count of genes
satisfying the condition associated with the row and column.
Genes in L Genes not in L Total
Genes in Gi n
′
i ‖Gi‖ − n′i ‖Gi‖
Genes in Gi ‖L‖ − n′i n− ‖Gi‖ − (‖L‖ − n′i) n− ‖Gi‖
Total ‖L‖ n− ‖L‖ n
The significance of the association between genes in Gi and genes in L can be assessed using Fisher’s




f(j;n, ‖Gi‖, ‖L‖) = 1−
n′i−1∑
j=0
f(j;n, ‖Gi‖, ‖L‖) (2.2)
Fisher’s exact test gives the exact p-value for both small and large cell counts in Table 2.1. Less computa-
tionally demanding alternatives can also be used to calculate an approximation for the p-value.
Binomial distribution can be used to estimate the p-value for Fisher’s exact test [12]. For large values of




























where fb in Equation 2.3 and 2.4 represents the binomial distribution density function.
Another alternative to estimate the p-value is the χ2 test for equality of proportions [53]. This test has
also been used in the context of gene set enrichment analysis [12, 56, 30].
2.2.2 Functional scoring methods
The main assumptions of ORA are that genes are independent and equally effective in biological processes.
Although these assumptions simplify the problem modelling, they are not biologically valid. It is well-
established that genes, proteins, and other biomolecules often act in concert [51]. In addition, ORA disregards
quantitative information for all genes that are not predicted as differentially expressed. Usually, genes
predicted as differentially expressed are the result of applying a p-value cutoff, and all the quantitative
measures for genes with a p-value greater than the cut-off value are disregarded. However, a consistent
change even with a p-value slightly greater than the cutoff value may contribute to the detection of pathway
activities.
In contrast to ORA, the main goal of FCS methods is to use all information from an expression matrix
to address the enrichment problem without relying on the aforementioned biologically invalid assumptions.
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Figure 2.2: A schematic view of over-representation analysis (ORA) and univariate and multivariate
FCS methods.
Therefore, FCS methods—instead of working with a list of differentially expressed genes—take advantage of
an expression matrix of gene expression measures for all genes to discern differential enrichment of gene sets.
There are many FCS methods available [41, 19, 46, 32, 52, 5, 50, 39, 35, 4, 54, 49, 20, 44]. These methods
can be categorized into two classes: univariate and multivariate methods. In univariate FCS methods, usually
a per gene score is calculated for each gene using each row of the expression matrix. Then these per gene
scores are used to calculate a gene set score for each gene set. Finally, the significance of the gene set
scores is assessed and differentially enriched gene sets are reported. Multivariate methods skip the step for
calculating gene scores and directly calculate gene set scores from the expression matrix. Figure 2.2 illustrates
a schematic view of univariate and multivariate FCS methods and also ORA methods.
An FCS method often consists of a set of common components such as a per gene score that is a statistic
that summarizes the expression level of a gene across control and case samples; a per gene set score that
summarizes the expression level of genes within a gene set as a single statistic; a procedure for significance
assessment; and an adjustment for multiple comparisons.
Univariate functional scoring methods
GSEA [41] is the most widely used univariate FCS method. GSEA uses a gene score such as signal-to-noise
ratio (SNR) difference between gene expression measures in control and case samples to calculate a per gene
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i is the gene expression level for gene gi in sample A
(cj) (see Figure. 2.1); σ′c,i is the standard




t,i are defined analogously using
case samples.
GSEA ranks all genes according to their scores. Then to measure the association between members of a
given gene set Gi and treatments, it calculates a gene set score—also referred to as the enrichment score (ES)
in GSEA terminology—using a Kolmogorov-Smirnov statistic. The ES value for Gi, denoted as ES(Gi), is
calculated using a running sum initialized as 0. Assume g1, . . . , gn is the sorted list of all genes under study
according to SNR difference in decreasing order. For each gene in the sorted list starting with the first one
the running sum (enrichment score) is updated by adding a value of +
√
n−‖Gi‖
‖Gi‖ when the gene belongs to Gi
and by subtracting a value of
√
‖Gi‖
n−‖Gi‖ when the gene does not belong to Gi [41]. The ES value is calculated















n−‖Gi‖ gk /∈ Gi
After calculation of the actual ES value for all gene sets, the method determines the maximum ES, denoted
as MES. The significance of the calculated MES value is assessed using a permutation test. The sample
labels are permuted 1000 times, and for each permutation a MES value is calculated. Finally, the significance
of MES of the actual data is calculated as the fraction of permutations that lead to an MES higher than the
MES of the actual data.
It should be mentioned that the significance of the MES does not provide any insight about the significance
of the enrichment score of a given gene set Gi, although this is the main purpose of enrichment analysis. In
fact, assessing the significance of the MES tests the null hypothesis that “no gene set is associated with the
class distinction” [41], where the rank ordering is used as the measure of association. Therefore, rejection
of this null hypothesis only suggests that there is at least one gene set for which the rank ordering of its
members is associated with the sample classes, i.e. phenotypes.
The method suggested by Mootha et al. [41] as inferred from Equation 2.6 calculates ES as the “maximum
observed positive deviation of the running sum” [41] and, therefore, it does not detect differential enrichment
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of gene sets that have the majority of their genes up-regulated unless the phenotypes are swapped and the
GSEA procedure is run again. Hence, GSEA should be considered as a one-sided test [50]. In addition, in
order to be able to rely on the enrichment scores, the significance of each ES should be assessed. However,
the method proposed by Mootha et al. [41] tested the null hypothesis that “no gene set is associated with
the class distinction” which is not extendable to the ES for each gene set.
Damian et al. [10] raised concern about the capabilities of GSEA by suggesting a synthesized example.
They showed that GSEA may ignore highly enriched gene sets solely due to the size of gene sets. In their
hypothetical example they assumed that there is a given dataset of gene expression values for genes in three
gene sets G1, G2, and G3 of size n, 5n, and 4n, respectively, where—after calculation of per gene scores
and sorting them—genes in G1 ranked higher than genes in G2, and genes in G2 ranked higher than genes
in G3. In order to better demonstrate the problem, assume that G1 is the only enriched gene set with all
genes being down-regulated, and also G2 and G3 are not differentially enriched. GSEA assigns enrichment
scores of 3n, 4n, and 0, respectively to G1, G2, and G3. Therefore, G2 is preferred to G1, although G1 is the
only enriched gene set. Furthermore, Subramanian et al. [46] reported that GSEA leads to high enrichment
scores for gene sets clustered around the middle of the sorted list of all genes. These gene sets are often not
associated with the phenotypes under study [46].
Considering these shortcomings, Tian et al. [50] suggested using the t-test or Wilcoxon rank-sum test
statistics as alternative gene set scores instead of the Kolmogorov-Smirnov statistic in GSEA. They suggested
that these scores are able to detect moderate but coordinated shift from the background distribution. In
order to generate the background distribution, they used both gene sampling and phenotype permutation
(see Section 2.3). In fact, instead of testing differences in distribution of per gene scores across treatments,
they tested a location change, i.e. shift in mean or median. The shortcoming of the method is its lack of
sensitivity in detecting a differentially enriched gene set where some of its genes are up-regulated and some
down-regulated [26]. This is due to the inherent inability of the average to detect those effects.
PAGE, a parametric method for gene set enrichment analysis, was proposed as a statistically more sensitive
and computationally less demanding alternative for gene set enrichment analysis [32]. PAGE tests the
null hypothesis that “all genes in a given microarray dataset are independent of each other and identically
distributed, that is they are not co-regulated” [32]. It uses fold change between sample groups, i.e. treatments,
to calculate a Z-score for a given gene set Gi. The significance of this Z-score is then calculated using a
normal distribution. PAGE starts with calculating the fold change value of each gene as the per gene score.
Next, it calculates mean (µ) and standard deviation (σ) of all fold change values. Then, for a given gene set







Finally, the significance of Zi is assessed using the standard normal distribution. The rationale behind using
the normal distribution is that according to the Central Limit Theorem [14], the sampling distribution of the
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average of an independent random variable for large sample sizes is normal, regardless of the distribution of
the sampling population. Therefore, the distribution of average fold change values for gene sets should be
normal. This method has been reported to achieve a high sensitivity while suffering from a low specificity.
In another attempt to address the aforementioned shortcomings of GSEA, Subramanian et al. [46]—almost
the same group who proposed GSEA—adjusted the method by using a weighted Kolmogorov-Smirnov statistic
as the gene set score. They also used False Discovery Rate (FDR) to adjust for multiple comparisons [46].
The outline of the method is as follows. First, the per gene score for each gene is calculated. Assuming





















where p is a positive constant and a parameter of the method; rt is the per gene score for the t
th gene
in the sorted list. The enrichment scores are normalized to account for gene set size. The significance of
the normalized enrichment scores (NES) is assessed using gene sampling or phenotype permutation (see
Section 2.3). Finally, an adjustment for multiple comparisons is made.
It should be mentioned that the enrichment score in the adjusted GSEA is similar to, but not the same
as, the enrichment score in GSEA. To calculate the enrichment scores, both methods calculate a running
sum by traversing the list of all genes ranked according to their per gene scores. For each gene in the list,
the original GSEA method updates the running sum by a constant value, while the adjusted GSEA increases
the running sum with a value of |rt|
p∑
gt∈Gi |rt|p
for genes in Gi. This increases the effect of genes with higher
absolute value of the per gene score (|rt|p), i.e. genes at the beginning or at the end of the ordered list, and
to decrease the effect of genes in the middle of the ordered list on gene set scores. Hereafter, we use GSEA
to refer to the updated GSEA, unless stated otherwise. GSEA is still a one-sided test. In addition, it is not
obvious how GSEA addresses the effect of gene set size, as it was reported to affect the results of the original
GSEA [10]. Further, an ad hoc choice of 1 for p has been used in the updated version of GSEA.
Irizarry et al.[26] proposed the use of a simple parametric method as an alternative to GSEA. They men-
tioned that GSEA is based on a Kolmogorov-Smirnov test which is known for its lack of sensitivity. In order
to avoid using a Kolmogorov-Smirnov test statistic and also a permutation test, which is computationally
demanding, they suggested using a parametric method that employs standard normal distribution to assess
the significance of each enrichment score. They used the two-sample t-test statistic as the per gene score
to measure the degree of association between each gene and phenotypes. For a given gene g, this value is
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denoted by t(g). They evaluated the assumption of normality of t(g) values for all genes using a Q-Q plot
for 8 datasets—all datasets used by Subramanian et al. [46] and Mootha et al. [41]. Based on the observed
Q-Q plots, they suggested that assuming standard normal distribution for the distribution of t(g) values in
practice is valid. For a given gene set Gi, they suggested a Z-score as follows:
Z-Score(Gi) =
√





By accepting the assumption that the t-test statistic has standard normal distribution and also ignoring the
correlation between gene set members, they inferred that the Z-score has standard normal distribution as
well. Therefore, they assessed the significance of Z-scores using standard normal distribution. Hereafter, we
refer to this method as SEA.
Irizarry et al. [26] admitted that a limitation of the proposed Z-score is that it may not be able to detect
gene sets where almost half of the genes are up-regulated and the rest are down-regulated. To deal with this
issue, they suggested a standardized χ2-test score as follows:
χ2-score(Gi) =
∑
g∈Gi (t(g)− t¯ (Gi))
2 − (‖Gi‖ − 1)
2 (‖Gi‖ − 1) (2.10)
They approximated the distribution of χ2-score for a gene set of large size, e.g. 20 or higher, using the
standard normal distribution to calculate the significance of the gene set score.
Tamayo et al. [47] refuted the claim made by Irizarry et al. [26] that their simple enrichment analysis
method outperforms GSEA [46]. They focused on the assumption made by Irizarry et al. [26] to ignore gene-
gene correlation, questioning its practicality and whether it is realistic. Comparing the results of SEA and
GSEA, they reported that SEA uniformly produces more significant gene sets. For example, they reported
that in a pancreas dataset [1], SEA predicted 42% of gene sets as significantly differentially enriched, a
number almost 5 times more than that from GSEA.
In addition, Tamayo et al. [47], using the approach of Gatti et al. [16], tested the effect of gene-gene
correlation on the results of GSEA and SEA, where there is no significant correlation structure between gene
profiles and phenotypes. In this regard, for each dataset, they produced results for both SEA and GSEA for
1000 datasets with random permutation of phenotype labels in the expression profile. Since after random
permutations of gene profile labels there is almost no relation between gene profiles and phenotypes, we
expect almost no significant gene set to be reported as differentially enriched by gene set enrichment analysis
methods. Tamayo et al. reported that while GSEA predicted almost 0% of gene sets as differentially enriched,
SEA predicted many gene sets as differentially enriched.
Jiang and Gentleman [27] suggested several per gene and per gene-set scores as extensions to gene set
enrichment analysis. They suggested a linear model for calculating a per gene score. Equation 2.11 shows
the linear model.
Yg,i = µg + βgXi + g,i (2.11)
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where Yg,i is the measured expression value for gene g from the i
th sample; for a given gene g and i (1 ≤ i ≤ n),
g,i is assumed to be a independent normally distributed variable with mean of zero; Xi is a binary variable
showing phenotype, i.e. class, of the ith sample. For a given gene g, µg represents the mean of expression
measures for the phenotype corresponding to Xi = 0, and βg represents the difference between mean of
expression measures of g for the phenotype corresponding to Xi = 1 and µg. They used
βˆg
sg
as the per gene
score, where βˆg is the estimate of β and sg is an estimate for standard deviation of expression measurements
for gene g. In addition, they suggested using median and also a signed-test, which is a non-parametric test
to assess consistent differences in paired samples, as alternatives to the per gene set statistic. The sign-test
was used to assess the prevalence of up- or down-regulation of genes within a gene set, regardless of the
magnitude of this regulation. They found a lack of sensitivity when using the sign test as gene set score.
Also, they suggested that median is less susceptible to outlier effects in comparison to using mean as a gene
set score.
Multivariate functional scoring methods
Multivariate FCS methods, unlike univariate FCS methods, directly calculate gene set scores from expression
data and skip the intermediate step of calculating gene scores (see Figure 2.2).
Goeman et al. [19] proposed the GlobalTest method, based on a generalized linear model, to address the
question whether the global expression patterns of genes in a given gene set Gi is significantly associated
with a biological outcome of interest. The outcome of interest may be a binary group label representing
two experimental conditions or a continuous variable. The idea behind the GlobalTest method is that if
genes in a given gene set Gi can be used to correctly predict a biological outcome, then genes in Gi should
have different expression patterns for different outcomes. In GlobalTest, the expression profile of genes in Gi
across samples is represented using a matrix X, where Xk,j is the expression value of the j
th gene of Gi in
the kth sample; the biological outcome of interest is represented as an n× 1 vector, where Yk is the outcome
of interest for the kth sample. In a pairwise comparison of phenotypes, Yk is a binary value representing the
phenotype of the kth sample. In order to model the relation between X and Y , GlobalTest uses the following
generalized linear model:




where βj (1 ≤ j ≤ m) is the regression coefficient for the expression value of gene gj ; α is an intercept value;
h is a link function that can be the identity function resulting in a linear regression model, or logit function
resulting in a logistic regression model. In order to test if genes in Gi are able to predict the biological
outcome, the following null hypothesis should be tested:
H0 : β1 = β2 = · · · = βm = 0
Considering the fact that the number of samples is usually less than the number of variables, i.e. gene set size
‖Gi‖, this null hypothesis cannot be tested in a classical way. In order to address this problem, Goeman et
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al. accepted the simplifying assumption that the regression coefficients all come from the same distribution
with a mean of zero and an unknown variance of τ2. In this case, the aforementioned null hypothesis is
equivalent to the following null hypothesis.
H0 : τ
2 = 0
An implementation of the GlobalTest method is available as an R-package from Bioconductor [17]. The
implementation of GlobalTest uses a diagonal covariance matrix, which means that the correlation between
genes in a given gene set is ignored [2].
Analysis of covariance, another multivariate statistical method, has been used in gene set enrichment
analysis [38, 22]. In addition, Kong et al. [33] used Hotelling’s T 2-test for enrichment analysis. This test is the
natural generalization of the t-test for testing the difference between multivariate means of two populations.
The test statistic for a given gene set Gi is as follows:
T 2 = (X¯C − X¯T )tr(Sn1 + n2
n1n2
)−1(X¯C − X¯T ) (2.13)
where X¯C and X¯T are the mean expression vectors of genes in the gene set for control and treatment
samples, respectively; n1 and n2 are the number of control and treatment samples, respectively; tr denotes
the matrix transpose operator. Under the null hypothesis and when n > m+ 1, the following statistic has an




Since m, i.e. gene set size, is often bigger than n, i.e. sample size, Kong et al. [33] employed singular value
decomposition for dimension reduction to be able to use this approach.
2.3 Significance assessment of gene set score
Gene sampling, phenotype permutation, parametric methods, and dynamic programming are four main
approaches that have been used to assess the significance of gene set scores. In this section we study these
approaches.
In gene sampling the significance of a gene set score for a given gene set Gi is assessed by comparing it
to the scores of randomly assembled sets of ‖Gi‖ genes from the reference set U , i.e. all genes under study.
In this method, a large number of random gene sets are assembled, and their scores are calculated. Then
the significance value of the gene set score of Gi is calculated as the fraction of assembled gene sets that
lead to stronger scores than the score of Gi, where a score in comparison to another is considered stronger
if it is more in favour of rejecting the null hypothesis of interest. Since gene sampling does not depend on
the number of samples, it has been widely used for gene set analysis [46, 50, 2]. The main shortcoming
of gene sampling is that it relies on the unrealistic assumption of independence between genes within a
gene set. Usually genes within a gene set show a highly correlated behaviour; therefore, the gene sampling
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method may incorrectly predict a gene set as differentially enriched only because of high correlation between
its genes. In this regard, it may cause false positive predictions. Another shortcoming of gene sampling
is being computationally demanding. For each gene set Gi, the whole process of gene set score calculation
should be repeated for a large number of randomly assembled gene sets. In implementations of gene-sampling
approaches, usually the number of assembled gene sets is an order of magnitude of 1000. This number of
repetitions makes the significance evaluation computationally demanding. Moreover, gene sampling may lead
to a lack of statistical reliability of the significance values for large gene sets [29]. Even using an order of
magnitude of 1000 assembled gene sets may not be big enough to represent the background distribution;
therefore, the significance value for large gene sets may not be statistically reliable.
Phenotype permutation, also known as sample permutation, assesses the significance of a gene set score of
a given gene set Gi by permuting sample labels. First, the gene set score of Gi is calculated. Let SGi denote
the gene set score of Gi according to the actual gene expression profile. Then a large number of expression
profiles are synthesized by permuting the sample labels, i.e. the column labels of the actual expression profile.
For a synthesized expression profile, we expect no association between the expression patterns of genes in
Gi and the phenotypes. Next, for each synthesized expression profile, the gene set score of Gi is calculated.
Finally, the significance of SGi is calculated as the fraction of the synthesized expression profiles that lead
to a stronger score than SGi , where a score in comparison to another is considered stronger if it is more in
favour of rejecting the null hypothesis of interest.
Phenotype permutation, unlike gene sampling, does not rely on the unrealistic assumption of gene inde-
pendence, but it requires a large number of samples with almost equal number of samples for each phenotype.
This condition most often is not satisfied. Instead, due to limited budgets, lack of technicians, or ethical
conduct in animal and human research, having a large number of samples is not a choice for many researchers.
In some cases, like for rare diseases, having a large sample size is not possible at all. Therefore, phenotype
permutation is not applicable, and some gene set analysis tools provide gene sampling as an alternative to
phenotype permutation [46].
The parametric approach is another way to assess the significance of gene set scores [32, 26]. In this ap-
proach, first, a gene set score is proposed. Then, under the null hypothesis and by accepting some simplifying
assumptions, a parametric distribution for the gene set statistic is proposed. Finally, the parametric distri-
bution is used to assess the significance of gene set statistics. Although this approach, unlike gene sampling
and phenotype permutation, is not computationally demanding, it has been criticized as being too simplistic
and unable to detect truly differentially enriched gene sets [47].
Keller et al. [29] used a dynamic programming approach to assess the significance of the enrichment score
used in the method proposed by Mootha et al. [41]. Their dynamic programming approach assessed the
significance of the gene set scores derived from the unweighted Kolmogorov-Smirnov statistic. For a given
array containing n genes and a given gene set Gi, first, they calculated the gene set score RSGi . Then
they calculated its p-values as the probability of obtaining a gene set score equal to or greater than RSGi ,
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enrichment scores possible [29], they calculated the number of enrichment scores less than RSGi
and then used the following formula to calculate the p-values:
p-value(RSGi) = 1−




In order to calculate the number of enrichment scores that are less than RSGi using a dynamic program-
ming approach, they initialized a 2‖Gi‖(n−‖Gi‖+1)× (n+1) matrix M , where the different rows—indexed
from −(n− ‖Gi‖)× ‖Gi‖ to (n− ‖Gi‖)× ‖Gi‖—represent all possible running sum scores. They initialized
M(0, 0) = 1 and the rest of the elements of M as 0. Starting from the second column (k = 1), they updated
all elements of the matrix, column by column, according to Equation 2.16.
M(j, k) =
M(j − n+ ‖Gi‖, k − 1) +M(j + ‖Gi‖, k − 1) if − |RS| < j < |RSGi |0 otherwise (2.16)
Finally, M(0, n) was reported as the number of enrichment scores with a maximum deviation smaller than
RSGi . Keller et al. [29] suggested that their proposed dynamic programming approach is more efficient than
the permutation approach and that their method does not suffer from the statistically unreliable results
produced by the permutation method, when the number of permutations is not large enough. They claimed
that their approach is almost 10 times faster than phenotype permutation and gene sampling. It should
be mentioned that the main shortcoming of this approach is that, unlike permutation approaches, it is not
extendable to other gene set scores such as weighted Kolmogorov-Smirnov statistic in GSEA.
2.4 Null hypothesis in gene set enrichment analysis
Defining a null hypothesis is an essential step in conducting any statistical inference. Different null hypothe-
ses have been used in gene set enrichment analysis: Competitive null hypothesis [18], self-contained null
hypothesis [18], and hybrid null hypothesis [2]. Understanding the implications of these null hypotheses is
essential for having a valid interpretation of the the result of gene set analysis. In this section, we discuss
the limitations and requirements of each class of hypothesis.
For a given gene set Gi, a competitive null hypothesis states that genes in Gi do not have a different
expression pattern in comparison to the rest of the genes under study. The competitive approach, for detecting
differentially enriched gene sets, compares the expression patterns of genes in Gi with the rest of the genes
under study. To conduct the hypothesis test, a gene sampling approach is used. Consequently, the competitive
approach has been criticized for using genes as sampling units, whereas the purpose of the experiment is to
detect changes across phenotypes [18, 2]. It also has been criticized for ignoring the correlation between genes
within a gene set. Therefore, methods based on the competitive approach may detect a gene set as being
differentially enriched just because of the correlation between its genes [18, 2].
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For a given gene set Gi, a self-contained null hypothesis states that genes in Gi do not have a different
expression pattern across phenotypes. To test this hypothesis, methods based on the self-contained approach
use phenotype permutation. Consequently, testing a self-contained null hypothesis leads to preserving the
complex correlation of genes within a gene set. However, it requires a large and almost equal number of
samples for each phenotype. This condition may not be met by many experiments.
The hybrid null hypotheses are a subclass of the self-contained null hypotheses. Hybrid null hypotheses
state that genes in Gi are not differentially associated with a phenotype of interest, where the measure of
association is defined according to all genes under study. Methods based on this approach calculate a gene
set score for a given gene set Gi using all genes, i.e. genes in Gi ∪ G¯i; then they assess the significance of
this score in a similar way to the self-contained approach. Therefore, testing these hypotheses requires a
large and almost equal number of samples for each phenotype. GSEA and its variants, which are based on
Kolmogorov-Smirnov statistic, use the hybrid null hypotheses [41, 46, 23].
2.5 Discussion
Despite having a well-established underlying statistical model, ORA suffers from several shortcomings. ORA
relies on the gene-gene independence assumption that is known to be biologically invalid [16, 48]. Also, ORA
uses a list of differentially expressed genes as input and treats all genes equally regardless of their magnitude
of differential expression. Differentially expressed genes are determined using a single gene analysis method,
where the use of arbitrary thresholds is often a common practice. It has been shown that the choice of these
thresholds might affect the result of the downstream analysis [43]. ORA is also incapable of detecting low
but concordant signals, i.e. below the used threshold, from genes within a gene set. These concordant signals
are believed to be biologically important.
FCS methods aim at solving some of these problems. There are many FCS methods available, but there is
no consensus among researchers about the method of choice for a given experiment [18, 34, 2, 26, 15, 24, 47].
Therefore, a systematic methodology for evaluation of gene set analysis is of great value for the research
community.
A gold standard dataset for evaluation of gene set analysis methods requires the enrichment status of
all gene sets in a given gene set database to be known a priori. Currently, such a dataset is not available;
therefore, simulated datasets have been widely used to evaluate gene set analysis methods [13, 42, 2]. These
simulated datasets often rely on oversimplifying assumptions that are not capable of capturing the true nature
of gene expression and gene set collections. Most often expression data have been simulated by ignoring the
complex correlations between genes within gene sets [13, 42, 2]. Moreover, gene set collections have usually
been simulated to be a small number of non-overlapping sets of equal size, a situation that is substantially
different from the real gene set databases. Due to oversimplifying assumptions, evaluation of gene set analysis
using these datasets has led to inconsistent and contradictory results [36]. Synthesizing datasets that preserve
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the true nature of gene expression data and gene set databases is an essential step in the evaluation of new
and existing gene set analysis methods.
Competitive gene set analysis methods rely on gene sampling for the significance assessment. Gene
sampling is based on the assumption that genes are independent. This assumption is known to be biologically
invalid and may cause some gene sets to be predicted as being differentially enriched solely due to the
correlation between its genes. This issue introduces false positives and decreases the specificity of these
methods. Self-contained gene set analysis methods also suffer from a lack of specificity.
Lack of specificity of gene set analysis methods is one of the main drawbacks to gaining insight from the
results of gene set analysis. One of the main reasons behind this issue is gene set overlap which is an integral
part of gene set databases [37]. For example, if the null hypothesis for a self-contained method is that there is
no difference in the average expression of genes in a gene set between case and control samples, a significant
change in the expression of a gene within a gene set might result in differential enrichment of that gene set.
The problem arises in the presence of gene set overlap. In the presence of gene set overlap, such gene(s)
may occur in several gene sets; therefore, differential expression of a gene or a few genes may cause a large
number of gene sets to be predicted as being differentially enriched. Hence, gene set overlap seems to be the
main challenge facing these methods [37]. There have been several attempts to alleviate the effect of gene set
overlap [49, 44]. Although these methods lead to a higher specificity, they suffer from low sensitivity. Further
research in developing gene set analysis methods that increase specificity without sacrificing sensitivity is
required.
Self-contained gene set analysis methods rely on phenotype permutation for significance assessment; there-
fore, in an experiment where the number of samples is small, the calculated significance score by phenotype
permutation is not reliable; therefore, the use of these methods is highly discouraged. For example, in a
case-control study where there are 3 control and 3 case samples, the total number of unique ways that one
can divide these 6 samples into two groups each of size 3 is 20; therefore, the smallest non-zero p-values
achievable is 0.5. Competitive methods should be preferred for such experiments.
2.6 Conclusion
In this paper, we reviewed a set of well-established gene set analysis methods. We discussed the shortcoming
and strengths of gene set analysis method based on their various components such as their gene set score, null
hypothesis, and their methods of significance assessment. We also set the direction for conducting further
research in gene set analysis.
A systematic methodology for evaluating gene set analysis methods can help to resolve the lack of con-
sensus about the method of choice for a given experiment. A method for synthesizing expression datasets
that represent the characteristics of real expression data and developing benchmark datasets based on this
method will prove useful. In addition, developing benchmark datasets using such methods will facilitate the
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evaluation of gene set analysis methods. A quantitative study of characteristics of gene set databases, such
as gene set overlap, can help researchers better understand the effect of these characteristics on the results
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3 Size Matters: How Sample Size Affects the
Reproducibility and Specificity of Gene Set
Analysis
Irreproducibility of high-throughput experiments has been a major challenge for the research community.
Small sample size is known to be one of the major causes behind the irreproducibility of high-throughput
experiments. Despite the existence of general guidelines, there is no quantitative approach for suggesting a
sufficient sample size to be used for a given gene set analysis method. Therefore, gene set analysis methods
have often been proposed without providing specific guidance regarding the required number of samples.
This chapter presents a quantitative approach for such an evaluation.
An initial version of this work was accepted as a regular paper at the “2018 IEEE International Conference
on Bioinformatics and Biomedicine (BIBM18)” with 534 full paper submissions and an acceptance rate of
19.6%. An extended version of this paper has been subsequently invited for consideration by “BMC Human
Genomics”. In this Chapter, we present the extended version submitted to “BMC Human Genomics”.
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Abstract
Gene set analysis is a well-established approach for interpretation of data from high-throughput gene ex-
pression studies. Achieving reproducible results is an essential requirement in such studies. One factor of a
gene expression experiment that can affect reproducibility is the choice of sample size. However, choosing an
appropriate sample size can be difficult, especially because the choice may be method-dependent. Further,
sample size choice can have unexpected effects on specificity.
In this paper, we report on a systematic, quantitative approach to study the effect of sample size on the
reproducibility of the results from 13 gene set analysis methods. We also investigate the impact of sample
size on the specificity of these methods. Rather than relying on synthetic data, the proposed approach uses
real expression datasets to offer an accurate and reliable evaluation.
Our findings show that, as a general pattern, the results of gene set analysis become more reproducible
as sample size increases. However, the extent of reproducibility and the rate at which it increases vary
from method to method. In addition, even in the absence of differential expression, some gene set analysis
methods report a large number of false positives, and increasing sample size does not lead to reducing these
false positives. The results of this research can be used when selecting a gene set analysis method from those
available.
3.1 Introduction
The choice of sample size is an important decision to make when designing a gene expression experiment.
Choosing an appropriate sample size for obtaining a desired statistical power is feasible for basic statistical
procedures; however, making such choices for complex procedures such as gene set analysis is not straightfor-
ward. To the best of our knowledge, there is no methodological approach to determine the optimal sample
size for reaching a predetermined statistical power or achieving reproducible results in gene set analysis,
where sample size refers to the number of biological replicates per treatment, tissue, or condition. Conse-
quently, researchers either use the largest possible number of samples considering available resources—such
as funding, specimens, and technicians—for conducting the experiments, or they use an arbitrary sample
size—as small as two or three samples per treatment. Using unnecessarily large sample sizes wastes resources
and might involve ethical concerns. On the other hand, using small sample sizes may yield unreliable and
irreproducible results.
The impact of the number of used samples on the results of differential expression analyses has been
studied. Tsai et al. [27] suggested a methodology for sample size estimation. They assumed an equal
standardized effect size and a constant gene-gene correlation for differentially expressed genes. Relying on
these assumptions, they estimated an appropriate sample size as that which led to the highest number of
true positives using a beta-binomial distribution for the two-sample z-test. Their proposed approach, as
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they reported, might underestimate the number of required samples when the gene-gene correlation is not
constant. Stretch et al. [20] reported that using a small number of samples may lead to irreproducible results
in differential expression studies. Schurch et al. [19] evaluated 11 tools for differential expression analysis
using a dataset with 48 controls and 48 cases. The results of these methods when using subsets of 3 controls
and 3 cases were compared to the results when using all samples. They reported that for 8 methods only 20 to
40% of the differentially expressed genes were among the genes reported when using all samples. Furthermore,
they suggested that to increase this percentage to a value larger than 85%, at least 20 samples per treatment
are required.
Gene expression analysis typically reports several hundred genes as differentially expressed. Biological
interpretation of such a large number of genes is laborious and prone to investigator bias(es) in favour of, or
against the hypothesis under study. The main aim of gene set analysis—also known as enrichment analysis—
is to alleviate these problems. Many gene set analysis methods are available. These methods, unlike basic
statistical tests, are complex procedures; therefore, estimating sample size for obtaining a predetermined
statistical power or reproducible results is challenging.
In this paper, we extend an earlier work on sample size and reproducibility in the context of gene set
analysis [15]. We study a comprehensive list of 13 gene set analysis methods: PAGE [11], GAGE [13],
Camera [30], ROAST [29], FRY (from the R package limma) [17], GSEA (both gene permutation (GSEA-
G) and sample permutation (GSEA-S) versions) [21], ssGSEA [3], GSVA [10], PLAGE [26], GlobalTest [9],
PADOG [25], and over-representation analysis (ORA) [6]. All of the methods can be used for pairwise
comparison of phenotypes or treatments (e.g. case versus control). Using real datasets, we evaluate the
reproducibility of the results of these methods across sample sizes that are commonly used in gene expression
studies.
In addition, we assess the specificity of gene set analysis methods across sample sizes. Tarca et al. [24]
evaluated the specificity of gene set analysis methods by calculating the number of false positives for datasets
generated from permutations of sample/phenotype labels of actual expression datasets. Since after per-
mutation of sample labels there should be no association between differential enrichment of gene sets and
phenotypes, all gene sets predicted as differentially enriched by a method were considered as false positives.
However, each group of samples corresponding to a condition (case or control) in their generated datasets
contained a mixture of both case and control samples from the original dataset; therefore, the characteristics
of the generated dataset could be different from that of the original dataset. Furthermore, they did not
evaluate the specificity of gene set analysis methods across sample sizes. To avoid the shortcoming of the
approach used by Tarca et al., we conduct an experiment by generating datasets of various sizes, where
case and control samples for each generated dataset are the result of sampling without replacement from
control samples of an actual expression dataset. Since in the generated datasets control and case samples are
from actual controls, any gene set predicted as differentially enriched by a method can be considered a false
positive.
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3.2 Data and methodology
3.2.1 Data
Repositories such as Gene Expression Omnibus (GEO) [7] and ArrayExpress [18] make large scale expression
datasets publicly available. In this research, three such case-control datasets with unrelated phenotypes from
the Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray platform were obtained from GEO: 1)
renal cell carcinoma tissue (77 controls and 77 cases, GSE53757) [28], 2) gingival tissues (64 controls and
183 cases, GSE10334) [5], and 3) skin tissue in psoriasis patients (64 controls and 58 cases, GSE13355) [22].
The raw data were preprocessed with the GEOquery v2.46.15 R package and normalized with justRMA
normalization from the affy v1.56.0 package.
MDS (multidimensional scaling) plots in Figures B.1, B.2, and B.3 in Supplementary Materials visualize
the similarity between samples, respectively, for datasets GSE53757, GSE10334, and GSE13355. These plots
illustrate that dataset GSE10334 has the lowest intra-class similarity and less distinction between control and
case samples, while dataset GSE13355 has highest intra-class similarity and shows a clear distinction between
case and control samples. All visualizations in this paper are produced for the dataset with intermediate
characteristics, GSE53757, unless otherwise noted.
Probe IDs were converted to their corresponding Entrez gene identifiers using the hgu133plus2.db v3.2.3
R package. To avoid over-emphasizing genes with a large number of probes on the arrays, it is a common
practice in gene set analysis to collapse duplicate IDs. This was accomplished by using the collapseRows
function from WGCNA v1.61 with the MaxMean method that selects the probe that has the maximum
average value across samples when multiple probes map to the same gene. Collapsing the probes resulted in
20,514 genes in each experiment from an initial 54,675 probes.
3.2.2 Methodology
A proper study of the effect of sample size on the results of gene set analysis methods requires conducting
expression studies with datasets of various sizes. These studies must be conducted while all potentially
confounding factors such as phenotype under study, the platform for measuring gene expression, experiment
protocol, laboratory technician skill level, and environmental conditions stay constant. Datasets of various
sizes for which these factors are constant is not currently available. In this research, we utilize a systematic,
quantitative approach to study the effect of sample size on the reproducibility and specificity of gene set
analysis methods using large scale publicly available gene expression datasets.
Assume that D is a dataset containing nC control samples and nT case samples, where both nC and nT
are relatively large numbers (> 50). Given an integer n, where n < nC , and n < nT , we generate a balanced
case-control dataset by randomly selecting n samples from the nC controls of D and n samples from the nT
case samples of D. The random sampling is performed without replacement; therefore, the chosen samples
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are unique within the generated dataset. Hereafter, we refer to such a balanced case-control dataset as a
replicate dataset of size 2×n and the entire process for assembling a replicate dataset as the data generation
procedure. Also, to avoid confusion, we refer to D as the original dataset.
To obtain results that do not depend on a specific composition of samples, for each given n, we repeat the
dataset generation procedure m times to construct m replicate datasets of size 2×n. These replicate datasets
are then used for downstream analysis. Due to the nature of random sampling, these replicate datasets are
different.
The dataset generation procedure assembles replicate datasets from an original dataset; therefore, con-
founding factors remain almost invariable. For instance, all these replicate datasets have the same platform
and use the same experiment protocol; they also have been made by the same technician(s). This makes
it possible to study the effect of sample size on the result of gene set analysis methods while keeping the
confounding factors nearly constant.
Different gene set analysis methods then are applied to replicate datasets of various sample sizes and
their results are used to investigate the effect of sample size on the reproducibility and specificity of gene set
analysis.
In this research, 13 widely used gene set analysis methods are studied—PAGE [11], GAGE [13], Cam-
era [30], ROAST [29], FRY [17], GSEA [21], ssGSEA [3], GSVA [10], PLAGE [26], PADOG [25], Global-
Test [9], and ORA [6]. The following R packages are used for conducting gene set analysis. PLAGE, GSVA,
and ssGSEA are obtained from GSVA package version 1.18.0 ; the phyper method from the stats package
version 3.4.4 is used to implement ORA; the GSEA.1.0.R script downloaded from the Broad Institute soft-
ware page for GSEA are used to run GSEA-S and GSEA-G; ROAST, FRY, and Camera are run using the
limma package version 3.34.9 ; GAGE and PAGE are obtained from the gage package version 2.20.1. For
each sample size n (n ∈ {3, . . . , 20}), m = 10 replicate datasets of size 2× n are generated. Then a gene set
analysis method is applied to each replicate dataset. For all gene set analysis methods the default parame-
ters are used. A Benjamini-Hochberg correction [4] with a false discovery rate of 0.05 is performed for a fair
comparison across methods. Also, the GO gene sets are extracted from MSigDB version 6.1 [21] and used
as the gene set database for all experiments. Hereafter, this database is referred to as G.
After generating D
(2×n)
1 , . . . , D
(2×n)
m , each replicate dataset D
(2×n)
i (1 ≤ i ≤ m) and the gene set database
G are used as inputs to a gene set analysis method ψ, and the results after correction for multiple comparisons




. The kth component of this vector is the adjusted p-value resulting from testing
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that is less than α, the
corresponding gene set in G is considered as differentially enriched, and non-differentially enriched otherwise.






We use the Jaccard similarity coefficient, also known as Jaccard index [2], to quantify the reproducibility

















































. Hereafter, we refer to the Jaccard similarity
coefficient as the overlap score.















j . The resulting overlap score is stored in position (i, j) of an upper triangular matrix, which























(1 ≤ i, j ≤ m) indicate the extent to which the results of a gene set analysis method is reproducible when
analyzing replicate datasets of size 2× n. High overlap indicates that method ψ using datasets of size 2× n
yield reproducible results. For each method ψ, we conduct a Kruskal-Wallis test to statistically assess if there
is a significant difference between the overlap scores across sample sizes (3 ≤ n ≤ 20). The overlap scores for
each sample size 2× n is represented as a multiset Pψ(2×n), which is a set but with repetition allowed. Pψ(2×n)
is defined as follows:





) | 1 ≤ i < j ≤ m} (3.2)
The adjusted p-values resulting from the gene set analysis of a given expression dataset are often sorted
based on their adjusted p-values. Then gene sets with the smallest adjusted p-values are considered for
further investigation and interpretation. Therefore, not only is the differential enrichment status of gene
sets important but also the order of their significance. To assess the agreement in the order of gene sets
reported as differentially enriched when analyzing replicate datasets of the same size using a method ψ, we
use Kendall’s coefficient of concordance [2]. The Kendall’s coefficient of concordance ranges between 0 and
1, with 0 indicating no agreement and 1 indicating complete agreement, i.e. the same order of gene sets
when sorted by their adjusted p-values. Since we aim to quantify the agreement in the order of gene sets
predicted as differentially enriched across replicate datasets of the same size, we only consider gene sets that
are predicted as differentially enriched for at least one replicate dataset.
Further, we compare the overlap between the results of a gene set analysis method ψ when applied to
dataset D2×n and D. This is done to evaluate if the dataset with the smaller sample size is enough to
reproduce the results when using the whole dataset D. Therefore, we construct a multiset Wψ(2×n) of m
overlap scores, as follows:
Wψ(2×n) = {J(SψD(2×n)i , S
ψ
D) | 1 ≤ i ≤ m} (3.3)
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High overlap scores suggest that a sample size of 2 × n might be enough for obtaining equivalent results as
those achieved using the whole dataset.
Also, to evaluate the specificity of gene set analysis methods, we conduct an additional experiment,
referred to as the control-control experiment. The procedure for generating control-control replicate datasets
in this experiment is similar to that of the balanced case-control replicate datasets with the sole difference
being that only actual control samples are used for constructing the replicate datasets. In other words, each
replicate dataset for the control-control experiment is made by random sampling (without replacement) of n
samples from the nC controls of D (where n <
nC
2 ) and another n samples from the nC control samples of
D. The former group of n samples are considered controls in the replicated dataset and the latter group are
considered cases.
3.3 Experimental results
To visualize the change in reproducibility of a gene set analysis method across sample sizes, we utilize an
arrangement of modified heat maps, hereafter referred to as a pine plot. Each triangular heat map in a
pine plot—referred to as a layer—represents values above the diagonal in an overlap matrix (as described in
Methodology). Each layer visualizes the overlap scores calculated based on the results of the gene set analysis


















). When i = j, a value of 1 is assigned to the cell (i, i) of the overlap matrix, which is
represented with a red colour and serves as a visual reference point.
The pine plots in Figures 3.1 and 3.2 depict the change in reproducibility of results from GSEA-S, GSEA-
G, ORA, and GAGE for replicate datasets of size 2 × 3, 2 × 5, 2 × 10, 2 × 15, and 2 × 20, where 2 × n
represents the size of a dataset with n controls and n cases. These methods were chosen as they represent the
range of results shown by all 13 methods. The pine plots for the remaining methods for dataset GSE53757
are provided as Supplementary Material. Visualizations and tables corresponding to datasets GSE10334 and
GSE13355 are available from the authors.
The plots in Figures 3.1 and 3.2 show that reproducibility increases as sample size increases. However,
the extent of the increase in the overlap scores is not the same across all methods. GSEA-S, as depicted
in Figure 3.1, has lower overlap scores overall compared to GSEA-G. In Figure 3.2, ORA and GAGE have
higher overlap scores when using sample sizes larger than 2× 10 compared to GSEA-S and GSEA-G.
The pine plots for all 13 methods illustrate the following results. PADOG, GSEA-S, and Camera show the
lowest overlap scores. Pine plots for ROAST, PAGE, ORA, GSVA, and GSEA-G show a distinct transition
from low overlap (for sample sizes less than or equal to 2× 5) to high overlap scores (for sample sizes more
than 2 × 10) as sample size increases. ssGSEA, GlobalTest, GAGE, and PLAGE report a large number of
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Figure 3.1: Pine plots for dataset GSE53757 showing reproducibility of the results from GSEA-S (left)
and GSEA-G (right) across sample sizes. Reproducibility is quantified by overlap score (Equation 3.1).
Each layer of the pine plot illustrates the overlap score of the results of a method for 10 replicate
datasets with the same sample size. From top to bottom, the pine plots show replicates with sample
size 2 × 20, 2 × 15, 2 × 10, 2 × 5, and 2 × 3. The overlap score ranges from 0 to 1 represented by a
gradient from blue to red, respectively, separated by yellow in the middle (overlap of 0.5). The overlap
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Overlap
Figure 3.2: Pine plots for dataset GSE53757 showing reproducibility of the results from ORA (left)
and GAGE (right). See Figure 3.1 caption for more information. The pine plots suggest that the
overlap between replicates is larger in comparison to that of GSEA-S and GSEA-G. GAGE has more
agreement between replicates when using lower sample sizes such as 3 compared to the other methods
shown (including in Figure 3.1), and the overlap scores continue to improve for higher numbers of
samples.
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Figure 3.3: Box plots showing the distribution of overlap scores resulting from gene set analysis
utilizing GSEA-S when using the original dataset GSE53757 for generating replicate datasets. The
panel on the left shows the overlap scores from replicate datasets, while that on the right depicts
the overlap scores of each replicate dataset and the whole dataset. Dataset sample sizes are 2 × n
(3 ≤ n ≤ 20), where n is the sample size per group. The x-axis shows n, the sample size per group,
and the y-axis shows the overlap scores.
The box plots in Figures 3.3, and 3.4, and 3.5 illustrate the distribution of the overlap scores across sample
sizes when the results of the replicate datasets are compared to each other (calculated using Equation 3.1),
as well as when the results of replicate datasets are compared to the results using the entire dataset, i.e.
original dataset (calculated using Equation 3.3). Figures 3.3, 3.4, and 3.5 show representative results from
three methods; plots for the remaining methods are in Supplementary Materials. For all methods except
GSEA-S and PADOG, the agreement between overlap scores increases as sample size increases.
To statistically assess if there is a significant difference between the overlap scores across sample sizes, i.e.
Pψ(2×3), . . . , P
ψ
(2×20), for each method, a Kruskal-Wallis test was used. The p-values resulting from these tests,
shown in Table B.1 in Supplementary Materials, suggest that the overlap scores significantly vary across
sample sizes irrespective of the original dataset being used.
Figure 3.6 depicts Kendall’s concordance coefficients for replicate datasets across sample sizes for all
methods under study. The figure illustrates that concordance coefficient increases as the sample size increases.
Figure 3.7 illustrates the average number of gene sets reported as differentially enriched across sample
sizes. PADOG, GSEA-S, and Camera tend to report a small number of differentially enriched gene sets
compared to the other methods. The number of gene sets reported as differentially enriched by GAGE,
GSVA, ROAST, and FRY substantially increases as sample size increases, while the rest of the methods reach
an almost constant number of gene sets predicted as being differentially enriched. Visualizations analogous to
Figures 3.6 and 3.7 for datasets GSE10334 and GSE13355 are provided in Supplementary Materials. These
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Figure 3.4: Box plots showing the distribution of overlap scores resulting from gene set analysis
utilizing GAGE when using the original dataset GSE53757 for generating replicate datasets. The
panel on the left shows the overlap scores from replicate datasets, while that on the right depicts
the overlap scores of each replicate dataset and the whole dataset. See Figure 3.3 caption for more
information.
The control-control experiment was conducted using dataset GSE53757. Table B.2 in Supplementary
Materials shows the average number of differentially enriched gene sets across sample sizes in the control-
control experiment for all of the methods. Since there is no true differential enrichment expected in the
control-control experiment, the average values in this table represent the average number of false positives.
ssGSEA, GAGE, PAGE, and PADOG are methods with non-zero false positive counts across sample sizes.
ssGSEA results in the largest number of false positives followed by GAGE, and then PAGE. Also, increasing
sample size for these methods does not reduce the frequency of false positives. Surprisingly, an increase in
sample size leads to an increase in false positives when using GAGE. The number of false positives reported
by PADOG decreases rapidly as sample size increases, and for sample sizes larger than 2× 5, it only reports
a small number of false positives. Camera reports almost no false positives for sample sizes less than 2× 9,
but it reports a small number of false positives as sample size increases. ORA, GSVA, GlobalTest, PLAGE,
ROAST, and FRY rarely, if ever, report any false positives.
3.4 Discussion
Reproducibility of the results of gene set analysis methods, as in any other scientific context, is an essential
condition for having confidence in the methods. In this research, we applied a systematic approach for
quantitatively assessing the reproducibility of gene set analysis methods. By using real expression datasets,
the proposed approach strives for a realistic assessment of the reproducibility of gene set analysis methods
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Figure 3.5: Box plots showing the distribution of overlap scores resulting from gene set analysis
utilizing ORA when using the original dataset GSE53757 for generating replicate datasets. The panel
on the left shows the overlap scores from replicate datasets, while that on the right depicts the overlap
scores of each replicate dataset and the whole dataset. See Figure 3.3 caption for more information.
To visualize overlap between the results of a gene set analysis method across sample sizes, we introduced
and used pine plots. The utility of pine plots, however, is not limited to this application. In general, pine
plots can be used to visualize the interaction between several variables defined using a symmetric function
while controlling for potentially confounding factors. In practice, most functions for measuring the interaction
between variables are symmetric functions—for example, Pearson correlation and Spearman’s rank correlation
coefficients. Also, symmetry is a necessary condition for any well-defined metric or distance function [12].
Therefore, the symmetric condition does not limit the usability of pine plots. The pine plots in this paper
illustrated a general increase in reproducibility as sample size increases. While boxplots can only show the
distribution of overlap scores, pine plots are capable of showing the extent of the overlap between each pair
of replicate datasets, further highlighting the reproducibility of replicate datasets of the same size.
The reproducibility of gene set analysis across replicate datasets is a necessary condition for obtaining
biologically meaningful results, but not a sufficient one. To illustrate, consider a hypothetical method that
always predicts all of the gene sets in a gene set database as differentially enriched regardless of the phenotype
being examined. Obviously, the results of this method are perfectly reproducible (always an overlap score
of 1). However, such a method produces a large number of false positives—i.e., suffers from a lack of
specificity—and, as a consequence, does not provide any biological insight. Therefore, we also investigated
the specificity of gene set analysis methods. Gene set analysis methods that tend to predict very few gene
sets as differentially enriched achieve high specificity. However, these methods often suffer from a lack of
sensitivity. In this research, we used the number of differentially enriched gene sets predicted by each method
to reveal such scenarios.
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Figure 3.6: Kendall’s coefficient of concordance for each method under study when using the original
dataset GSE53757 for generating replicate datasets. The x-axis shows the sample size. The y-axis
shows concordance coefficients of the results of gene set analysis of 10 replicate datasets of the same
size.
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Figure 3.7: The number of gene sets predicted as differentially enriched for each method under study
when using the original dataset GSE53757 for generating replicate datasets. The x-axis shows the
sample size per group. The y-axis shows the average number of gene sets predicted as differentially
enriched across 10 replicate datasets of the same size. The red line parallel to the x-axis shows the
size of the gene set database being used, i.e. the maximum possible number of gene sets that could be
predicted as being differentially enriched.
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extent of reproducibility and the rate at which it grows by sample size was different across methods.
We evaluated reproducibility not only based on the differential enrichment of gene sets but also on the
order in which they are predicted, where the order is defined using significance values of gene sets. Kendall
concordance coefficients were used to determine if the gene sets predicted as significantly differentially enriched
by each method are consistently reported in the same order across replicated datasets of the same sample
size.
This research provides insights into the behaviour of specific gene set analysis methods. For instance,
GSEA-S achieves low overlap scores across replicate datasets, even for larger sample sizes such as 2 × 20.
Meanwhile no differentially enriched gene sets are predicted by this method using small sample sizes (see
Figures 3.1, 3.3, and 3.7). GSEA-S was expected to predict few differentially enriched gene sets using
small sample sizes since large sample sizes are required for this method to assess significance based on
sample permutation. For example, for an experiment with 3 control and 3 case samples, 20 distinct sample
permutations exist—the combination of 3 out of 6. Therefore, the smallest non-zero p-value is 0.05, which we
did not consider significant. For a sample size of 2×10 or higher, GSEA-S predicts an average of 15 gene sets
as differentially enriched (Figure 3.7). This number remains steady while Kendall’s concordance increases
(Figure 3.6), which suggests that 2× 10 samples might be a reasonable lower bound for using GSEA-S.
PADOG, which has been designed to take gene set overlap into account and increase specificity, has low
overlap scores between replicate datasets even for the largest sample sizes considered. Like GSEA-S and
Camera, PADOG also predicts few gene sets as differentially enriched. Lack of reproducibility across large
sample sizes for both methods may suggest that the gene sets predicted as differentially enriched are false
positives, i.e. gene sets incorrectly predicted as being differentially enriched.
PLAGE, ssGSEA, and GlobalTest tend to report nearly all gene sets as differentially enriched. This is
always the case for ssGSEA regardless of the sample size of the replicate datasets used. For small sample sizes,
PLAGE and GlobalTest report fewer gene sets as differentially enriched, but this number rapidly increases
for larger sample sizes. Furthermore, PLAGE appears to be more sensitive to the dataset used since it
predicts far fewer gene sets as differentially enriched for the dataset with higher variability across case and
control samples, as with GSE10334 (see Figures B.2 and B.21 in Supplementary Materials). The number of
gene sets predicted explains why these methods achieve high overlap scores. Since it is unlikely that such a
large number of gene sets are differentially enriched in a living organism, we assume that these methods also
predict a large number of false positives.
Given the above, relying on gene sets predicted as being differentially enriched by GlobalTest, PLAGE or
ssGSEA may lead to interpretations that are incorrect or biased towards a hypothesis of interest. However,
the most statistically significant gene sets, i.e. gene sets with the lowest adjusted p-value, suggested by these
methods may still be biologically relevant. Therefore, we suggest further research be conducted to evaluate
how best to use these methods and interpret their results.
GlobalTest’s and PLAGE’s relatively low Kendall concordance coefficients depicted in Figure 3.6 show
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that the order in which they predict the differentially enriched gene sets is not conserved across replicate
datasets. For PLAGE this may be explained by considering that for each gene set, the method defines “the
activity level in terms of the first eigenvector, ‘metagene’, in the singular value decomposition” [26]. By
ignoring other eigenvectors of an expression profile for a gene set, it cannot completely capture the variability
of expression of genes within a gene set. This means that the gene sets predicted as being differentially
enriched by PLAGE could show variation in statistical significance across replicate datasets, and therefore,
be ranked differently for each replicate dataset.
For sample sizes larger than 2 × 5, ORA remains consistent in the number of gene sets reported as
differentially enriched suggesting that 2 × 5 is a reasonable lower bound for sample sizes when using ORA.
PAGE also shows a behaviour similar to that of ORA. Since PAGE and ORA are parametric methods and
their calculated gene set scores are a function of the number of differentially expressed genes, this behaviour
was expected.
When replicate datasets of various sizes are generated from one original dataset, it is expected that a
gene set analysis method analyzing these replicate datasets will report approximately the same number of
differentially enriched gene sets. However, this is not the case with GAGE, GSVA, FRY, and ROAST. A
dramatic increase in the number of gene sets predicted as being differentially enriched was observed for these
methods as sample size increases. This increase may also be partially responsible for the observed increase
in the overlap scores of these methods as sample size increases.
FRY and ROAST closely mirror each other in the number of gene sets predicted as being differentially
enriched as well as their Kendall concordance coefficients across sample sizes. As FRY was designed to be a
fast approximation of ROAST, this behaviour is understandable. However, since these methods, as well as
GAGE and GSVA, report large numbers of gene sets as being differentially enriched, we assume that these
methods may lead to more false positives as sample size increases.
Measuring sensitivity using real datasets is challenging, if not impossible, as the differential enrichment
status of gene sets for real datasets are not known. Simulated data, on the other hand, often suffer from
oversimplified assumptions such as constant or zero gene-gene correlation or normally distributed expression
values [8, 16, 1] leading to biased evaluations of gene set analysis methods [23]. We suggest development
of standard synthesized datasets without relying on such assumptions as future research in the community.
This would alleviate the challenges caused by the lack of gold standard datasets for the evaluation of gene
set analysis methods. A methodology such as the one utilized in this paper could be used for such standard
datasets.
The results of the control-control experiment indicate that some methods suffer from a lack of specificity,
even in the absence of differential expression. It would be expected that as the number of samples increases,
the number of false positives reported would decrease, i.e. specificity increases; however, it is not the case for
some methods. As depicted in Table B.2, GAGE and ssGSEA report the highest number of false positives.
Almost all gene sets are predicted by ssGSEA as differentially enriched in both the control-control experiment
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and case-control experiments (see Figures 3.7, B.21, and B.22), regardless of the sample size. GAGE reports
a large number of false positives as sample size increases. PAGE and GSEA-G also report a large number
of false positives, but this number remains relatively consistent and is not affected by the sample size used.
Therefore, increasing the sample size is not a viable solution for improving the results of these methods.
PADOG reports fewer false positives as sample size increases; however, PADOG also reports a small number
of differentially enriched gene sets in the case-control experiments as well. This shows that although PADOG
achieves a high specificity, it may suffer from a lack of sensitivity, as the reported false positives might
overwhelm the results. GSEA-S and Camera have a similar issue with being overwhelmed with false positives
since they also report a small number of gene sets as differentially enriched. GSVA, Globaltest, FRY, and
ROAST do not appear to report false positives in the control-control experiment regardless of sample size
being used. However, this control-control experiment measures the number of false positive in the absence
of differential expression and does not say anything about the specificity of these methods in the presence
of differential expression. The large number of gene sets predicted as differentially enriched in the case-
control experiments, as depicted in Figures 3.7, B.21, and B.22 suggests that these methods suffer from
a lack of specificity in the presence of differential expression, as such a drastic change in gene expression
is unlikely for a living organism. ORA, as expected, did not report any false positive in the absence of
differentially expressed genes. It also reported a smaller number of differentially enriched gene sets in the
case-control experiments—in comparison to GSVA, Globaltest, FRY, and ROAST. However, it still reported
a substantially large number of differentially enriched gene sets for each case-control experiment (almost
20% of gene sets in G). This suggests that ORA could still suffer from lack of specificity in the presence of
differential expression though not to the degree of the other methods such as GSVA, Globaltest, FRY, and
ROAST. This can be attributed to the presence of gene set overlap [14].
In this paper, we evaluated the results of gene set analysis methods using balanced datasets, i.e. datasets
with the same number of cases and controls. While we expect consistent results for datasets that are not
drastically imbalanced, we suggest investigating the effect of dataset imbalance on the results of gene set
analysis methods.
3.5 Conclusion
The systematic methodology described in this paper can be successfully used to evaluate the reproducibility of
results from gene set analysis methods, allowing comparison across methods and sample sizes. The methodol-
ogy was employed to evaluate the reproducibility of 13 widely used gene set analysis methods. The proposed
methodology also made it possible to measure the specificity of these methods using real datasets. From the
results we conclude that, as a general pattern, reproducibility, as measured by an overlap score, increases with
sample size. However, the rate of increase is method-dependent. Our findings suggest that for all methods in
the study, achieving reproducible results using small sample sizes—such as 3, 4, or 5 samples per group—is
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unlikely. However, we observed that increasing sample size is not a panacea for achieving biologically reliable
results, as for some methods it decreased the specificity, i.e. introduced more false positives.
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4 Method Choice in Gene Set Analysis has
Important Consequences for Analysis Outcome
There are a large number of gene set analysis methods available. These methods vary in their components
such as their underlying null hypothesis. This raises a question about the choice of gene set analysis method
for a given experiment and to what extent that choice may affect the outcome of the analysis. This chapter
presents the evaluation of 10 widely used gene set analysis methods.
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Gene set enrichment analysis is a well-established approach for gaining biological insight from expression
data. With many gene set analysis methods available, a question is raised about the consistency of the
results of these methods. In this paper, we answer this question with a systematic analysis of ten commonly
used gene set analysis methods when applied to microarray data. The statistical analysis suggests that there
is a significant difference between the results of these methods. Comparison of the 20 most statistically
significant gene sets reported by these methods showed little to no agreement regardless of the dataset being
used. This observation suggests that the outcome of a study can be highly dependent on the choice of the
gene set analysis method. Comparing the 100 most statistically significant gene sets also led to the same
conclusion. Furthermore, biological evaluation using a juvenile idiopathic arthritis dataset agreed with the
results of the statistical analysis. The 20 most statistically significant gene sets for some methods showed
relevance to the biology of juvenile arthritis, supporting their utility, while most methods led to results that
were irrelevant or marginally relevant to the known biology of the disease.
4.1 Introduction
High-throughput technologies have made it possible to study the expression activity of a large number of
genes in a single experiment. These technologies are commonly used to investigate the effect of different
stimuli on the expression activity of genes and detect differential expression. A typical gene expression study
may lead to reporting several hundred genes as being differentially expressed. Biological interpretation of
such an extensive list of genes is difficult. Gene set analysis, also referred to as gene set enrichment analysis,
has been widely used to alleviate this problem by detecting a concordant change in the expression pattern
of groups of genes that are known to be related to particular functions, processes, or cellular components.
Such groups of genes are known as gene sets.
Due to the lack of gold standard datasets where the enrichment status of gene sets are a priori known,
evaluation of gene set analysis methods is challenging. In the absence of such gold standard datasets,
researchers have used artificial datasets to evaluate the sensitivity and specificity of gene set analysis methods.
These datasets often rely on simplifying assumptions about the distribution of gene expression measures. Also,
they either ignore the complex gene-gene correlation pattern among genes within gene sets or model it using
a constant value [7, 16, 1], even though gene-gene correlation has been reported to have a profound impact
on the results of enrichment analysis methods [28]. Real expression datasets have also been used to evaluate
the sensitivity and specificity of gene set analysis methods [29]. Since the true enrichment status of gene sets
are not a priori known in real datasets, relying on unverified assumptions about the differential enrichment
of gene sets in these datasets does not provide an authentic framework for the evaluation of gene set analysis
methods [15]. Consequently, there is no consensus among researchers about the method to use for a given
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experimental design.
Many gene set enrichment analysis methods are available. These methods vary in their underlying sta-
tistical model and the way they quantify a change in the expression pattern of genes within a gene set. A
natural question that arises is whether the results of gene set analysis are comparable across methods. In
this research, we compare the results of 10 widely used gene set analysis methods to test if the choice of gene
set analysis method significantly affects the result of a gene expression study. In addition, since the most
statistically significant gene sets are of more value to researchers, we statistically and biologically assess the
agreement of the most significant gene sets for all methods under study.
In the rest of the paper, Section 4.2 describes the data and methodology used. Section 4.3 presents the
experimental results. The biological evaluation of the results of gene set analysis methods are presented
in Section 4.4. Section 6.4 offers insight gained from the experiments and provides suggestions for further
research. Finally, Section 6.5 ends the paper with a short summary and conclusions.
4.2 Data and methodology
4.2.1 Data
In this study, four large case-control experiments in humans from the Affymetrix GeneChip Human Genome
U133 Plus 2.0 microarray platform were selected for evaluation of gene set analysis methods. These datasets
originated from 1) renal cell carcinoma tissue and healthy controls (77 controls and 77 cases, GSE53757) [32],
2) skin from patients with psoriasis and healthy control tissue (64 controls and 58 cases, GSE13355) [27],
3) gingival tissues from healthy and diseased individuals (64 controls and 183 cases, GSE10334) [5], and 4)
blood samples from individuals with rheumatoid factor (RF)-negative polyarthritis and healthy individuals
(23 controls and 35 cases, GSE26554) [30].
The raw data were preprocessed by first reading the CEL files into R using the GEOquery version 2.46.15
R package, and generating the normalized expression table using the affy version 1.56.0 package and justRMA
normalization [10], which have been widely used for normalizing Affymetrix data [17, 33, 37]. Probe IDs were
converted to their corresponding Entrez gene identifiers using the hgu133plus2.db version 3.2.3 R package.
To avoid over-emphasizing genes with a large number of probes on the arrays, it is a common practice in gene
set analysis to collapse duplicate IDs. This was accomplished by using collapseRows from WGCNA version
1.61 with the MaxMean method. MaxMean selects the probe that has the maximum average value across
samples when multiple probes map to the same gene. Collapsing the probes resulted in 20,514 genes in each
experiment from an initial 54,675 probes.
The multidimentional scaling (MDS) plots visualizing the case and control samples from each dataset are































Figure 4.1: MDS plots for samples from the datasets under study. The MDS plots from top to bottom
are for datasets with GEO IDs GSE35757, GSE13355, GSE10334, and GSE26554, respectively.
4.2.2 Methodology
In this research, we compare 10 gene set analysis methods: PAGE [12], GAGE [13], Camera [35], ROAST [34],
FRY (from the limma package) [25], GSEA [26], ssGSEA [3], GSVA [9], PLAGE [31], and over-representation
analysis (ORA) [6].
The following R packages are utilized in this study: GSVA package version 1.18.0 is used for GSVA,
PLAGE, and ssGSEA; the phyper method from the stats package version 3.4.4 is utilized to implement
ORA; the GSEA.1.0.R script downloaded from the Broad Institute software page for GSEA provides GSEA;
the limma package version 3.34.9 is used to run Camera, ROAST, and FRY; the gage package version 2.20.1
is used for PAGE and GAGE.
In addition to a gene expression dataset, gene set analysis requires a database of gene sets as input. In
this research, we used the GO gene sets—hereafter referred to as G—extracted from MSigDB version 6.1 [26].
The GO database is widely used for gene set analysis.
For each gene expression dataset Di and method ψj , gene set analysis is conducted using the default
parameters proposed by the authors of ψj . To adjust for multiple comparisons, the Benjamini-Hochberg








(n)—the nth element of this vector—represents the adjusted p-value resulting from
gene set analysis of the nth gene set in the gene set database G using method ψj .

















represents the predicted differential enrichment status of gene sets in G—1 for differentially
enriched and 0 for non-differentially enriched—and E
ψj
Di
(n) is the nth element of E
ψj
Di
. This is accomplished
using cochran.qtest method from the RVAideMemoire R package version 0.9.69.3.
For a given dataset Di, we statistically assess whether there is a significant difference between these
predictions across different methods or not. Since the enrichment status is a dichotomous variable and there
are paired data for each gene set (enrichment status for the same gene set across methods), we conduct
Cochran’s Q test for E
ψj
Di
across all values of ψj , i.e. all methods. As post hoc analysis, Wilcoxon sign test is
conducted for pairwise comparisons if the Cochran’s Q test suggests a significant difference across methods.
Moreover, given the result of two gene set analysis methods ψj and ψk, we compare the similarity of their

















is the set of all statistically significant gene sets—i.e. gene sets with an adjusted p-value less








and SψkDi both are empty sets. In this paper, we interchangeably refer to the Jaccard index as overlap
score.
In addition, since the most statistically significant results—i.e. gene sets predicted as being differentially
enriched with the lowest p-values—are of the most interest to researchers, we investigate the agreement
among the methods regarding their most significant results. In this regard, we define S (Di, ψj , t) to be
the set of up to t statistically most significant gene sets predicted as being differentially enriched—with an
adjusted p-value less than α—when analyzing dataset Di using ψj . It should be noted that in cases where the
number of differentially enriched gene sets is less than t, S (Di, ψj , t) is equal to the entire set of differentially
enriched gene sets resulting from analysis of Di using ψj . After determining S (Di, ψj , t) for each method
ψj , we quantify the agreement of different methods for their most significant results using an overlap score
of J(S (Di, ψj , t) , S (Di, ψk, t)). In this research, we investigate agreement between the top 20 (and also the
top 100) most significant results reported by each method.
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4.3 Experimental results




differential enrichment status of gene sets in G, were determined. For each dataset Di a Cochran’s Q test
with a significance level α = 0.05 was used to statistically assess if there is a significant difference between
the differential enrichment status of gene sets in G across the methods under study. The Cochran’s Q test
for all datasets showed a statistically significant difference between the results of the methods under study
(see Tables C.1 to C.5 in the Appendix C for test results and the post hoc analysis).
Figure 4.2, using a series of triangular heat maps, illustrates the extent of overlap between the results
of the 10 gene set analysis methods for the four datasets and three different scenarios: 1) when overlap is
measured from the top 20 most significant gene sets predicted by each method, 2) when overlap is measured
from the top 100 most significant gene sets predicted by each method, and 3) when overlap is measured from
all the significant gene sets predicted by each method. Each cell in these heat maps represents the overlap
score between the results of two methods. A blue hue of a cell indicates low overlap and a red hue indicates
high overlap in enriched gene sets between two methods. The heat maps in Figure 4.2 show that, regardless
of the datasets being used, the consistency—as measured by overlap score—between the results of different
gene set analysis methods is generally low. However, as we move from scenario 1 to 3, the overlap between
the results of some of the methods increases. In some instances, such as ROAST and FRY, the amount of
overlap remains consistently high across scenarios. The consistency among methods when considering the
top 20 most statistically significant results is much lower than the consistency when considering all significant
results. This pattern is also observed when comparing the top 100 most statistically significant gene sets to
all gene sets predicted as being differentially enriched. Also, Camera and GSEA have little consistency with
all other methods under study.
Table 4.1 shows the total number of differentially enriched gene sets reported for all the datasets and
all ten methods. GSEA, Camera, and ORA predict a smaller number of gene sets as differentially enriched
compared to the other methods.
Figure 4.3 visualizes the distribution of the size of the top 20 and the top 100 most significant gene sets
predicted as being differentially enriched for each method. These box plots further highlight the difference
between the results of the gene set analysis methods. GAGE, ORA, and ssGSEA tend to report larger gene
sets, i.e. gene sets that contain higher numbers of genes, in comparison to the other methods regardless of
the dataset being analyzed.
4.4 Biological evaluation
Juvenile idiopathic arthritis (JIA) is a class of childhood arthritis with unknown cause developing before the
age of 16 years and persisting for at least 6 weeks. JIA comprises seven categories including: 1) systemic
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Figure 4.2: A set of triangular heat maps depicting the consistency of the results of gene set analysis
methods—as measured by overlap score—across databases. Each triangular heat map illustrates the
overlap score of the results of gene set analysis methods when analyzing a gene expression dataset. The
layers in the plot, from top to bottom, correspond to datasets with GEO id of GSE53757, GSE13355,
GSE10334, and GSE26554, respectively. Ranging from 0 to 1, the overlap score is represented by color
hues from blue to red, separated by yellow in the middle (overlap of 0.5). The plot suggests that there
is little consistency between the results of the gene set analysis methods under study. This lack of
consistency is more pronounced among the top 20 (left column) and top 100 (middle column) most
statistically significant results compared to all differentially enriched gene sets (right column).
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Figure 4.3: Box plots visualizing the distribution of gene set size among the top 20 (left) and top
100 (right) most statistically significant gene sets reported by each method. The plots, from top to
bottom, correspond to datasets with GEO ID of GSE53757, GSE13355, GSE10334, and GSE26554
respectively.
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Table 4.1: Number of gene sets predicted as being differentially enriched by each method for each
dataset.
GSE53757 GSE13355 GSE10334 GSE26554
FRY 4937 4876 4241 3660
GSEA 19 17 17 33
ORA 1547 573 130 222
Camera 155 73 3 313
ssGSEA 5844 5869 5862 5846
PAGE 1967 1400 1375 1054
GSVA 4730 3847 3819 2988
PLAGE 5900 5830 5242 5698
ROAST 4949 4737 4256 3380
GAGE 3951 3899 3887 2441
arthritis, 2) oligoarthritis, 3) polyarthritis rheumatoid factor (RF)-negative, 4) polyarthritis RF-positive, 5)
psoriatic arthritis, 6) enthesitis-related arthritis (ERA), and 7) undifferentiated [19]. For biological validation
of methods under study, a JIA dataset containing RF-negative polyarthritis samples and healthy controls
was obtained from the same Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray platform as
the other datasets (23 controls and 35 cases, GSE26554).
Expression profiles tend to be distinguishable among JIA categories. Gene expression and genome-
wide genotyping have identified genes associated with different JIA subtypes, particularly HLA gene com-
plex, PTPN22, PTPN2, STAT4, ANKRD55, Interleukin (IL)2-IL21, IL-2RA, IL-6, SH2B3-ATXN2, MIF,
SLC11A1 (NRAMP1 ), TNFA, TNFAIP3, TRAF1/C5, VTCN1, CCL5, CD14, and WISP3 [21, 20, 23, 14,
36, 8]. The functions of these genes are chiefly regulating production and function of inflammatory biomarkers
and their receptors. For instance, PTPN2 modulates the expression of IL-2, IL-4, IL-6, and IFN. Variants
of this gene can cause impairment in the regulation of inflammatory pathways, including joint inflammation
[11, 22, 24]. The inflammatory process is mediated by an array of innate regulators including interleukins,
chemokines, growth factors, and matrix metalloproteinases (MMPs)[18]. There has been increasing interest
in identifying molecules involved in regulating immune responses related to susceptibility to, and outcome
of, JIA.
Biological evaluation of the 10 gene set enrichment analysis methods under study was performed based
on the gene sets/pathways that are known to play a role in JIA using the dataset GSE26554 to determine
the biological relevance of the gene sets predicted as being differentially enriched.
All of the top 20 gene sets predicted as being differentially enriched by GAGE showed general relevance to
JIA. For example, the top 3 gene sets were “immune response” (GO:0006955), “regulation of immune system
process” (GO:0002682), and “immune system process” (GO:0002376). All these gene sets are relatively
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large and nonspecific to the actual disease or related pathways, with sizes approaching or exceeding 1000
genes. Several gene sets contained fewer genes, while still potentially relating to JIA, including “response to
cytokine” (GO:0034097) and “inflammatory response” (GO:0006954). Furthermore, many of the gene sets
in the top 20 predicted using GAGE had many terms relating to a general immune process or response (8 of
the top 20 gene sets predicted as being differentially enriched).
GSEA also predicted a moderate number of gene sets that are thought to play a role in JIA, but unlike
GAGE, these gene sets were much smaller and related to more specific processes. The small predicted
gene sets related to JIA included the HLA complex in the gene set “trans-Golgi network” (GO:0005802).
Other gene sets predicted as differentially enriched included “positive regulation of antigen receptor-mediated
signaling pathway” (GO:0050857), which involves the cross-linking of antigen receptors of immune cells, and
“cellular response to interferon-beta” (GO:0035458), which involves responses to a particular cytokine.
ORA also predicted a moderate number of gene sets related to cytokines, while PAGE predicted gene
sets related to immune response. The few gene sets relevant to JIA reported by ORA and PAGE were also
reported by GAGE. This agrees with our observations in Section 4.3, as the results of these three methods
moderately overlap. The other six methods produced few gene sets—among their top results—associated
with immune response or inflammation, as shown by the overlap scores (in the triangular heat maps for
dataset GSE26554) for the top 20 and top 100 most significant results reported by these methods.
4.5 Discussion
In this research, we showed that there is a significant difference between the results of ten commonly used
gene set analysis methods. We quantified the similarity between the results of the methods using Jaccard
index. Since researchers value the most statistically significant results, we studied the distribution of gene
set size for the top 20 and top 100 most significant results of each method.
The results showed that ROAST and FRY share the same top 20 and top 100 significantly enriched gene
sets. This is expected as FRY was designed to be a computationally efficient approximation of ROAST. Also,
there are moderate overlaps between the top 20 (and top 100) most significant results reported by ORA,
GAGE, and PAGE. This similarity can be explained as all three of these methods are parametric gene set
analysis methods; ORA and GAGE are based on two-sample t-tests, and PAGE is based on a z-score. These
observations support the validity of the experimental design in this research.
When considering all gene sets predicted as being differentially enriched, there are moderate to high
overlaps between the results of all methods, with the exception of ORA, Camera, and GSEA. These high
overlaps appear to be a consequence of the high number of gene sets reported as being differentially enriched.
As seen by combining the results in Figure 4.2 and Table 4.1, two methods with high overlap between
their results also report a high number of gene sets as being differentially enriched. This happens when
some methods report a large proportion of gene sets as being differentially enriched. At the extreme, if two
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methods report all gene sets, the overlap will be its maximum value, i.e. 1. However, as also depicted in
Figure 4.2, there is no or very small overlap between the top 20 (and top 100) differentially enriched gene sets
reported by methods that achieve high overlap scores when considering all of their significant results. These
observations suggest that the methods under study generally do not agree in the gene sets they reported as
most statistically significant.
The high numbers of reported differentially enriched gene sets (for some methods) are not an artifact of
the choice of the expression datasets or the preprocessing steps. Single gene expression analysis reported that
GSE53757 had 571 differentially expressed genes, GSE13355 had 121, GSE10334 had 12, and GSE26554 had
5 differentially expressed genes. These results were produced using the limma package with a log fold change
cutoff of ±2, a Benjamini-Hochberg correction for multiple comparisons, and a significant level α = 0.05.
The number of differentially enriched gene sets reported by ORA and Camera, compared to all other
methods under study, seem to be more sensitive to the variation between the case and control groups of each
dataset (see Figure 4.1). For the datasets that have more distinct groups, more gene sets are reported as
differentially enriched. When the variation is low, ORA—for example—predicts fewer differentially enriched
gene sets. One explanation is that the list of genes predicted as being differentially expressed, an input to
ORA, is based on a t-test. The t-test statistic denominator represents the variance of expression measures
for a gene, and when the sample variation is high, as with GSE10334, the statistic value decreases and the
derived p-value increases; this results in a small number of differentially expressed genes. This, in turn,
decreases the number of differentially enriched gene sets reported by ORA.
GSEA and Camera typically report a small number of differentially enriched gene sets for each data set.
Since the number of reported differentially enriched gene sets is small, these methods have a very small
overlap with the results of other methods and also to each other.
Gene sets extracted from GO are associated with GO terms, where the more general terms usually
correspond to larger gene sets, and specific terms correspond to smaller gene sets. As depicted in Figure 4.3,
for the 20—and also top 100—most statistically significant gene sets reported, ORA, GAGE, PAGE, and
ssGSEA tend to report gene sets with larger sizes. Although there could be cases where a gene set with
a large size is associated with a phenotype of interest, these three methods consistently report larger gene
sets across the datasets compared to the other methods. This may be a sign of systematic bias in favour of
large gene set sizes, which are usually less informative. With ORA in particular, the amount of variation
between gene set sizes tends to be high as well; also, the median gene set size is typically higher than all
other methods. On the other hand, reported gene sets by GSEA have a low median size, although variation
between sizes is larger than some of the other methods such as Camera, FRY, ROAST, and GSVA. This is
because GSEA reports a mixture of small gene sets followed by large gene sets in the top 20 and 100 results.
Camera also reports a small number of gene sets, usually with small sizes. PLAGE, FRY, ROAST, and
GSVA—on the other hand—report a large number of gene sets as differentially enriched but, like Camera,
their most significant gene sets have small sizes. This could suggest that the reported gene sets are very
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specific to a particular biological process, molecular function, or cellular component. However, this does not
necessarily mean these gene sets are biologically informative to the phenotype under study. To assist with
interpreting these results, the relevancy of the most significant genes sets for the JIA dataset was explored
by biological interpretation.
The biological evaluation in Section 4.4 suggests that GAGE performed the best followed by GSEA,
ORA, and PAGE at predicting the most gene sets that were relevant to the phenotype of interest. This is
on par with the overlap scores where GAGE achieved moderate overlap scores with ORA and PAGE. GSEA
reports a small number of gene sets as being differentially enriched and therefore achieves low overlap scores
with other methods. However, some of its reported gene sets showed relevance to specific immune system
processes, which could be more informative compared to some of the more general gene sets reported by
GAGE, ORA, and PAGE. We suggest that these results be confirmed further with validation performed on
a wide variety of datasets to ensure the results are not dataset or phenotype dependent.
These observations further highlight the lack of agreement between the results of gene set analysis methods.
Our results support the utility of methods such as GAGE, GSEA, ORA, and PAGE in gaining biological
insight. Drawing a conclusion based on the results of the other methods, even their most significant results, is
more challenging and prone to investigator bias toward a hypothesis of interest. This is even a more serious
problem for methods that report a large number of gene sets as being differentially enriched. Since it is
unlikely for a living organism to undergo such a dramatic change involving several thousand gene sets, this
can be interpreted as the lack of specificity, i.e. incorrectly reporting a large number of gene sets as being
differentially enriched. We suggest developing methods with higher specificity without sacrificing sensitivity
as future research.
Often, it is the case that researchers studying the same phenomenon come up with different results (e.g.
different implicated gene sets) even though they appear to have each followed a valid methodology. We are
left searching for an explanation for the difference in results. Since our study shows that there is a lack of
consistency between the results of gene set analysis methods, part of the explanation could be using different
gene set analysis methods, if different gene set analysis methods were used.
4.6 Conclusion
In this paper, we studied the consistency of the results of ten commonly used gene set analysis methods when
applied to real expression datasets. The data analysis showed that there is a significant difference between
the results of these methods. Our study suggests that not only do these methods differ in the gene sets
reported as being differentially enriched, but they also differ in the distribution of the size of the reported
gene sets. Further, there is little to no overlap between the results of top 20 (and top 100) most statistically
significant gene sets reported, except between FRY and ROAST.
The biological validation of the most significant results using a JIA dataset revealed that GAGE performs
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the best followed by GSEA, ORA, and PAGE at predicting the most gene sets relevant to the phenotype of
interest. The biological evaluation of the most significant results reported by the gene set analysis methods
revealed that the majority of the methods reported gene sets that are not related to the known biology of
JIA. GAGE was the only method with all of its top 20 gene sets relevant to the biology of juvenile arthritis.
In addition, GSEA, ORA, and PAGE reported relevant gene sets, with GSEA reporting fewer but more
specific gene sets. This supports the utility of these methods for gene set analysis. However, any more
general conclusion would require a broader study incorporating datasets from various phenotypes.
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5 Gene Set Overlap: An Impediment to Achieving
High Specificity in Over-representation Analysis
Often, gene set analysis leads to predicting a large number of biologically irrelevant or uninformative
gene sets as being differentially enriched [40]. This makes gaining biological insight from the results of gene
set analysis difficult. It also may lead to a biased interpretation of the results in favour of a hypothesis of
interest. This chapter presents a study of gene set overlap and its effect on over-representation analysis. We
quantify gene set overlap, show that it is a ubiquitous phenomenon across gene set databases, and assess its
effect on the specificity of over-representation analysis. Particularly, we assess the hypothesis that there is a
significant correlation between gene set overlap and specificity of over-representation analysis.
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Abstract
Gene set analysis methods are widely used to analyze data from high-throughput “omics” technologies. One
drawback of these methods is their low specificity or high false positive rate. Over-representation analysis is
one of the most commonly used gene set analysis methods. In this paper, we propose a systematic approach to
investigate the hypothesis that gene set overlap is an underlying cause of low specificity in over-representation
analysis. We quantify gene set overlap and show that it is a ubiquitous phenomenon across gene set databases.
Statistical analysis indicates a strong negative correlation between gene set overlap and the specificity of over-
representation analysis. We conclude that gene set overlap is an underlying cause of the low specificity. This
result highlights the importance of considering gene set overlap in gene set analysis and explains the lack of
specificity of methods that ignore gene set overlap. This research also establishes the direction for developing
new gene set analysis methods.
5.1 Introduction
High-throughput “omics” technologies have been widely used to investigate biological questions that require
screening of a large number of biomolecules. The main challenge facing these technologies is analyzing the
generated data to gain biological insight. An RNA-Seq experiment, for example, may suggest several hundred
genes as being differentially expressed. Manual interpretation of such a large set of genes is impractical and
susceptible to investigator bias toward a hypothesis of interest.
Gene set analysis is a well-established computational approach to gain biological insight from data result-
ing from high-throughput gene expression experiments [22]. It relies on the assumption that most biological
processes are the consequence of a coordinated activity of a group of genes. Therefore, the primary goal
of gene set analysis is to detect concordant changes in expression patterns of predefined groups of genes,
referred to as gene sets. Members of a given gene set often share a common biological function or attribute.
MSigDB [29], GeneSigDB [11], GeneSetDB [3], Go-Elite [45], and Enrichr [27] are among the most widely used
gene set databases. These databases have been generated from various sources including GO [4], KEGG [26],
Reactome [25], and BioCarta [34].
Often gene set analysis methods report a large number of gene sets as being differentially enriched, where
the majority of the reported gene sets are biologically irrelevant or uninformative [40]. The rapid growth
of the size of gene set databases is intensifying this issue. Consequently, gaining biological insight from
the results of gene set analysis is becoming more challenging and prone to investigator biases in favour of
a hypothesis of interest. For example, Araki et al. used GeneSetDB to analyze a list of 79 differentially
expressed Affymetrix probe sets [3] resulting from an experiment where endothelial cells were induced to
undergo apoptosis [24]. After correction for multiple hypothesis testing, they reported 1694 gene sets as
statistically significant, i.e. differentially enriched. Interpreting this large number of gene sets is challenging.
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Understanding the factors contributing to low specificity in gene set analysis helps in choosing methods
that are more robust against these factors. Such an understanding also facilitates interpreting the results of
gene set analysis methods and accelerates the development of new methods that address these contributing
factors to achieve higher specificity without sacrificing sensitivity and accuracy.
Specificity of gene set analysis methods in the absence of differential expression of genes has been studied.
Tarca et al. [40] investigated the specificity of sixteen gene set analysis methods in the absence of differential
expression and showed that even when there is no differential expression, some gene set analysis methods
produce a large number of false positives. However, their approach cannot be used to assess the specificity
of a gene set analysis method in the presence of differentially expressed genes.
Overlap between gene sets has been suggested as being responsible for the low specificity of gene set
analysis methods. To deal with overlap between gene sets, PADOG [41] assigns lower weights to genes that
belong to more than one gene set. For a given gene g, this weight is negatively correlated with the number
of gene sets containing g. TopGO [2] is another attempt to deal with gene set overlap. It considers that
Gene Ontology (GO) terms are organized as a directed acyclic graph encoding a hierarchy of general-to-
more-specific terms. This structure leads to commonality between the genes corresponding to a child node
and those of its parent(s). TopGO proposes a gene elimination and a gene down-weighting procedure to
decorrelate the GO graph structure resulting from these relations. MGSA [6] utilises a Bayesian approach
that considers the overlap between GO categories to reduce the number of false positives. SetRank [38] is
another attempt at reducing the number of false positives by considering the overlap between gene sets.
Parallel to the development of gene set analysis methods, various gene set databases have been developed.
The prevailing trend in developing gene set databases has been introducing more gene sets and increasing
database size. Figure 5.1 illustrates the growth of MSigDB across its versions. This gene set database has
been designed for gene set analysis in human, and its current version includes gene sets from various sources
such as GO, KEGG, Reactome, and BioCarta. This gene set database has undergone a 13-fold increase in
the number of gene sets compared to its first version. Given the limited number of known genes for human,
this steep growth leads to an increase in the number of gene sets overlapping with each other.
The MSigDB Hallmark gene set collection is an attempt to reduce gene set overlap by computational and
manual curation of gene sets from MSigDB. However, this collection currently (version 6.2) only includes 50
gene sets [28]. “Enrichment Map” is another approach of dealing with gene set overlap using a network-based
visualization approach [31]. To the best of our knowledge, there is no systematic study of the effect of gene
set overlap on the results of gene set analysis. In this paper, we investigate the hypothesis that gene set
overlap plays a prominent role in the lack of specificity of over-representation analysis (ORA), which is one
of the most widely used gene set analysis methods [15].
The rest of the paper is organised as follows. In Section 5.2, we briefly describe ORA. In Section 5.3, we
show that gene set overlap is a ubiquitous phenomenon in gene set databases; we use quantitative measures
to visualize gene set overlap in GeneSetDB [3], GeneSigDB [12], and MSigDB [29], which are well-established
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Figure 5.1: The number of gene sets in different versions of MSigDB
gene set databases. In Section 5.4, using these quantitative measures, we introduce a methodology to study
the effect of gene set overlap on the specificity of ORA. In Section 5.5, we describe the experimental results;
using the methodology introduced in Section 5.4, we statistically investigate the effect of gene set overlap on
the specificity of ORA by assessing the correlation between gene set overlap and specificity. In Section 6.4,
we discuss the implication of gene set overlap and the challenges it entails. We also provide suggestions
for developing and evaluating gene set analysis methods. Finally, Section 6.5 offers a short summary and
conclusion.
5.2 Over-representation analysis
Many algorithms have been proposed and used for gene set analysis, of which ORA is one of the most widely
used. Due to its simplicity, well-established underlying statistical model, and ease of implementation, ORA
is available through many tools [7], [8], [10], [23], [30], [42], [43], [44], [46], [47], [48]. This method defines
a concordant change in expression pattern of members of a given gene set as a change that is unlikely to
happen by chance. It also quantifies the concept of change as the number of differentially expressed genes in
a pairwise comparison of phenotypes, e.g. “cancerous” versus “non-cancerous”.
ORA can be outlined as follows [16]. Suppose that data analysis for an experiment using a high-throughput
technology predicts a set of differentially expressed genes L, and that the intersection of L and a given gene
set Gi contains n
′
i genes. In addition, assume that the set of background genes, i.e. all genes with a non-
zero probability of being differentially expressed, contains n genes. For example, the background genes in a
microarray study can be the set of all genes represented on the arrays. Denote the background set as U . Let
Gi refer to the complement of Gi with respect to U , i.e. all genes in U but not in Gi. Given L, Gi, and U ,
ORA assesses whether the number of differentially expressed genes in Gi is more than what it should be just
by chance, i.e. it is over-represented. Table 5.1 represents ORA as a contingency table, where ‖ • ‖ is the
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Table 5.1: Representation of ORA as a contingency table. Each cell contains a count of genes
satisfying the condition given by the row and column.
Genes ∈ L Genes /∈ L Total
Genes ∈ Gi n′i ‖Gi‖ − n′i ‖Gi‖
Genes ∈ Gi ‖L‖ − n′i (n− ‖Gi‖) -(‖L‖ − n′i) n− ‖Gi‖
Total ‖L‖ n− ‖L‖ n
cardinality operator.
Assuming that genes are selected using a simple random sampling approach, ORA can be modeled using a
hypergeometric distribution [16]. Accordingly, the probability of having n′i genes from Gi among differentially
expressed genes, i.e. L, is as follows:







In addition, Fisher’s exact test can be used to examine the significance of the association between genes in








f(j;n, ‖Gi‖, ‖L‖) (5.2)
5.3 Overlap in gene set database
ORA, as with other gene set analysis methods, relies on availability of a gene set database. Gene set
databases are developed by collecting genes that are manually or computationally inferred to share a common
biological function or attribute. The availability of a priori knowledge through public repositories such as
GO [4], KEGG [26], and OMIM [21] makes it possible to develop gene set databases. There are many
publicly available gene set databases including L2L [33], SignatureDB [36], CCancer [13], GeneSigDB [12],
GeneSetDB [3], and MSigDB [29]. The latter three are widely used for gene set analysis.
MSigDB is the gene set database integrated with GSEA [39]. MSigDB acquires gene sets through manual
curation and computational methods [29]. As a meta-database, MSigDB extracts gene sets from several
sources including GO [4], KEGG [26], Reactome [25], and BioCarta [34].
GeneSigDB is another database of gene sets extracted from published experimental expression studies of
genes, proteins, or miRNAs. GeneSigDB relied on PubMed searches to collect papers relevant to a set of
search terms mainly focused on cancer, lung disease, development, immune cells, and stem cells. To develop
the database, the authors downloaded the relevant papers and then manually transcribed gene sets from
them or their supplementary documents.
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Figure 5.2: A hypothetical example: gene set overlap leading to lack of specificity of ORA. Each
circle represents a gene set. Rectangles coloured in red and white represent differentially expressed
and non-differentially expressed genes, respectively. Gene set B (and also C) is predicted as being
differentially enriched by ORA solely due to partial overlap with A, a truly differentially enriched gene
set.
GeneSetDB, as another meta-database, is a collection of 26 public databases focused on pathways, phe-
notypes, drugs, gene regulation, or Gene Ontology. The primary focus of GeneSetDB is human, although it
supports mouse and rat using computationally inferred homology [3].
5.3.1 Gene set overlap and ORA: A hypothetical example
To show how overlap of gene sets can affect the results of ORA, in this section we present a hypothetical
example. Suppose that in a high-throughput experiment, the expression activity of 10000 genes has been
measured. After conducting the experiment and performing single gene analysis, 100 genes have been pre-
dicted as being differentially expressed. Consider gene sets A, B, and C as illustrated in Figure 5.2, where
gene sets are depicted as circles, and genes belonging to each gene set are depicted as rectangles. In each
gene set, genes predicted as being differentially expressed are coloured in red and the rest of the genes are
coloured in white. As shown in Figure 5.2, all genes in A have been predicted as being differentially expressed.
Table 5.2 illustrates the contingency table for over-representation of B.
Table 5.2: The contingency table for the over-representation of B. DE stands for differentially
expressed and Non-DE stands for non-differentially expressed.
DE Genes Non-DE Genes Total
Genes in B 2 18 20
Genes not in B 98 9882 9980
Total 100 9900 10000
According to Fisher’s exact test, B is predicted as being differentially enriched with a 95% confidence
level (p-value = 0.0167). This result is primarily due to the overlap between A and B. This example suggests
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that gene set overlap can lead to a lack of specificity in gene set analysis methods.
In this paper, we use GeneSigDB version 4, GeneSetDB for Human (downloaded on February 2, 2018),
and MSigDB version 6.0, unless stated otherwise.
5.3.2 Measuring gene set overlap
To study gene set overlap and its effect on the specificity of ORA, we use the Jaccard coefficient to quantify
the overlap between two gene sets. We then use this quantitative measure to visualize gene set overlap in
MSigDB, GeneSetDB, and GeneSigDB.




The Jaccard coefficient is a value between 0 and 1, where J(A,B) = 0 means that there is no overlap between
A and B; J(A,B) = 1 means that there is a complete overlap between A and B, i.e. A = B; and other
values (0 < J(A,B) < 1) represent partial overlaps between A and B. The Jaccard index can be used to
quantify the overlap between two sets; for example, it can be used to measure the overlap between two gene
sets from a gene set database or the overlap between a gene set and a set of differentially expressed genes
resulting from a gene expression study. Hereafter, we refer to Jaccard index as overlap score.
For a given set of genes Li and a gene set database G, we define the overlap coefficient, or overlap score,





This measure is representative of the cumulative overlap of Li with all gene sets in the gene set database G.
For the sake of brevity, whenever gene set database G can be inferred from the context, we use the phrase
“overlap score of Li” to refer to O(Li,G). Note that O(Li,G), which is the summation of overlap between
Li and each gene set in the gene set database G, should not be mistaken with overlap between two sets of
genes. The latter is calculated using the Jaccard index (Equation 5.3).
5.3.3 Visualization of gene set overlap
Graph-based visualizations have been used to facilitate the interpretation of gene set analysis results [9, 31].
We also visualize a gene set database as a graph, where each gene set Gi is represented as a vertex vi,
and there is an edge between two vertices vi and vj if J(Gi, Gj) > 0; the value of J(Gi, Gj) is used as the
weight for this edge. Since the Jaccard coefficient is symmetric, the graph defined using this measure is an
undirected graph. Due to the sheer number of overlapping gene sets, such a graph has a large number of
edges. To visualize substantial overlaps between gene sets, we only show overlap scores greater than or equal
to 0.5, while retaining all vertices. In other words, in all graph visualizations in this paper, an edge between
two vertices vi and vj indicates that their corresponding gene sets, i.e. Gi and Gj , share at least half of
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Figure 5.3: The graph representing the overlap between gene sets in MSigDB. In this graph, each
vertex represents a gene set in MSigDB, and each edge represents an overlap with Jaccard coefficient
greater than or equal to 0.5 between two gene sets (see Equation 5.3). The “hairball” is the result of
a large number of gene sets with a substantial overlap (≥ 0.5) with each other.
their genes. The “hairballs” in Figure 5.3 and also Figures D.1 and D.2 (in the Appendix D) are due to
the existence of a large number of edges, i.e. pairs of gene sets with a substantial amount of overlap. These
graphs highlight the existence of gene set overlap as a ubiquitous phenomenon in gene set databases. The
graph visualization can be generated using Fruchterman Reingold layout [19] in Gephi (version 0.9.2) [5].
To further visually inspect the gene set overlap in a given gene set database G, we use a frequency plot.
For each gene set Gi in G, we calculate fi = ‖{Gj | J(Gi, Gj) > 0 (j 6= i) and Gj ∈ G}‖. fi is the number
of gene sets Gj (j 6= i) in G with a non-zero overlap with Gi. After calculating fi values for all Gi in G, we
use a frequency plot to show the distribution of fi values. Figure 5.4 and also Figures D.3, and D.4 (in the
Appendix D) illustrate the distribution of fi values for MSigDB, GeneSetDB, and GeneSigDB, respectively.
These figures are in agreement with Figure 5.3, D.1, and D.2 and show the prevalence of gene set overlap in
the aforementioned gene set databases.
Figure 5.4 suggests that overlap scores in MSigDB follow a multimodal distribution. This can be attributed
to the fact that MSigDB is a meta-database that extracts gene sets from several sources including GO, KEGG,
Reactome, and BioCarta. A compelling result revealed by Figure 5.4 is that majority of gene sets in MSigDB
have at least a non-zero overlap with more than 1000 other gene sets in MSigDB (out of a total of 17778 gene
sets). Also, there is no gene set in MSigDB without overlap with some other gene set(s). Finally, there are
gene sets that overlap with the majority of gene sets in MSigDB. For example, the gene set associated with
the “cellular response to organic substance” GO term (GO:0071310) has one non-zero overlap with 17292

















Figure 5.4: A frequency plot for fi values in MSigDB illustrates the prevalence of gene set overlap.
For each gene set Gi in a gene set database G (MSigDB here), fi is the number of gene sets Gj (j 6= i)
in G with J(Gi, Gj) > 0.
sets including the gene sets defined using relatively more specific GO terms.
5.4 Methodology
Evaluation of ORA using a quantitative measure such as specificity requires a gold standard dataset for which
the differentially enriched gene sets are a priori known. Such a gold standard does not exist. In this section,
we propose a methodology for a quantitative evaluation of the effect of gene set overlap on the specificity of
ORA in the absence of such a gold standard dataset.
To perform ORA, a single gene analysis method must be conducted to predict the set of differentially
expressed genes. This set serves as one of the inputs to ORA. In practice, often noise and biological variability
introduce errors—i.e. false positives and false negatives—in the result of single gene analysis. In the context
of single gene analysis, false positives are genes that are not differentially expressed but predicted as being
so, and false negatives are genes that are differentially expressed but predicted as not being such. False
negatives in single gene analysis may reduce the sensitivity of ORA, while false positives may reduce the
specificity. To avoid the interference of the single gene analysis errors in the study of gene set overlap and its
effect on the specificity of ORA, we assume that differentially expressed genes have been identified correctly;
also, this is the same assumption that ORA relies on. Therefore, to perform the quantitative evaluation, a
scenario in which all genes in a given gene set have been accurately detected as being differentially expressed
is considered.
To deal with the absence of a gold standard dataset, in this paper the following procedure is used to
identify the true enrichment status of gene sets. Given a gene set database G = {Gj | 1 ≤ j ≤ m} and Li,
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a set of differentially expressed genes, and a fixed parameter γ, for each gene set Gj ∈ G we consider Gj
as being truly differentially enriched if at least 100 × γ percent of its members are differentially expressed
genes, i.e.
‖Gj∩Li‖
‖Gj‖ ≥ γ. Otherwise, Gj is considered as not being truly differentially enriched. γ serves as
a threshold; since there is no consensus about such a threshold value, we repeat the main experiments for a
wide range of values for γ, and we show that regardless of the value chosen for γ the results are consistent.
In the rest of the paper, the set of truly differentially enriched and truly nondifferentially enriched gene sets
are denoted by T+i (γ) and T
−
i (γ), respectively, and are defined as follows:
T+i (γ) = {Gj ∈ G |
‖Gj ∩ Li‖
‖Gj‖ ≥ γ} (5.5)
T−i (γ) = {Gj ∈ G |
‖Gj ∩ Li‖
‖Gj‖ < γ} (5.6)
Hereafter, for the sake of brevity, we avoid writing the parameter γ; for example, we refer to T+i (γ) and





Given γ and Li, Equations 5.5 and 5.6 determine the true enrichment status of all gene sets in G. Knowing
the true enrichment status of gene sets, we run ORA. The parameters (inputs) for running ORA are: a list
of differentially expressed genes Li, a significance level α, a background set U , and a gene set database
G = {Gj : 1 ≤ j ≤ m}.
In this research, the experiments were conducted using python version 3.6.2. To implement ORA, the
fisher exact method from the stats module of scipy version 0.19.1 was used. Also, the Benjamini-Hochberg
FDR adjustment for multiple comparisons was performed using the multipletests method (with method
parameter equal to fdr bh) from statsmodels version 0.8.0.
For each gene set Gj in G, ORA calculates a p-value pj . After calculating p1, . . . , pm—the p-values
corresponding to the over-representation of gene sets G1, . . . , Gm in G according to Equation 5.2—the Ben-
jamini-Hochberg FDR adjustment [14] for multiple comparisons is applied. All gene sets with an adjusted
p-value less than α are predicted as significant, i.e. being differentially enriched. G+i is defined as the set of
all such significant gene sets. G+i includes both true positives and false positives. G
−
i is defined as the set of
all nonsignificant gene sets, i.e. G−i = G−G+i . G−i includes both true negatives and false negatives. For the
given value of γ, true positives (TPi), false positives (FPi), true negatives (TNi), and false negatives (FNi)








FNi = G−i − T−i (5.10)





To be able to gain insight that is unbiased toward a single set Li, this process is repeated many times, each
time with a different Li. We denote the set of all Li as L = {Li | 1 ≤ i ≤ l}.
Algorithm 1 (see the Appendix D) illustrates the methodology for conducting the experiment. In each
iteration of the algorithm, i.e. the outer loop, a gene set Li from L is used, and the process is repeated for
all gene sets in L. In addition, for each set Li ∈ L, the overlap score of Li with respect to gene set database
G, i.e. O(Li,G), is calculated according to Equation 5.4. Having overlap score and specificity measure for
each Li ∈ L, the relationship between overlap and the specificity of ORA can be assessed using statistical
methods (see Section 5.5).
5.5 Experimental results
To study the effect of gene set overlap on the specificity of ORA using Algorithm 1, MSigDB—one of the
most widely used gene set databases devoted to gene set analysis—was used as the gene set database G.
Since ORA requires a list (set) of differentially expressed genes as input, Algorithm 1 requires a collection of
such lists (denoted as L in the algorithm). ImmuneSigDB [20] version 6.0 was used to provide such a collec-
tion. ImmuneSigDB contains lists of differentially expressed genes, each created by identifying differentially
expressed genes in a dataset extracted from Gene Expression Omnibus (GEO) [17]. Therefore, each list in
ImmuneSigDB represents a set of differentially expressed genes derived from a high-throughput study.
To investigate the association between gene set overlap and the specificity of ORA results, first the
overlap score O(Li,G) was calculated for each list Li in ImmuneSigDB. In this experiment, a significance
level α = 0.05 and γ values equal to 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 0.99 were used. For each
value of γ, Algorithm 1 was run to calculate SPCi corresponding to each Li ∈ L. Figure 5.5 illustrates
the relationship between gene set overlap and the number of false positives for γ = 0.5. As overlap score
increases, we observe an increase in the number of false positives and therefore a decline in the specificity.
We observed the same pattern for all the aforementioned values of γ.
To study the relationship between gene set overlap and the specificity of ORA, we used a statistical test
of correlation. Choosing a proper test of correlation requires assessment of the normality assumption. To
test the null hypothesis that specificity values are normally distributed, we used the Shapiro-Wilk test [37].
Table D.1 shows the test results for the aforementioned values of γ. Considering those results, as confirmed
by the histogram in Figure D.5 (see Appendix D), we concluded that specificity values are not normally
distributed. Therefore, a Spearman’s rank correlation coefficient test, a nonparametric test, was conducted
for each value of γ to test the null hypothesis that there is no correlation between specificity and overlap
scores. Table 5.3 shows the result of this test for various values of γ. Considering these results, we concluded
that there is a strong negative correlation between gene set overlap and specificity of ORA.
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Figure 5.5: Number of false positives increases as overlap score increases (γ = 0.5). A similar pattern
was observed for other values of γ.














In this research, we proposed a systematic approach for evaluating the specificity of over-representation
analysis. Using the proposed method, we demonstrated that there is a significant negative correlation between
the specificity of ORA and gene set overlap. In other words, gene set overlap increases the number of false
positives, i.e. gene sets incorrectly predicted as being differentially enriched. The increase in the number
of false positives makes interpreting the results of ORA difficult and prone to investigator biases toward a
hypothesis of interest. It also hinders reproducibility of gene set analysis results.
We also showed that gene set overlap is a ubiquitous phenomenon across gene set databases. The ex-
istence of multifunctional genes is one contributor to this phenomenon. Multifunctional genes are genes
associated with several molecular functions or biological processes; therefore, they appear in several gene
sets, contributing to gene set overlap. Multifunctional genes are commonplace; for example, Pritykin et
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al. [35] identified 2517 multifunctional genes in the human genome. As a consequence, gene set overlap is
an integral characteristic of gene set databases. Another factor contributing to the prevalence of gene set
overlap in databases that define some (or all) of their gene sets based on GO is the child-parent relationship
between GO terms. GO terms are organized as a directed acyclic graph; each node represents a GO term;
and each edge between two nodes represents a parent-child relationship between terms, with the child term
being more specific than its parent term(s). Therefore, gene sets derived from GO terms that are involved
in such child-parent relationships share common genes; this, in turn, contributes to the existence of gene set
overlap.
Being an integral part of gene set databases, gene set overlap should be considered in the design and
evaluation of gene set analysis methods. However, many gene set analysis studies have used simulated
collections of non-overlapping gene sets for method evaluation and comparison [1], [18], [32]. Therefore, gene
set overlap and its effect on the outcome of gene set analysis methods have been overlooked. We suggest
using datasets that account for overlap as a requirement in the evaluation of gene set analysis methods.
Although many gene set analysis methods and tools have been developed, there are very few methods
that consider gene set overlap. For example, PADOG is an attempt for addressing gene set overlap that leads
to a small number of false positives (has high specificity), but its sensitivity has been reported to be lower
than that of other gene set analysis methods (see Table S2 from the work by Tarca et al., 2013). SetRank
is another gene set analysis method designed with gene set overlap in mind to increase specificity [38]. The
authors of SetRank claimed that due to a lower number of false positives, the significant results reported by
this method are more reliable than other methods. Therefore, it may be a viable solution for the lack of
specificity of gene set analysis methods. A rigorous evaluation of the specificity and sensitivity of this method
is suggested as future research.
The existence of gene set databases that accurately represent biological processes and functions is essential
to the success of gene set analysis. Increasing the size of gene set databases by depositing more gene sets
has been the common trend in developing gene set databases. The increase in the number of gene sets has
introduced more gene set overlap, which in turn leads to a higher false positive rate. There is a need to focus
on quality rather than sheer quantity in developing gene set databases. We suggest further research on the
quality control of gene set databases.
Another suggestion for improving the specificity of current methods is to exclude irrelevant or uninfor-
mative gene sets before conducting gene set analysis. Considering the size of gene set databases, filtering
these gene sets is laborious and, if done manually, prone to investigator bias toward gene sets considered
“relevant”. Developing a computational approach for filtering irrelevant or uninformative gene sets would be
worthwhile.
In the proposed method for evaluating ORA, we considered scenarios with only one differentially enriched
gene set. In practice, a specific phenotype may be the result of altering several biological processes or
functions, i.e. multiple gene sets. We expect that the differential enrichment of several gene sets intensifies
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the extent to which gene set overlap reduces specificity. In other words, we expect to see a larger number
of false positives compared to the situation considered in this work. The proposed method is capable of
handling scenarios with several differentially enriched gene sets. Also, Algorithm 1 can be used seamlessly
with sensitivity or accuracy instead of specificity.
Since the input to ORA is a list of differentially expressed genes, we utilized ImmuneSigDB [20] for
evaluating ORA. However, some gene set analysis methods require an expression matrix that represents
expression level of genes under study across control and case samples. The proposed methodology is capable
of evaluating such gene set analysis methods. To do so, the only requirement is developing expression profiles
with the differentially enriched gene set(s) encoded in expression values. Therefore, our methodology can
be used as a systematic approach to study specificity, sensitivity, and accuracy of other gene set analysis
methods. For example, we suggest the study of the relationship between gene set overlap and the specificity
of GSEA [39], which is another well-established gene set analysis method, as future work.
In the absence of gene set overlap, gene set analysis is a trivial problem, as many methods have achieved
high specificity when being evaluated (by their authors) using simulated gene set databases with non-
overlapping gene sets. If gene set overlap was considered in the evaluation of these methods, the lack of
specificity of many gene set analysis methods would be obvious. For example, assume a gene set analysis
method that uses average expression value of genes within a gene set (in control versus case samples) to
predict the enrichment status of a gene set. Also assume that there is a single differentially expressed gene
that appears in 100 gene sets. Such a method would report all 100 gene sets as being differentially enriched,
while most of these gene sets might be biologically irrelevant. Therefore, we strongly recommend considering
gene set overlap in any attempt for evaluating gene set analysis using simulated data.
5.7 Conclusion
In this paper, we proposed a systematic approach to study the effect of gene set overlap on the result of
ORA (over-representation analysis). Using the proposed method and statistical analysis, we showed that
there is a significant negative correlation between gene set overlap and specificity of ORA. We quantified
gene set overlap and showed that it is a ubiquitous phenomenon across gene set databases. The proposed
approach for the study of the relationship between gene set overlap and specificity of ORA can easily be
used to investigate the effect of gene set overlap on different gene set analysis methods using quantitative
measures such as specificity, sensitivity, and accuracy.
Considering the effect of gene set overlap on the results of ORA, it is essential to develop and use methods
that address gene set overlap and achieve higher specificity without sacrificing sensitivity in the prediction of
differentially enriched gene sets. Due to the lack of gold standard datasets, where the differentially enriched
gene sets are known a priori, simulated datasets have been widely used for evaluation of gene set analysis
methods. The databases used in these studies are often a collection of non-overlapping gene sets of the same
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size. This setting is substantially different from a real gene set database where gene set overlap is common.
By completely ignoring gene set overlap, some methods achieve high specificity on simulated data but behave
inadequately when working in real settings. We strongly recommend that the use of non-overlapping datasets
be avoided for evaluation of gene set analysis methods.
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6 Silver: Forging Almost Gold Standard Datasets
for Evaluation of Gene Set Analysis Methods
Despite the existence of many studies comparing gene set analysis methods, there is no consensus re-
garding the method of choice for a given experiment, and existing guidelines and suggestions are most often
contradictory [12] (See Appendix A for examples of such inconsistent and contradictory guidelines and rec-
ommendations). In view of these inconsistencies, it is necessary to identify and tackle obstacles leading to
such disagreements. The lack of gold standard datasets is one of the main factors that prevents researchers
from a sound and unbiased evaluation of gene set analysis methods. In the absence of gold standard datasets,
where the differential enrichment status of gene sets are known prior to conducting gene set analysis, both
simulated and real datasets have been used. In this paper, we discuss the shortcomings of the available
approaches for evaluation of gene set analysis methods and propose a framework for evaluation of gene set
analysis methods. This paper built on top of the methodology we published earlier (see reference below) for
simulating kinome microarray data.
Maleki, F., & Kusalik, A. (2015). A Synthetic Kinome Microarray Data Generator. Microarrays, 4(4),
432-453.
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Abstract
Gene set analysis has been widely used to gain insight from high-throughput expression studies. Although
various tools and methods have been developed for gene set analysis, there is no consensus among researchers
regarding best practice(s). Most often, evaluation studies have reported contradictory recommendations of
which methods are superior. Therefore, an unbiased quantitative framework for evaluation of gene set analysis
methods is valuable. Such a framework requires gene expression datasets where enrichment status of gene sets
is a priori known. In the absence of such gold standard datasets, artificial datasets are commonly used for
evaluation of gene set analysis methods; however, they often rely on oversimplifying assumptions that make
them biased in favour of or against a given method. In this paper, we propose a quantitative framework for
evaluation of gene set analysis methods by synthesising expression datasets using real data without relying
on oversimplifying and unrealistic assumptions while preserving complex gene-gene correlations and retaining
the distribution of expression values. The utility of the quantitative approach is shown by evaluating ten
widely used gene set analysis methods. An implementation of the proposed method is publicly available.
6.1 Introduction
High-throughput technologies are widely used to monitor the expression activity of many genes in a single
experiment. Analyzing high dimensional data resulting from these technologies is challenging. Gene set
analysis, also known as enrichment analysis, is widely used to address this challenge and to gain insight from
the resulting data. Gene set analysis employs a priori knowledge of groups of genes that are known to be
associated with cellular components, processes, or functions. Such groups of genes, also referred to as gene
sets or pathways, can be extracted from knowledgebases such as GO [2] and KEGG [9]. Hereafter, we refer
to such a collection of gene sets as a gene set database. Given a gene set database and a case-control gene
expression dataset, gene set analysis aims to find gene sets from the database that are differentially enriched
when comparing case to control samples; for example, a pathway that is activated (or deactivated) in case
samples when compared to controls.
Many gene set analysis methods have been developed [3, 8, 10, 11, 20, 23, 25] and it has been shown that
different gene set analysis methods may lead to significantly different results in terms of gene sets reported
as differentially enriched [16]. Considering the large number of available methods, it is natural to wonder
which method should be used. Answering this question in a quantitative manner requires a gold standard
expression dataset where differentially enriched gene sets are a priori known. Due to the absence of such
gold standard datasets, real datasets with presumed enrichment status of gene sets [22, 26] and synthesized
datasets [1, 7, 18] have been used. Unfortunately, these have had shortcomings and evaluating gene set
analysis methods remains a challenge.
Evaluations using real datasets are often based on questionable assumptions about the differential enrich-
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ment status of the gene sets. For example, Tarca et al. [22] used 42 microarray datasets from GEO. For each
dataset, they defined a particular KEGG or Metacore disease gene set to be differentially enriched whenever
the dataset was from a similar phenotype. Such assumptions make this kind of evaluation unreliable.
Evaluations using synthesized datasets have also been conducted relying on oversimplifying assumptions
that may not represent the true nature of real data [1, 7, 18]. Such evaluations have often used normally dis-
tributed expression values with no gene-gene correlations [7, 18] or constant correlations [1], even though more
complex gene-gene correlations exist and profoundly impact the results of gene set analysis [21]. Moreover,
normally distributed values with constant mean and standard deviation ignores heterogeneity of variance,
which is a common phenomenon in high-throughput data [13]. Hence, the resulting datasets may be biased
in favour or against a specific method or class of methods. Furthermore, these evaluations often utilize gene
sets of equal size, as opposed to gene sets of varying sizes (the typical situation), which have been reported to
affect some methods [5]. Another shortcoming of these evaluations is that they only consider non-overlapping
gene sets. Therefore, overlap of gene sets and its effect on the specificity of gene set analysis [14] have been
overlooked.
Recently Mathur et al. created artificial gene expression datasets in a more realistic manner [17]. They
conducted a systematic comparison of 4 gene set analysis methods using real expression datasets by sampling
with replacement from control and case samples; i.e. simulating controls (and also cases) from both actual
controls and cases. They simulated differential expression “by shifting the gene expression in the [simulated]
case groups according to a range of values”. The authors followed a bootstrap approach, repeating this pro-
cedure 100 times and reported the average behaviour of each gene set analysis method across the datasets.
However, in each generated dataset, the simulated controls (and also cases) contained a heterogeneous mix-
ture of both actual control and case samples; therefore, the simulated datasets were not representative of
the actual data. This approach is also computationally demanding, and almost impractical for evaluating
computationally expensive methods such as SetRank [19].
Despite the existence of many studies comparing gene set analysis methods, there is no consensus re-
garding the method of choice for a given experiment, and existing guidelines and suggestions are often
contradictory [12]. In this research, we propose Silver, a framework for evaluating gene set analysis methods.
The framework synthesizes gene expression datasets without relying on oversimplifying assumptions such as
normally distributed expression values and zero or constant gene-gene correlations. The synthesized expres-
sion datasets preserve the true distribution of gene expression values and retain complex gene-gene correlation
patterns. This approach incorporates gene set overlap, which has been shown to have a significant impact
on the results of gene set analysis methods [14]. Also, it is computationally affordable as it does not rely on
bootstrapping. We showcase the utility of Silver by providing a comprehensive evaluation of nine commonly
used gene set analysis methods together with a recent method aimed at increasing specificity.
82
6.2 Framework for evaluating gene set analysis methods
Silver, the proposed framework for evaluation of gene set analysis methods, is presented in this section.
The framework consists of a methodology for synthesizing “almost gold” standard expression datasets and a
quantitative approach for comparing gene set analysis methods. Silver is available as a GitHub repository.
6.2.1 Synthesizing expression datasets
To synthesize an expression profile with nC controls and nT cases, first we identify an actual expression
dataset Λ = (ΛC ,ΛT ) where ΛC = {A(C1), . . . , A(Cn)} are n control samples and ΛT = {A(T1), . . . , A(Tn′ )}
are n′ case samples. Each A(Ci) and A(Tj) is a vector of the expression levels of m genes for some positive
integer m. Also, it is required that n ≥ nC + nT and n′ ≥ nT . Then, ΛC = {A(Ci1 ), . . . , A(CinC )} and
ΛT = {A(Cj1 ), . . . , A(CjnT )} are created through a random sampling without replacement so that ΛC and ΛT
are disjoint subsets of ΛC . ΛC and ΛT together form an expression matrix, where each column corresponds
to a member of ΛC or ΛT and each row corresponds to the expression values for a gene gk (1 ≤ k ≤ m)
across samples in ΛC and ΛT . In other words, the generated expression matrix contains nC + nT columns
and m rows, where m is the number of genes in the original case and control samples.
Given a set X ⊂ {g1, . . . , gm}, where X is a user input, for each gene gt in X we adjust the expression
levels of gt in ΛT by simulating differential expression through the following process. We first create <,
which is a table of expression values with m rows and nT columns; each column is selected from the actual
cases ΛT through random sampling without replacement. The columns of < are A(T`1 ), . . . , A(T`nT ), where
1 ≤ `1 < · · · < `nT ≤ n′. Each row of < represents the expression values for a gene across A(T`1 ), . . . , A(T`nT ).
This table is used to simulate differential expression of each gene in X according to some specified criterion.
To simulate differential expression of a gene gt in X by a given fold change FC(gt), we randomly choose
a row e from rows of < that satisfies the differential expression criterion considering the simulated control
expression values for gt (from ΛC) and FC(gt). Among criteria one can use are t-test, Wilcoxon Rank-Sum
test, and median fold change. The current expression values for gene gt in ΛT (a vector of size nT ) are
replaced with the vector of expression measures from row e of <. The choice of genes selected for differential
expression (X) depends on the purpose of simulation. Note that given the initial expression level of gt, if the
intended fold change value—which is a user input—is unrealistically high or low considering the distribution
of expression values in the original dataset, a row e that meets the criterion might not exist. In such cases,
optionally, expression values for gt can be shifted in a manner similar to Mathur et al. [17]. After updating
expression values for genes in X, (ΛC ,ΛT ) is returned as the synthesized dataset. As the proposed method
inherits the characteristics of an input dataset, care should be taken when choosing input datasets. Having a
MDS (multidimensional scaling) plot of the input datasets where controls and cases cluster separately might
be a good rule of thumb for choosing a dataset of reasonably high quality [16].
Another required component for gene set analysis is a gene set database. Instead of following the common
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approach of generating a small number of non-overlapping gene sets of equal size, we use real gene set
databases to evaluate gene set analysis methods. This is possible as we synthesize expression profiles using
real data and therefore retain real gene identifiers along with their gene expression characteristics from an
actual dataset.
6.2.2 Quantitative approach
We utilize the aforementioned procedure to synthesize expression datasets where the enrichment status of
given gene sets are known a priori. To achieve this goal, we select a group of gene sets G1, . . . , Gq—from a
gene set database G—and synthesize an expression dataset with genes in these gene sets being differentially
expressed. However, not only do we need to consider G1, . . . , Gq as being differentially enriched, but we
also need to consider gene sets that “substantially overlap” with G1, . . . , Gq as being differentially enriched.
However, there is no consensus about what should be considered as a “substantial overlap”. We use a
methodology similar to that proposed by Maleki and Kusalik [14] to address this ambiguity and to determine
the enrichment status of gene sets.
Assuming that L is the list of all genes that are differentially expressed in the synthetic dataset (ΛC ,ΛT ),




where γ is a value between 0 and 1 and ‖ • ‖ is set cardinality. f(Gi, L) represents the proportion of genes in
Gi that are differentially expressed. Hereafter, we refer to f as the coverage score of Gi given L or simply as
the coverage score of Gi in situations where L can be inferred from the context. Since there is no consensus
in the research community about an appropriate value of γ, we use a wide range of values for γ and evaluate
a gene set analysis method for each value. Knowing the truly enriched gene sets in a simulated dataset and
results of a gene set analysis method for that dataset, we can then quantitatively evaluate the result of a
gene set analysis method in terms of sensitivity and specificity.
6.3 Results
Using the proposed framework, we evaluate nine commonly used gene set analysis methods: PAGE [10], GSEA
(both gene permutation and phenotype permutation versions) [20], PLAGE [23], GAGE [11], ssGSEA [3],
ROAST [25], GSVA [8], over-representation analysis (ORA) [6], as well as SetRank [19], a more recent method
claiming to increase specificity. We use the following R packages in this study: GSVA package version 1.18.0
for GSVA, PLAGE, and ssGSEA; the limma package version 3.34.9 for ROAST; the gage package version
2.20.1 for PAGE and GAGE; the SetRank version 1.1.0 for SetRank. ORA was run using the WebGestalt
online service [24]. GSEA was obtained from the Java-based application v3.0 (build 0160) at the Broad
Institute software page for GSEA.
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The gene set analysis methods were evaluated using data simulated from 2 microarray datasets and 1
RNA-seq dataset, downloaded from GEO. The microarray experiments were case-control experiments in
humans from the Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray platform from studies of
renal cell carcinoma tissue (77 controls and 77 cases, GSE53757) and skin tissue in psoriasis patients (64
controls and 58 cases, GSE13355). These datasets were normalized as described in a previous work [15].
The RNA-seq dataset originated from normal and lesional psoriatic skin (82 controls and 92 cases,
GSE54456). The 80-base single-stranded reads were trimmed with Trimmomatic 0.36 and mapped to the
GRCh38 human genome using STAR 2.2.51 to obtain raw counts. The dataset was normalized using TMM
normalization from the edgeR R package. The Ensembl gene IDs were translated to human Entrez gene IDs
using biomaRt. Ensembl IDs (and also Probe IDs for microarrays) were collapsed to obtain a unique set of
Entrez gene identifiers using methods described in a previous work [15]. GO gene sets (a total of 5917) were
extracted from MSigDB version 6.1. For each expression dataset, genes not represented in the dataset were
removed from these gene sets.
From each original dataset, we simulated a dataset containing 20 controls and 20 cases. Ten gene sets—
(1) GO:0003823, (2) GO:0019724, (3) GO:0060070, (4) GO:0005126, (5) GO:0008009, (6) GO:0030851, (7)
GO:0002544, (8) GO:0045087, (9) GO:0002253, and (10) GO:0006954—of various sizes (see Table 6.1) associ-
ated with immune system processes were selected for being differentially enriched in each simulated dataset.
The genes in the ten gene sets were differentially expressed with mixed proportions of up- and down-regulated
genes (see Table 6.1) and absolute log2 fold change values between 1 and 3. Hereafter, we refer to these ten
gene sets as the target gene sets. Also, independent two-sample t-test was used as the differential expression
criterion.
Figure 6.1 illustrates the volcano plot and also a Q-Q plot of the average expression value of cases versus
controls for a synthesized dataset generated from GSE53757. This volcano plot resembles a typical volcano
plot resulting from differential expression analysis. Further, a two-sample Kolmogorov-Smirnov test was
used to assess if the average expression levels in a simulated dataset follows the same distribution as the real
dataset it was generated from. As indicated in Table 6.2, the null hypothesis cannot be rejected for any of
the datasets, suggesting that the distributions are the same.
Table 6.1: Information about the target gene sets in this study.
Gene sets as numbered above
1 2 3 4 5 6 7 8 9 10
Up-regulated 24 27 65 206 24 3 7 245 155 218
Down-regulated 13 21 2 44 17 5 8 229 142 210
Size 76 67 92 250 41 15 15 538 383 428








































Figure 6.1: (Left) Volcano plot shows differentially expressed genes resulting from simulated data
(20 control and 20 case samples) using dataset GSE53757. The blue points represent genes that were
differentially expressed and the red points represent non-differentially expressed genes. The vertical
dotted lines indicate the log fold change thresholds that were considered significant. The red horizontal
line indicates the p-value cutoff 0.05. The p-values were obtained by performing differential expression
analysis using the limma R package. (Right) A Q-Q plot of the average expression value of cases versus
controls for a synthesized dataset generated from GSE53757.
We now demonstrate the utility of Silver as a means to evaluate the ten gene set analysis methods. For
each method, the default parameters—as suggested by its author(s)—were used. To achieve comparable
results, the Benjamini-Hochberg adjustment [4] for multiple comparison with a false discovery rate of 0.05
was applied to the reported p-values for each method.
Each plot in Figure 6.2 illustrates the reported p-values—resulting from running a method—for each
gene set versus its coverage score given the list of differentially expressed genes for the dataset synthesized
from GSE53757. These plots show the lack of specificity of the methods under study. Almost all methods
reported a large number of gene sets as being differentially enriched regardless of the coverage scores. As
depicted in Figure 6.2, ORA, GAGE, PAGE, and PLAGE reported gene sets with high coverage as being
differentially enriched, while other methods reported some gene sets with high coverage—i.e. gene sets with
a large proportion of their genes being differentially expressed—as non-enriched.
Figure 6.3 shows the rank of the target gene sets based on adjusted p-values reported by each method.
The heat map shows that the ranking of the target gene sets substantially differs across methods, with some
methods not being able to report some of the target gene set as differentially enriched. Also, GSEA-G and
GSVA only ranked gene sets highly when most of its genes were up-regulated. GSEA-S and ssGSEA reported
the majority of target gene sets near the bottom of their results. GAGE, PAGE, PLAGE, and ORA ranked
the target gene sets higher in comparison to other methods. SetRank, while ranking six of the ten target
gene sets highly, failed to report the other four target gene sets.
Figure 6.4 shows the Receiver Operator Characteristic (ROC) curves for the results of each method for
all three synthetic datasets. The ROC curves suggest that GSEA (both gene permutation and phenotype
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Table 6.3: The sensitivity (TPR) and specificity (TNR) of gene set analysis methods for data simu-
lated from GSE53757.
γ = 0.1 γ = 0.3 γ = 0.5 γ = 0.9 γ = 0.99
Method TNR TPR TNR TPR TNR TPR TNR TPR TNR TPR
GAGE 0.73 0.98 0.40 1.00 0.35 1.00 0.32 1.00 0.32 1.00
GSEA-G 1.00 0.05 0.98 0.07 0.97 0.03 0.97 0.14 0.97 0.16
GSEA-S 0.68 0.39 0.59 0.13 0.61 0.01 0.64 0.00 0.64 0.00
GSVA 1.00 0.07 0.99 0.16 0.98 0.19 0.96 0.42 0.96 0.44
PAGE 0.97 0.90 0.59 1.00 0.52 1.00 0.48 1.00 0.47 1.00
PLAGE 1.00 0.49 0.89 0.99 0.78 1.00 0.72 1.00 0.72 1.00
Roast 0.76 0.67 0.57 0.72 0.53 0.74 0.51 0.92 0.51 0.92
ssGSEA 0.01 0.98 0.01 0.96 0.01 0.94 0.02 0.97 0.02 0.96
SetRank 1.00 0.01 1.00 0.03 1.00 0.05 0.99 0.22 0.99 0.28
ORA 0.99 0.69 0.60 1.00 0.50 1.00 0.44 1.00 0.44 1.00
permutation versions) and ssGSEA performed poorly regardless of the value of γ. Also, GSVA performed
moderately better than these methods. ORA, ROAST, PAGE, GAGE, and PLAGE achieved a relatively
higher area under the curve. This supports the reliability of the most statistically significant results reported
by these methods.
Table 6.3 shows the sensitivity and specificity of the methods under study when analyzing the dataset
synthesized from GSE53757 across γ values. As depicted in Table 6.3, GSEA-G, GSVA, and SetRank achieve
high specificity with the consequence of having low sensitivity. GAGE, PAGE, and ssGSEA achieve high
sensitivity while sacrificing specificity, with ssGSEA being the least specific. These results are consistent
across all γ values. PLAGE, while achieving high sensitivity (across γ > 0.1), also achieves 0.7 or higher
specificity. However, due to the sheer size of gene set databases (5,000+ for GO gene sets, and 16,000+
for MSigDB), such a specificity is not high in absolute terms and leads to hundreds to thousands of false
positives, depending on the database size.
Results using the other two datasets were consistent with the observations reported in Figures 6.2 and
6.3 and Table 6.3 (data not shown due to limited space).
6.4 Discussion
We proposed Silver, a framework for evaluating gene set analysis methods consisting of a method for syn-
thesizing expression datasets and a quantitative approach for evaluating gene set analysis methods. While
the proposed methodology does not generate gold standard datasets, it is capable of generating expression
datasets without relying on common oversimplifying assumptions and preserves the characteristics of real
(input) datasets; therefore, it is not limited to a specific gene expression platform. The synthesized datasets
inherit the distribution of expression values and complex gene-gene correlations from real data, preserving
technical and biological variability. This was expected as the proposed method incorporates real data and was
confirmed by Kolmogorov–Smirnov tests and visualizations. Although we used the methodology for simulat-
ing expression datasets as part of an evaluation of gene set analysis methods, its utility is not limited to this
role, and it can be used in any context where one needs expression datasets with control over differentially
expressed genes.
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Moreover, Silver utilizes real gene set databases to avoid using artificial databases of non-overlapping gene
sets of equal size that are unrealistic and to also substantially affect the results of gene set analysis meth-
ods [14]. Using Silver, we evaluated a comprehensive list of gene set analysis methods providing key insights
into weaknesses and strengths of these methods. A compelling observation revealed by Figures 6.2 and 6.3 is
that some methods—such as ROAST, GSVA, SetRank, GSEA-G, and GSEA-S—did not report some gene
sets as being differentially enriched even when all the genes in those gene sets were differentially expressed.
For example, gene set GO:0002544—with 15 genes of which 7 were up-regulated and 8 were down-regulated—
was not reported as differentially enriched by the aforementioned methods. This suggests an inadequacy of
these methods in detecting gene sets with both up- and down-regulated genes. This leads to under-reporting
of pathways in which by definition some genes must be up- and some down-regulated during a biological
process or function.
The experiments showed that ssGSEA suffers from a lack of specificity, although it should be mentioned
that the available R package implementing this method [8] was not from the authors of ssGSEA. We strongly
recommend against using the current implementation in GSVA package version 1.18.0 with default parame-
ters.
SetRank was designed with the goal of increasing specificity. The available implementation does not
report the non-significant gene sets; as such, a fair comparison of it with other methods via ROC curves is
not possible. However, its scatter plot in Figure 6.2 and its sensitivity and specificity in Table 6.3 reveal
a lack of sensitivity. As illustrated by Figure 6.3, four out of the ten target gene sets were not detected
by SetRank. This might be due to SetRank explicitly removing some gene sets based on a level of overlap
between gene sets. However, excluding the small gene sets where most or all genes are differentially expressed
suggests that SetRank sacrifices sensitivity in favour of increasing specificity.
In this study, we showcased the utility of Silver using a scenario of differentially enriching ten gene sets
of processes related to immune system. However, this by no means is a comprehensive evaluation of these
methods. We suggest studying various scenarios using gene sets from different phenotypes, only up-regulated
(or down-regulated) gene sets of various sizes, and different levels of fold change gene expression values. In
addition, we only evaluated gene set analysis methods using balanced datasets of 20 case and 20 control
samples. The study of gene set analysis methods with different samples sizes and with unequal numbers of
cases and controls is suggested as future research.
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Figure 6.2: Scatter plots of the relationship between gene set coverage (x-axis) and the statistical
significance (adjusted p-value) of the results of each method (y-axis). Each point in green represents
a gene set. The red line shows a p-value cutoff of α = 0.05. Since SetRank only returned statistically
significant results (points under the red line), we assign a p-value of 1 to visualize the coverage scores
for non-significant results.
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Figure 6.3: Heat map of the rank of the 10 target gene sets as reported by each method. The results
of each method were sorted based on the adjusted p-values (smallest to largest); the rank of each target
gene set was determined as its rank in the sorted list. A black cell with no number shows that the
adjusted p-value was not less than α = 0.05.
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Figure 6.4: Receiver Operator Characteristic curves (ROC) for each method using γ = 0.3 (left
column) and 0.5 (right column) for the dataset synthesized based on microarray dataset GSE53757,
GSE13355, and RNA-Seq dataset GSE54456 (from top to bottom). The plots show the relationship
between the true positive rate (y-axis) and the false positive rate (x-axis). A method with higher area
under the curve (shown for each method) is considered better. The black dotted diagonal line (y=x)
represents a method with random ordering of significance values.
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6.5 Conclusion
In this paper, we proposed Silver, a framework for generating synthetic data that avoids common oversim-
plifying assumptions. We showed the utility of this framework by evaluating a comprehensive list of gene set
analysis methods. The evaluation revealed key insights about these methods. It showed a lack of specificity
as the main challenge facing these gene set analysis methods. Moreover, we found that some methods lack
sensitivity when dealing with gene sets/pathways that are a mixture of up- and down-regulated genes.
Considering the key insights revealed using Silver, we strongly discourage using artificial datasets that
rely on oversimplifying assumptions such as normally distributed expression values or non-overlapping gene
sets of the same size, as they are not realistic and do not provide an accurate evaluation of gene set analysis
methods. We anticipate that using Silver as a means for evaluation of existing and new gene set analysis
methods will provide a better understanding of these methods and lead to development of gene set analysis
methods that achieve a high specificity without sacrificing sensitivity.
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7 Gene Set Databases
Gene set databases, as an input to gene set analysis, have the potential to considerably impact the outcome
of the analysis. Therefore, understanding the characteristics of these databases is vital to the success of gene
set analysis. In this chapter, we propose and use quantitative measures for assessing the similarity between
gene set databases and calculating the degree to which a given gene is represented in the gene sets of a given
gene set database. We also propose a methodology to statistically determine whether a phenotype of interest
is well-represented in a given gene set database. This paper has been accepted as a regular paper in the 10th
ACM Conference on Bioinformatics, Computational Biology, and Health Informatics.
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Abstract
Gene set analysis is a well-established approach for analyzing high-throughput gene expression data. Gene
set databases used for gene set analysis may affect the outcome of the analysis. Therefore, understanding
characteristics of these databases is vital to the success of gene set analysis. Due to the sheer size of the gene
set databases, a comprehensive qualitative evaluation of these databases is impractical. In this paper, we
quantitatively study several well-established gene set databases. We propose and use a quantitative measure
for assessing the similarity between gene set databases. Also, we introduce a permeability score to quantify
the degree to which a group of genes of interest co-occur in gene sets of a database. Using the permeability
score, we propose a methodology to statistically determine whether a phenotype of interest is well-represented
in a given gene set database. To study the effect of the choice of gene set database on the result of gene set
analysis and show the utility of the permeability score, we conduct an experiment using two widely used gene
set analysis methods and three expression datasets. The results suggest that the choice of gene set database
might profoundly affect the outcome of the analysis. Also, our findings show that the permeability score can
be used as a guideline for selecting an appropriate gene set database for a given study.
7.1 Introduction
Gene set enrichment analysis is a common methodology in high-throughput gene expression studies. For
a case-control dataset, gene set analysis attempts to determine if a group of related genes shows different
expression patterns in case samples versus controls. Conducting gene set analysis requires a collection of gene
sets, hereafter refered to as a gene set database, containing groups of genes that are known to be associated
with biological pathways, functions, processes, or cellular components. Gene sets can be extracted from
knowledge bases such as Gene Ontology [4], KEGG [12], Reactome [8], and BioCarta [19].
MSigDb is a well-established gene set database designed for gene set analysis [14]. As a meta-database, it
includes several gene set databases, each extracted from a different source, such as one of the aforementioned
knowledge bases. MSigDB also contains gene sets constructed using differentially expressed genes resulting
from expression studies of various phenotypes.
Gene set databases vary regarding the gene sets/pathways they represent. Adriaens et al. [1] compared
pathways involved in fatty acid metabolism from several pathway databases including KEGG, BioCarta, and
Reactome. Based on their observations, they concluded that “biological pathway content varies greatly in
quality and completeness” [1]. In a different study of MSigDB, Tragante et al. reported a predominance
of immunological and cancer-related pathways among curated gene sets extracted from canonical pathways
(CP) such as BioCarta, KEGG, and Reactome, as well as gene sets from chemical and genetic perturbations
(CGP) [26]. It is currently not known to what extent using different gene set databases impacts the results
of gene set analysis. There are only a few general recommendations regarding gene set databases and no
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quantitative measure derived in a systematic way for choosing a gene set database for a given study. Among
these general recommendations are: choosing databases consistent with the hypothesis of interest [18], using
an up-to-date database [27], filtering out small genesets (with less than 15 genes) and large gene sets (more
then 500 genes) [25], and combining databases to take advantage of different knowledge bases [26]. However,
even these general recommendations are often method and data specific and might not be applicable to
other gene set analysis methods. Moreover, small gene sets often are associated with more specific pathways,
functions, processes, or cellular components; therefore, they can be more biologically informative, and filtering
out all gene sets with less than 15 genes might lead to information loss.
Due to the sheer size of gene set databases, a fine-grained qualitative evaluation of these datasets by an
expert is impractical. In this study, we propose new quantitative measures—similarity score, presence score,
and permeability score—to compare four well-established gene set databases: KEGG, GO, Reactome, and
BioCarta. We use similarity score to quantify the similarity between two gene set databases; presence score
to measure the degree to which a gene is represented in a database; and permeability score to assess the
co-occurrence of genes within gene sets of a database. Further, we statistically assess the significance of a
permeability score for a given list of genes and a gene set database. For this purpose, we use lists of genes
of interest from Human Phenotype Ontology (HPO) [13] as well as a list of genes compiled from literature.
Also, we study the impact of the choice of gene set databases on the results of two widely used gene set
analysis methods utilizing three microarray datasets.
The rest of the paper is organized as follows. Section 7.2 presents data acquisition and preprocessing
as well as the quantitative measures and the methodology for the significance assessment of permeability
scores. Section 7.3 presents the results of the quantitative study of the selected gene set databases as well as
a biomedical case study of three juvenile idiopathic arthritis (JIA) datasets using two widely used gene set
analysis methods across several gene set databases. The utility of the quantitative approach proposed in this
paper is shown in Section 7.4 with a focus on discussion of the relationship between permeability score and
gene set analysis results. Section 7.5 concludes the paper with recommendations for improving current gene
set databases and a method to identify an appropriate gene set database for a given experiment.
7.2 Materials and Methods
7.2.1 Data preprocessing
The gene set databases used for evaluation included gene sets from GO, KEGG, Reactome, and BioCarta,
which are subsets of MSigDB version 6.2 [14]. We also conducted the analyses using the entire MSigDB
version 6.2. Further, two additional gene set databases were derived to investigate how gene set analysis
results differ when using more current versions of the databases included in MSigDB. These databases were
constructed as follows. A current version of KEGG was downloaded using the KEGGREST v1.22.0 package
from R. All the pathways for human (KEGG organism ID: hsa) were downloaded (a total of 321 gene sets).
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Hereafter, we refer to this database as KEGG?.
A GO gene set database was extracted using the GO.db R package, which contains a snapshot of GO
gene sets from October 10, 2018. A gene set database was constructed by extracting all GO terms for human
and associating them with Entrez gene identifiers annotated with each GO term using the org.Hs.eg.db R
package. For each gene set associated with a term, genes with only “IEA” (electronically inferred) as their
evidence of association were removed from the gene set. We refer to this database, which contains 5,509 gene
sets, as GO?.
Three JIA case-control datasets collected using the Affymetrix GeneChip Human Genome U133 Plus
2.0 microarray platform were obtained from Gene Expression Omnibus (GEO). The three datasets were
from peripheral blood mononuclear cells (PBMCs): 1) GSE13501 (59 controls, 21 systemic JIA samples), 2)
GSE26554 (23 controls and 36 polyarthritis samples), and 3) GSE7753 (30 controls, 17 systemic JIA samples).
The GEOquery v2.46.15 R package was used for reading CEL files. The data were normalized using RMA
normalization from the affy v1.56.0 R package. Probe IDs were converted to Entrez gene identifiers using the
hgu133plus2.db v3.2.3 R package. Finally, the collapseRows function from WGCNA v1.61 with the MaxMean
method was used to collapse the expression measures based on Entrez gene identifiers.
7.2.2 Gene set database similarity





For given sets Gi and Gj , J(Gi, Gj) is a number between 0 and 1, with 0 representing no overlap between
two sets (disjoint sets) and 1 representing complete overlap between Gi and Gj (set equality). We use the
terms Jaccard index and overlap score interchangeably.
To assess the similarity between gene set databasesG andG′, whereG = {G1, . . . , Gn}, G′ = {G′1, . . . , G′m}
















Note that S is the summation of two components. In the first component, for each gene set Gi in G, we
find a gene set from G′ that is the most similar to Gi, i.e. a gene set that has highest overlap with Gi. The
second component performs the same task for each gene set G′j in G′. S(G,G′) is a value between 0 and 1,
with 0 showing no similarity between G and G′ and 1 showing highest similarity, i.e. equality. Each of the
two fractions is at most 0.5 due to the division by two, and therefore the similarity score is between 0 and 1.
98
7.2.3 Presence score
Genes vary in the degree to which they appear in different gene sets of a database. In an extreme case, a
gene might not appear in any gene set within a database. We define presence score (P (g,G)) to quantify the





where I(g,Gi) is defined as follows:
I(g,Gi) =
1 g ∈ Gi0 otherwise
For example, P (g,G) = 0 means that g is not in any gene sets of G. To further explore the presence of a gene
in more specific gene sets, we also calculate the presence score for subsets of G that contain gene sets of a
size less than or equal to a given threshold t. We use G|t to represent a gene set database G that is restricted
to gene sets of size less than or equal to t, and we consider P (g,G|t). In this paper, we use threshold values
of 500, 250, 100, and 50.
To statistically assess if genes are presented equally across the databases, we use a Friedman test, which
is an analogous nonparametric version of ANOVA for repeated measures. Presence scores are calculated
for a total of 25,052 genes acquired from the Ensembl human genome version 86 as Entrez gene identifiers.
Hereafter, we refer to this list of genes as E. To make presence scores comparable, they are normalized by
dividing by their corresponding database size.
7.2.4 Permeability score
While the presence score provides insight about the degree to which a gene is represented in a gene set
database, it does not measure the co-occurrence of genes from a given list. It is also affected by large gene
sets that often are general and less informative; such large gene sets inflate the presence score. The coverage
score of L by Gi is C(Gi, L) =
Gi∩L
Gi
, that represents the proportion of genes in Gi that are present in L.
The maximum achievable coverage score of L by G is defined as follows:
T (G, L) = max
Gi∈G
C(Gi, L) (7.4)
To quantify co-occurrences of a list of genes of interest L for a given gene set database G for a given threshold
τ , we define the permeability score of L in G as follows:
∆(G, L, τ) =
∑
Gi∈G
H (Gi, L, τ) (7.5)
where H(Gi, L, τ) is defined as follows:
H(Gi, L, τ) =
1 C(Gi, L) ≥ τ0 otherwise
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where τ is a given threshold for the proportion of genes in L that are also in Gi. ∆(G, L, τ) represents the
number of gene sets in G where at least τ × 100% of their genes are from L. Notice that the maximum
achievable coverage score is the maximum value of τ such that ∆(G, L, τ) > 0 or zero if there is none. Thus,
for any τ greater than the maximum achievable coverage score, D(G, L, τ) = 0.
In order to statistically assess if the maximum achievable coverage score for a given list of genes L by a
gene set database G is not solely due to chance, we use a bootstrapping hypothesis test. Fig. 7.1 provides a
step-by-step description of the bootstrapping procedure.
Step 1: k ←1
Step 2: 𝐿𝑘 = ∅
Step 3: Randomly select 𝐺𝑖, which is a gene set from 𝔾
Step 4: Randomly select 𝑔𝑖,𝑗, which is a gene from 𝐺𝑖 and
add 𝑔𝑖,𝑗 to 𝐿𝑘
Step 5: If 𝐿𝑘 < 𝐿 go to Step 3
Step 6: For 𝐿𝑘 and gene set database 𝔾 calculate and record
maximum achievable coverage score 𝑇(𝔾, 𝐿𝑘)
Step 8: For 𝐿 and gene set database 𝔾 calculate and record
maximum achievable coverage score 𝑇(𝔾, 𝐿)
Step 9: Calculate p-value as the proportion of 𝑇(𝔾, 𝐿𝑘) values
1 ≤ 𝑘 ≤ 𝐾 that are greater than 𝑇(𝔾, 𝐿)
Gene set database 𝔾
𝑔1,1,       …        𝑔1,𝑑1
𝑔𝑖,1, … 𝑔𝑖,𝑗 … 𝑔𝑖,𝑑𝑖






𝑔1,        …       𝑔𝑑L
Step 7: If k < K, k← k + 1 and go to Step 2
Input: K, L, and 𝔾
Figure 7.1: The methodology for significance assessment of the maximum achievable coverage scores.
This procedure assesses whether or not a maximum achieved coverage score of a list of genes in a gene
set database is due to chance. L = {g1, . . . , gd} is a list of genes; G = {G1, . . . , Gn} is a gene set
database. L, G, and K are inputs, with K representing the number of samplings for the significance
assessment. We used K = 1000 in this paper. Gi (1 ≤ i ≤ n) is a set of genes {gi,1, . . . , gi,j , . . . , gi,di}
from G. Also, ∅ represents the empty set.
The three measures presented in this section, as well as the proposed bootstrapping method, provide
guidance for selecting an appropriate gene set database for an experiment, rather than an ad-hoc approach
which is currently the common practice. Given two databases G and G′ with a low similarity score, i.e.
the existence of substantial differences between these two databases, the natural question is which gene set
database should be used for a given experiment? Often a list L of genes that are known or hypothesized
to be associated with the phenotype of interest is available. The presence score and permeability score help
to choose the gene set database that is more representative of the phenotype of interest. If the majority of
genes in L achieve a zero or low presence score for a database, that database is inappropriate for conducting
the gene set analysis. The gene set database that achieves a larger permeability score for higher values of
τ better represents the phenotype of interest. Finally, the bootstrapping approach presented in this section
assesses if the maximum achievable coverage score is due to chance or not.
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7.3 Results
Fig. 7.2 shows the number of gene sets available in major subcategories of MSigDB, including Biocarta,
KEGG, Reactome, and GO. As the plot shows, there was a major update for gene sets derived from GO in
version 5.2. Further, GO gene sets were the same for versions 3.1, 4.0, 5.0, and 5.1, with no update from 2012
to 2016. Also, BioCarta, KEGG, and Reactome were not updated between versions 3.1 and 6.2, while these
datasets have been actively updated outside of MSigDB. We obtained KEGG? and GO?, updated versions
of KEGG and GO, for further comparisons. Our observations showed that KEGG? and GO? substantially
differ from their counterparts from MSigDB version 6.2. For example, KEGG? contains 321 pathways (gene



















































Figure 7.2: The change in the number of gene sets within the major subcategories of MSigDB across
different versions. All of these databases have been added since version 2.5 of MSigDB.
Table 7.1 shows the similarity scores (Equation 7.2) between the gene set databases under study. The
highest achieved similarity scores were between KEGG and KEGG? with a similarity score of 0.68, followed
by GO and GO? with a similarity score of 0.36. These results are not surprising considering the differences
in the construction of GO and GO? and also KEGG and KEGG? (see Section 7.2). All other pairwise
comparisons of these gene set databases resulted in similarity scores below 0.25.
For a given gene set database G and the list of genes E, we calculated P (g,G) for each gene in E.
A Friedman test for assessing equality of presence score across gene set databases resulted in a chi-square
statistic of 32443.38 and a p-value < 1.00E-8 for the normalized presence scores. This suggests that there is
a significant difference between the normalized presence scores across gene set databases.
Also, we used Human Phenotype Ontology (HPO) to extract a gene list associated with “Arthritis”
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Table 7.1: Similarity scores for pairwise comparison of gene set databases GO, GO?, KEGG, KEGG?,
BioCarta, and Reactome.
Method GO GO? KEGG KEGG? BioCarta Reactome
GO 1.00 0.36 0.19 0.18 0.11 0.25
GO? 0.36 1.00 0.17 0.15 0.13 0.24
KEGG 0.19 0.17 1.00 0.68 0.11 0.23
KEGG? 0.18 0.15 0.68 1.00 0.11 0.22
BioCarta 0.11 0.13 0.11 0.11 1.00 0.16
Reactome 0.25 0.24 0.23 0.22 0.16 1.00
(HP:0001369). Since the majority of gene sets contain less than or equal to 250 genes, as shown in Fig. 7.3,
we restricted the gene set databases to gene sets of size 250 or less to calculate presence scores. Fig. 7.4 shows
plots of the presence scores for “Arthritis” gene list across the gene set databases. The genes in this list are
most represented within the GO database. GO? also has each gene from this list in at least one gene set.
However, gene set databases like BioCarta and Reactome have far less representation across the genes of this
list. In BioCarta in particular, more than half of the genes are not represented at all within the database.

















Figure 7.3: Distribution of gene set size for BioCarta, KEGG, Reactome, GO:BP, GO:CC, and
GO:MF—each extracted from MSigDB V6.2—where GO:BP, GO:CC, and GO:MF represent GO gene
sets from Biological Processes, Cellular Components, and Molecular Functions. GO contains large gene
sets of up to 1984 genes. More specifically, the biological processes, a subcategory of GO, contains
more gene sets of large sizes (outliers). Outliers are represented by circles.
Fig. 7.5 depicts the number of genes present in GO, GO?, KEGG, KEGG?, BioCarta, and Reactome,
where these databases have been restricted to gene sets of size t or less where t equals 500, 250, 100, or 50.
Fig. 7.5 also shows the number of genes present in each database with no restriction applied. In general
databases such as BioCarta, KEGG, and Reactome do not cover the majority of the known genes in humans.
Not all known genes for human are represented within some of these databases, with even fewer genes
represented in gene sets with sizes less than 50 genes (G|50). Also, while the Ensembl human genome version
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86 includes 25,052 Entrez gene identifiers, MSigDB contains over 30,000 Entrez gene identifiers.













































































































Figure 7.4: The presence scores for genes in the “Arthritis” gene set (HP:0001369) from HPO. All
databases have been filtered to only include gene sets of size 250 or less.
The plots in Fig. 7.6 show the permeability scores for genes associated with four phenotypes extracted
from HPO across thresholds of values (τ). Some databases show higher permeability scores than others
depending on the phenotype of interest. Table 7.2 illustrates the results of the significance assessment of the
maximum achievable coverage scores for the gene set databases under study and the phenotypes from HPO
as well as a list of genes associated with JIA extracted from literature.
Significant maximum achievable coverage values were reported for different gene set databases depending
on the phenotype of interest. The gene set for arthritis (HP:0001369) had a significant maximum achievable
coverage score of 0.58 in GO. None of the other databases, including GO? with a maximum achievable
coverage score of 0.50, had a statistically significant maximum achievable coverage score. The leukemia gene
set (HP:0001909) resulted in a significant maximum coverage values in GO?, followed by GO. Reactome,
BioCarta, and both versions of KEGG did not show significant scores for the genes associated with this
phenotype. Abnormal leukocyte count (HP:0011893) had significant maximum achievable coverage values
in KEGG and both versions of GO, while abnormal ciliary motility (HP:0012262) resulted in significant
maximum achievable coverage values in Reactome and both versions of GO. The list of genes associated with
JIA only had significant maximum coverage values reported for GO and GO?.
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Table 7.2: The results of significance assessment of maximum achievable coverage score for GO, GO?,
KEGG, KEGG?, Reactome, BioCarta, and MSigDB. Five gene lists (L) were extracted from HPO as
well as a list of genes reported to be associated with JIA extracted from the literature.











































































Figure 7.5: The number of genes present in each gene set database (y-axis) across four scenarios
A, B, C, and D (x-axis). In scenario A, all gene sets are considered; scenarios B, C, D, and E only
consider gene sets with size less than or equal to 500, 250, 100, and 50, respectively. KEGG? and GO?
represent the gene sets that were extracted from updated KEGG and GO, respectively.
7.3.1 Biomedical Case Study
Juvenile Idiopathic Arthritis is an autoinflammatory disorder in children that is currently divided into six
different subtypes [21]. The exact causes of JIA are unknown, but gene expression and genome-wide genotyp-
ing have identified genes that are associated with the development of this disease and the different subtypes.
Variants in these genes can impair the normal regulation of inflammatory processes, which involve the ac-
tivity of many innate regulators including interleukins, chemokines, and matrix metalloproteinases (MMPs)
resulting in joint inflammation [20, 23, 11, 22]. Many of the genes associated with JIA belong to a family of
genes that provide instructions for making a group of related proteins called the human leukocyte antigen
(HLA) complex, which helps the immune system identify proteins made by foreign invaders.
In this experiment, GSEA (gene permutation version) [25] and over-representation analysis (ORA) [9],
which are two widely used gene set analysis methods, were utilized with the gene set databases. To take into
account gene sets that are potentially relevent but contain less than 15 genes, we considered 5 as the lower
bound for the size of gene sets. Also, to avoid large and general gene sets, we used 500 as the upper bound
for gene set sizes. A Benjamini-Hochberg correction [6] for multiple comparisons with a false discovery rate
of 0.05 was applied to the results of all gene set analysis methods.
The results of these gene set analysis methods using three JIA datasets were used to conduct a biomedical
investigation of the outcome of gene set analysis when using different databases. The relationship between
maximum achievable coverage values in each database for genes associated with JIA and the enrichment
results obtained using each database were investigated.
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Figure 7.6: The permeability scores for five gene lists. Each gene list L has been extracted from
HPO gene-phenotype associations. Each plot corresponds to one list and each trace corresponds to a
gene set database. The x-axis shows τ values, i.e. different thresholds for coverage score. The y-axis
shows the logarithm of permeability scores. To visualize the permeability scores, a log transformation
is applied. Also, to to prevent taking the logarithm of 0, we add a pseudocount of 1.
106
Table 7.3 provides the number of differentially enriched gene sets predicted for each method across gene set
databases and expression datasets. GSE7753, GSE13501, and GSE26544 had 245, 279, and 262 differentially
expressed genes, respectively, when performing single gene analysis [9] with a fold change of 2 and an adjusted
p-value less than 0.05.
Table 7.3: The number of differentially enriched gene sets reported by each method using each GO,
GO?, KEGG, KEGG?, BioCarta, Reactome, and MSigDB when analyzing the JIA datasets.
Method
GSE7753 GSE13501 GSE26554
ORA GSEA-G ORA GSEA-G ORA GSEA-G
GO 42 184 50 248 55 436
GO? 23 96 26 90 5 86
KEGG 0 10 1 13 0 36
KEGG? 1 34 4 34 1 59
BioCarta 1 4 1 10 0 3
Reactome 0 57 1 59 0 145
MSigDB 588 2399 858 2301 627 3645
The maximum achievable coverage score for JIA was significant only using the GO and GO? databases,
with GO? achieving the highest coverage value of 0.429. When using GO as the gene set database, the 20 most
significant gene sets reported by ORA included “Humoral immune response” (GO:0006959), “Leukocyte mi-
gration” (GO:0050900), “Immune response regulating cell surface receptor signaling pathway” (GO:0002768),
“Activation of immune response” (GO:0002253), and “Cytokine mediated signaling pathway” (GO:0019221).
Results using GO and GO? were consistent when considering the most differentially enriched gene sets. When
using GO?, ORA was able to identify several different gene sets with potential implications for JIA. Some
of these potentially related gene sets, such as “Neutrophil degranulation” (GO:0043312), “Haptoglobin bind-
ing” (GO:0031720), and “Haptoglobin-hemoglobin complex” (GO:0031838), were not available from the GO
database from MSigDB.
Using MSigDB as a whole resulted in substantially more gene sets predicted as being differentially enriched
compared to using any of the other databases. The majority of these gene sets predicted as enriched were from
“C7: immunologic signatures” in MSigDB. The immunologic signatures have been created using differentially
expressed genes reported in immunology literature. These gene sets also have names that are more difficult
to interpret without further investigation. Examples include gene sets such as “MODULE 114”, “MODULE
114”, and “MODULE 151”.
Using KEGG, ORA predicted “Systemic lupus erythematosus” (hsa05322), while using KEGG?, ORA
predicted “Malaria” (hsa05144) and “Systemic lupus erythematosus”. Systemic lupus erythematosus (SLE)
and JIA are distinctly different both clinically and pathogenically. SLE is a prototypic autoimmune disease
with very specific serologic hallmarks (antibodies to double-stranded DNA and other distinctive autoantibod-
ies). However, both JIA and SLE are associated with inflammation so there are likely to be some downstream
immune and inflammatory responses common to many inflammation-mediated diseases [7]. This is also likely
the reason “Malaria” is a predicted gene set when using GO?. It is common to treat JIA with antimalarial
drugs to try and control the inflammation, though to variable degrees of success [3].
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Using KEGG, GSEA resulted in “Hematopoietic cell lineage” (hsa04640), “Antigen processing and pre-
sentation” (hsa04612), “Graft versus host disease” (hsa05332), and “Allograft rejection” (hsa05330) predicted
as being differentially enriched. GSEA also predicted “Antigen processing and presentation”, “Graft versus
host disease”, and “Allograft rejection” when using KEGG? (“Hematopoietic cell lineage” was still significant,
but not one of the 20 most significant gene sets). Using KEGG? also resulted in GSEA predicting gene sets
including “Complement and coagulation cascade” (hsa04610), and “IL-17 signaling pathway” (hsa04657),
“Malaria”, “Systemic lupus erythematosus”, and “Staphylococcus aureus infection” (hsa05150). A complete
list of gene sets predicted as most significantly differentially enriched for each method and each database is
available upon request.
7.4 Discussion
In this paper, we proposed similarity, presence, and permeability scores for the quantitative study of gene
set databases. We also proposed a statistical procedure for significance assessment of maximum achievable
coverage score.
The similarity scores between each pair of GO, GO?, KEGG, KEGG?, BioCarta, and Reactome in
Table 7.1 showed that these databases are substantially different from each other. If the databases all had
high similarity, any of these gene set databases would be expected to produce comparable results. However,
the low similarity scores observed suggest that many of the gene sets within a database are not comparable
with gene sets in other databases. Therefore, these databases cannot be used interchangeably in gene set
analysis.
We used presence score as an indication of the degree to which a gene is represented in a gene set
database. Our study of commonly used gene set databases showed that many genes from the HPO gene lists
and the JIA gene list have a presence score of 0, i.e. they are not represented in any gene set of some of the
databases. These genes might be differentially expressed in an experiment, but gene set analysis methods
will not be able to associate the differential expression of these genes to any gene sets of the database. For
example, no gene currently associated with “Abnormal ciliary motility” (HP:0012262) is present in BioCarta.
Therefore, performing gene set analysis for an experiment concerning “Abnormal ciliary motility” might lead
to no differential enrichment; however, this lack of differential enrichment must not be interpreted as there
being no association. As another example, Fig. 7.4 illustrates the presence score for genes associated with
“Arthritis” (HP:0001369), which involves many genes linked with the immune system. Many of these genes
are absent or rarely present in gene sets of size 250 or less for some databases. Therefore, such gene set
databases must not be used for gene set analysis of “Arthritis” related experiments.
We suggest using the presence score as an initial indicator of the utility of a gene set database to be
used for a given phenotype. When the majority of genes of interest are not represented in a database, i.e.
presence score of zero, such a database must not be used for gene set analysis. To investigate the presence of
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genes in more specific gene sets that are usually of smaller sizes, we suggest restricting a gene set database
to only include gene sets of the size smaller than, or equal to a given threshold. This threshold might vary
according to the phenotype of interest and the purpose of the expression study. As a rule of thumb, we
suggest considering threshold values of 250, 100, and 50, with the threshold of 50 restricting the database to
the most specific gene sets.
Although presence score is an informative indicator of the presence of genes in a given database, it does
not account for the co-occurrence of genes within gene sets. Given L—a set of genes of interest—and G—a
gene set database—the permeability score measures the co-occurrence of genes from L within gene sets of
G. Further, the maximum achievable coverage score shows the highest degree of co-occurrence of genes in L
within gene sets of G. To assess if the maximum achievable coverage score for a gene set database is solely
due to chance or a consequence of the size of L, we used a bootstrapping hypothesis test and associated a
maximum coverage achieved for a database to a p-value. Significant maximum coverage values can be used
to select the gene set database most appropriate for conducting gene set analysis in a given experiment.
Figure 7.7: Summary of recommendations for using permeability score and coverage score to select
a gene set database.
high low
high
• May be difficult to interpret results 
of a gene set analysis method using 
this database
• Database may be useable as input 
to a highly specific gene set analysis 
method
• This scenario may happen due to 
using a large list of genes L that are 
not specific to the phenotype of 
interest
• Database contains a few specific 
gene sets with high co-occurrence 
of genes in L
• Database recommended to be used 
as input for gene set analysis of the 
phenotype of interest
low
• Low representation of the 
phenotype of interest
• Difficult to interpret results of a 
gene set analysis method using this 
database
• Discourage use of this database as 
input to gene set analysis for 
phenotype of interest 
• Database does not contain gene 
sets representative of the 
phenotype of interest.
• Not a recommended database to 
use as input to gene set analysis for 
phenotype of interest 
Permeability Score
𝛕
For a given L and G, a small value of maximum coverage score indicates that a large proportion of L
or its subsets does not co-occur in any gene set of G. Therefore, G might not be an appropriate choice for
studying the phenotype of interest represented by L. It should be noted that genes in L can be chosen by a
domain expert or based on the literature consensus. Also, the choice of L can be made prior to conducting
an expression study. Human Phenotype Ontology can be used as a reliable source for the choice of L. HPO
has been actively developing phenotype-gene associations by curating literature to annotate abnormalities
in phenotypes that have been observed in human disease. We discourage using a list of genes L with more
than 250 genes (see Figure 7.3) since any gene list larger than this is likely too general and could result in
high coverage scores with a wide array of gene sets due to factors such as gene set overlap. In addition, we
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proposed the bootstrapping approach for significance assessment of the maximum coverage score. Such a
bootstrapping approach can be adjusted for any given value of τ with a non-zero permeability score. When
the bootstrapping approach leads to a significant p-value for the selected value of τ , Fig. 7.7 shows a summary
of recommendations when selecting a database using permeability and coverage score using a list of genes of
interest L. What is considered a high permeability and coverage score is at the discretion of the researcher,
and based on the phenotype of interest, but it is recommended that the scores are reported as evidence to
support the choice of a particular gene set database, just as the number of gene sets predicted as significantly
differentially enriched by a gene set analysis method should be reported to assess the usefulness of the results
and any downstream interpretation of these results.
An arbitrary choice of a gene set database, which includes gene sets extracted from a single source, de-
creases the chance of finding biologically meaningful associations. On the other hand, using meta-databases—
which include gene sets from several sources— often results in false positives [17, 16]. For example, using
MSigDB as the gene set database for analyzing JIA datasets (see Table 7.3) led to a large number of gene sets
predicted as being differentially enriched (over several thousand gene sets). Therefore, aggregating multiple
gene set databases into one meta-database without considering their biological relevance—with the sole pur-
pose of attaining a high maximum achievable coverage—is not a viable alternative. Rather, we suggest the
smallest but the most appropriate gene set database, as measured by the proposed quantitative approach.
The results of gene set analysis using the JIA datasets agree with the results achieved using the maximum
achieveable coverage score. We only observed significant maximum achieveable coverage scores for GO and
GO? using a list of genes suggested in the literature to be associated with JIA. The gene set in GO? with
the highest number of co-occurring genes known to be involved in the development of this disease contained
roughly 43% of the genes from our list. GO had a much smaller maximum achieveable coverage score of
0.273, though it was still considered significant. However, a maximum achieveable coverage of 0.273 is low,
so the relevance of the gene sets predicted using this database may not be as informative. Using GO? with
all three datasets resulted in a partial overlap with the results obtained when using GO. However, GO?
achieved the highest maximum achieveable coverage score, which was reflected in predicted gene sets such as
“Neutrophil degranulation” in all three datasets. Platelets and neutrophils interact during inflammation, and
excessive neutrophil degranulation is a common feature of many inflammatory disorders [15]. Also, two gene
sets predicted using GO? were “Haptoglobin binding” and “Haptoglobin-hemoglobin complex”. Haptoglobin
can become elevated during infection and inflammation and has been reported as a potential biomarker of
JIA [10, 24]. These gene sets are also very specific with 6 and 7 genes, respectively. As “Haptoglobin binding”
and “Haptoglobin-hemoglobin complex” are relatively small gene sets (less than 10), MSigDB removes any
gene sets that are smaller than 10, which means that these enriched terms would be missed by the gene set
analysis of the JIA datasets even though they are highly informative of this disease. Another gene set only
reported using KEGG? was “IL-17 signalling pathway”. Interleukin-17 is known to perpetuate inflammatory
pathways by inducing fibroblasts to make cytokines and matrix metalloproteinases [2]. This pathway is not
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a part of the MSigDB database, and as such, it was never predicted as being differentially enriched in any
scenario.
Mooney et al. [18] recommended selecting a subset of biologically relevant gene sets in order to perform
gene set analysis. However, this might be a biased approach. If a gene set database used for analysis has
been filtered to only contain gene sets relevant to a phenotype of interest, then any false positive is also going
to be biologically relevant to the phenotype. Considering the lack of specificity of some gene set analysis
methods [17], such an approach might lead to incorrect interpretations. Instead, in this work we suggested
selecting and using a gene set database in a systematic way that is not prone to an investigator bias(es)
toward a hypothesis of interest.
7.5 Conclusions
In this paper, we studied characteristics of gene set databases as an essential component of gene set analysis.
We introduced a measure to quantify the similarity between gene set databases. We proposed presence
and permeability scores as quantitative measures of occurrence and co-occurrence of genes within gene sets.
Further, we proposed a bootstrapping procedure for the significance assessment of permeability score.
The quantitative study of commonly used gene set databases showed that the current gene set databases
fall short in representing some phenotypes. Also, some of these databases may not be well maintained and
focused on increasing the number of gene sets in a given database. We suggest a shift towards developing
and curating gene set databases that are well maintained and cover a wider range of phenotypes.
We also observed that genes known to be associated with some phenotypes are rarely present or completely
absent in some widely used gene set databases. The differential expression of these genes cannot be associated
with any gene set; therefore, lack of differential enrichment might be interpreted as no association. The use
of the proposed scores helps with avoiding such erroneous conclusions. These scores also showed that some
databases represent particular phenotypes better than others, and indicate the databases that are most
appropriate for performing gene set analysis for a phenotype of interest.
We suggest using permeability score and coverage score as a means to select an appropriate gene set
database for a given experiment and avoiding assembling a gene set database by cherry-picking gene sets of
interest as it might lead to a biased conclusion.
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8 Summary and Future Research
In this chapter, we provide a short summary of the previous chapters of the thesis, highlighting its
contributions, and discuss some avenues for future research.
8.1 Summary and contributions
In Chapter 2, we reviewed gene set analysis methods, classified them based on their components, discussed
the shortcomings and strengths of each class, and established the direction of the research in this thesis.
Considering the gained insight from the literature review about the lack of consensus about the best practices
in gene set analysis methods, we designed and conducted two studies to investigate the reproducibility of the
results of gene set analysis methods.
In Chapter 3, we proposed a methodology to evaluate the reproducibility of a gene set analysis method
across sample sizes when analyzing a real expression dataset. Our study of thirteen commonly used gene
set analysis methods showed that the results of most methods are not reproducible for small sample sizes.
Therefore, one should be skeptical of the results from gene set analyses conducted with small sample sizes.
In Chapter 4, we investigated the consistency of the results of different gene set analysis methods when
analyzing an expression dataset. Our data analysis revealed that the outcome of gene set analysis significantly
differs across methods. Also, we observed that many gene set analysis suffer from a lack of specificity.
To further investigate the specificity of gene set analysis methods, in Chapter 5, we studied the impact
of gene set overlap—which has been suggested as a potential reason for lack of specificity [6]—on the results
over-representation analysis. We proposed a measure to quantify gene set overlap and visualized gene set
overlap for several gene set databases. We observed that gene set overlap is a ubiquitous phenomenon across
gene set databases. Also, our statistical analysis showed that there is a significant negative correlation
between gene set overlap and the specificity of over-representation analysis.
Since gene set overlap was shown to affect the results of a gene set analysis method, it should be considered
in the design and evaluation of these methods. However, this has not been the case in the evaluation of gene
set analysis methods. Due to the lack of gold standard datasets, where the enrichment status of gene
sets of a database are known a priori, artificial expression datasets and simulated gene set databases with
oversimplified assumptions have been used. Expression profiles have often been simulated with constant or
zero gene-gene correlation and with normally distributed expression values. Gene set databases also have been
simulated to be a collection of non-overlapping gene sets of equal sizes. Simulating expression datasets and
114
gene set databases that preserve the characteristics of real data is not a straightforward task. Considering the
insight gained from Chapters 2, 3, 4, and 5 on reproducibility, sensitivity, and specificity of gene set analysis
methods, we developed Silver (see Chapter 6). Silver is a framework for generating expression datasets that
preserves the characteristics of real data. It also offers a means for quantitative evaluation of the results of
different gene set analysis methods using the generated data. We showed the utility of Silver by developing
expression data sets and evaluating the results of ten commonly used gene set analysis methods. The results
confirmed the above key challenges facing gene set analysis and showed the inability of some of the most
widely used gene set analysis methods to detect differential enrichment of gene sets with a mixture of up- and
down-regulated genes. These shortcomings have been previously overlooked. Therefore, we suggest Silver
as a means for evaluating new gene set analysis methods, rather than using unrealistic and oversimplified
datasets.
Since a gene set database serves as an input to gene set analysis, in Chapter 7 we quantitatively study
gene set databases. There has been limited research on the quality of gene set databases and the common
approach has been to extend the size of databases by adding more and more gene sets. We defined measures
to quantify the similarity of gene set databases, the degree to which a given gene is represented in gene sets
of a database, and the proportion of genes of interest that are present in a given gene set (coverage score).
Further, we proposed a methodology for the significance assessment of a maximum achievable coverage
score given a list of genes and a gene set database. This methodology allows an unbiased selection of
appropriate gene set databases to be used for a given experiment; such a systematic methodology has not
been previously available, and researchers have have relied on their intuition or selected a gene set database
in an ad-hoc manner. The study of widely used gene set databases such as GO [2], KEGG [4], Reactome [3],
and BioCarta [5] using the proposed measures showed that genes associated with different phenotypes are not
equally represented in gene set databases. In addition, our study showed that merging different databases
without systematic curation to generate massive meta-databases leads to a lack of specificity and difficulty
in interpreting the results of gene set analysis.
Collectively, methodologies presented in Chapters 3, 4, 5, 6, and 7 of this thesis not only make it possible
to evaluate the current gene set analysis methods and gene set databases in a systematic and quantitative
manner, but also they can be used to guide the design and development of future methods and databases
for gene set analysis. As such, they should improve the sensitivity, specificity, and reproducibility of gene set
analysis, contributing to gaining better insight from the data resulting from high-throughput experiments.
8.2 Future work
In this section, we extend the ideas for future research presented in each chapter of the thesis and offer
possible avenues for addressing challenges in gene set analysis.
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8.2.1 Reproducibility of gene set analysis methods
In this research, we proposed a quantitative approach for assessing the reproducibility of gene set analysis
methods across sample sizes. The proposed method naturally extends to evaluating the reproducibility of
other methods such as gene regulatory network or coexpression network prediction, where there is no gold
standard (ground truth) dataset available. The proposed methodology can be seamlessly applied in such
contexts.
For a given sample size, reproducibility, though a necessary condition, is not a sufficient condition; a
given gene set analysis method should achieve high specificity and sensitivity scores to achieve biologically
valid results. We suggest using Silver, the proposed framework for evaluating gene set analysis methods, to
synthesize datasets where the enrichment status of gene sets are known a priori. The simulated datasets
then can be used for the study of specificity, sensitivity, and reproducibility of results of gene set analysis
methods across sample sizes.
8.2.2 Evaluation of gene set analysis methods
Using a quantitative approach, we studied the results of ten gene set analysis methods. Statistical analysis
showed that there is a significant difference between the results of most gene set analysis methods. This
conclusion was further confirmed by a biological evaluation of the gene set analysis methods when analyz-
ing a juvenile idiopathic arthritis dataset. We suggest using more datasets across different phenotypes for
conducting the biomedical evaluation. Further, we suggest the study of gene set analysis in the absence of
differential expression using datasets that preserve the true characteristics of real data. This can be accom-
plished using only data from control samples, or alternatively using Silver without differential enrichment
of gene sets, in contrast to the current approach using phenotype permutation, which does not preserve the
true characteristics of the expression data (See Chapter 6).
8.2.3 Specificity and gene set overlap
In this thesis, we proposed a methodology to study the relationship between gene set overlap and specificity
of ORA. We quantified gene set overlap and visualized it for several gene set databases. The statistical data
analysis suggested that there is a significant correlation between gene set overlap and specificity of ORA.
We found that gene set overlap is a ubiquitous phenomenon across gene set databases, partially due to the
existence of multifunctional genes.
Since gene set overlap can contribute to the lack of specificity of a gene set analysis method, it must
be considered in developing and evaluating gene set analysis methods and also gene set databases. Current
methods that consider gene set overlap sacrifice sensitivity in favour of specificity. We suggest developing
gene set analysis methods that achieve high specificity without significant loss in sensitivity to be the purpose
of developing new gene set analysis methods. More specifically, we highly discourage the evaluation of gene
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set analysis methods using artificial gene set databases of non-overlapping gene sets. Such contexts are
substantially different from the real gene set database and often lead to misleadingly high specificity values.
We studied the effect of gene set overlap on the specificity of ORA. Conducting similar studies for other
well-established gene set analysis methods is suggested as future research.
8.2.4 Benchmark datasets
Our study suggested that the lack of consensus about a gene set analysis method to be used for a given
experiment can be mainly attributed to the absence of gold standard datasets, where the enrichment status
of gene sets is known. In this thesis, we proposed Silver for evaluating gene set analysis methods. Silver
synthesizes datasets without making oversimplifying assumptions that have been commonly made in the
evaluation of gene set analysis methods and have led to inconsistent and contradictory guidelines.
We suggest developing a publicly available repository of benchmark datasets generated using Silver. This
repository can help a researcher to choose the best method for a given experimental design by providing
measures of performance for different methods across different experimental designs. Also, by automating
the evaluation of gene set analysis methods, this repository can set the direction for developing new gene
set analysis methods. To be biologically on par with the known biology of a given phenotype, the list of
differentially expressed genes in each benchmark dataset must be chosen by experts in that specific phenotype.
The high level and intuitive design of Silver make it easy to use for a wide range of users including experts
in domains with little exposure to software development.
The current version of Silver uses a t-test statistic to define the differential expression of genes. Silver was
designed to be easily extendable. Incorporating other measures of differential expression is suggested as future
research. One such measure can be the Wilcoxon rank-sum test. Having benchmark datasets synthesized
using various measures of differential expression reveal and prevent developing benchmark datasets that are
biased in favour or against a given gene set analysis method.
8.2.5 Gene set databases
Online knowledge-bases such as GO [2], KEGG [4], Reactome [3], and BioCarta [5] have been used to develop
gene set databases. Also, computational methods have been utilized to create gene sets from the expression
datasets that are publically available through GEO and ArrayExpress. In addition, gene sets have been
extracted from gene expression literature.
There are two common approaches for choosing a gene set database when conducting gene set analysis:
using gene sets obtained from a single source such as KEGG or GO and using gene sets obtained from several
sources including online knowledge-bases and/or computational methods. Each of these approaches come
with their shortcomings. Single source databases often include a small number of gene sets. Informative
gene sets (relatively small gene sets) in single source databases often represent a fraction of known genes
for a species of interest and differential expression of the genes that are absent in these informative gene
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sets will be ignored in gene set analysis. On the other hand, merging different gene set databases with
the goal of generating a massive meta-database without biological justification and systematic curation is
not recommended. Such an approach could introduce more gene set overlap and consequently more false
positives. Another shortcoming of such multi-source databases is that often they are either not updated or
partially updated with gene sets from some sources not being updated for several years. Since for a typical
user evaluating these databases is not practical, often outdated gene set databases of low quality have been
used for gene set analysis.
For meta-databases that extract or curate gene sets from several sources, we suggest providing timestamps
for gene sets to track the last update for each source. Updating gene sets from one source and providing a
version and time-stamp for the whole meta-database makes it difficult to monitor which part of the meta-
database is updated and which part is not.
In gene set analysis, a gene set is represented as a collection of genes that are involved in a biological
component, process, or function. Information such as up-regulated and down-regulated genes in a pathway
is currently not represented in databases used for gene set analysis. Consequently, detecting such gene
expression patterns is difficult, if not impossible. Moreover, having the direction of change in gene expression
can facilitate distinguishing gene sets that have a large proportion of their gene in common but with a
substantially different direction in their expression patterns. Therefore, we suggest developing such a gene
set database as future research to improve the specificity of gene set analysis methods.
In addition, we suggest extracting gene sets from literature through text mining. Currently, such gene
sets are available in commercial gene set analysis tools such as Ingenuity Pathways Analysis from QIAGEN
(http://www.ingenuity.com) and Bibliosphere by Intrexon (http://www.genomatix.de) [1]. Making such
knowledge publicly available would be of great value to the research community. Also, providing a mechanism
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Appendix A
Supplementary Material for Chapter 2
In this Appendix, we provide a set of examples of inconsistent and contradictory guidelines in gene set
analysis from literature.
• Goeman and Bu¨hlmann [3] argued that gene sampling as a method of significance evaluation for gene
set statistics leads to a statistical model that does not agree with the performed biological experiments,
and results in misleading interpretations. They discouraged using competitive gene set analysis methods
since they rely on gene sampling for significance evaluation.
• According to an empirical study, Liu et al. [6] concluded that Globaltest, ANCOVA and SAM-GS
achieve comparable statistical power.
• Based on a simulation study of self-contained gene set analysis methods, Fridley et al. [2] concluded
that the Globaltest and the Fisher’s method are the most statistically powerful.
• Based on an experimental study of 132 datasets, Hung et al. [4] reported that the Wilcoxon rank sum
test statistic and the Weighted Kolmogorov Smirnov score, utilized by GSEA method, better cover
predictions made by the mean test, the median test, the χ2 test, and Hotelling’s T 2 test, compared to
the converse.
• Ackermann and Strimmer [1] discouraged using GSEA, and argued that the enrichment score, used by
GSEA, is not as reliable as simpler methods such as mean or median score.
• Irizarry et al. [5] discouraged using GSEA as it is based on Kolmogorov Smirnov test, which is well-
known for its lack of sensitivity. Alternatively, they suggested using the z-score and the χ2 test as gene
set scores. Using an experimental study, they showed that these simple methods outperform GSEA.
• Tamayo et al. [7] strongly disagreed with Irizarry et al. [5] and argued that the method proposed by
Irizarry et al. ignores gene-gene correlations that can significantly affect the gene set analysis results.
They also showed that the method suggested by Irizarry et al. suffers from a lack of specificity.
• Wu and Lin [8] studied several gene set analysis methods and concluded that the choice of gene set
analysis method may affect the outcome of gene set analysis.
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Supplementary Material for Chapter 3
Table B.1: Kruskal-Wallis test results show that there is a statistically significant difference between
the reproducibility of gene set analysis methods across sample sizes for all three original datasets.
Method GSE53757 GSE13355 GSE10334
FRY 6.28e-13 2.99e-26 2.60e-13
GSEA-S 1.07e-11 1.45e-15 4.72e-05
GSEA-G 5.99e-12 6.72e-19 3.58e-13
ORA 5.03e-18 2.39e-19 1.67e-14
Camera 1.81e-19 2.11e-20 9.74e-05
ssGSEA 4.71e-25 8.70e-26 1.87e-26
PAGE 1.81e-16 5.26e-20 1.50e-10
GSVA 5.30e-20 7.17e-27 4.21e-07
PLAGE 2.10e-05 4.88e-06 4.89e-03
ROAST 1.37e-14 1.80e-26 1.10e-13
GAGE 2.34e-28 3.37e-28 4.51e-27
GlobalTest 6.73e-21 7.29e-25 2.58e-16
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Figure B.1: MDS plot showing the relation between samples in dataset GSE53757. Each sample is
represented as a point on the plot. The control samples are coloured in dark red and the case samples
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Figure B.2: MDS plot showing the relation between samples in dataset GSE10334. Each sample is
represented as a point on the plot. The control samples are coloured in dark red and the case samples
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Figure B.3: MDS plot showing the relation between samples in dataset GSE13355. Each sample is
represented as a point on the plot. The control samples are coloured in dark red and the case samples
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Figure B.4: Pine plots for dataset GSE53757 showing reproducibility of the results from ROAST (left)
and FRY (right) across sample sizes. Reproducibility is quantified by overlap score (Equation 4.2).
Each layer of the pine plot illustrates the overlap score of the results of a method for 10 replicate
datasets with the same sample size. From top to bottom, the pine plot shows replicates with sample
size 2 × 20, 2 × 15, 2 × 10, 2 × 5, and 2 × 3. The overlap score ranges from 0 to 1 represented by a
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Figure B.5: Pine plots for dataset GSE53757 showing reproducibility of the results from Camera (left)
and PADOG (right) across sample sizes. Reproducibility is quantified by overlap score (Equation 4.2).
Each layer of the pine plot illustrates the overlap score of the results of a method for 10 replicate
datasets with the same sample size. From top to bottom, the pine plot shows replicates with sample
size 2 × 20, 2 × 15, 2 × 10, 2 × 5, and 2 × 3. The overlap score ranges from 0 to 1 represented by a
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Figure B.6: Pine plots for dataset GSE53757 showing reproducibility of the results from PAGE (left)
and GSVA (right) across sample sizes. Reproducibility is quantified by overlap score (Equation 4.2).
Each layer of the pine plot illustrates the overlap score of the results of a method for 10 replicate
datasets with the same sample size. From top to bottom, the pine plot shows replicates with sample
size 2 × 20, 2 × 15, 2 × 10, 2 × 5, and 2 × 3. The overlap score ranges from 0 to 1 represented by a
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Figure B.7: Pine plots for dataset GSE53757 showing reproducibility of the results from PLAGE
(left) and GlobalTest (right) across sample sizes. Reproducibility is quantified by overlap score (Equa-
tion 4.2). Each layer of the pine plot illustrates the overlap score of the results of a method for 10
replicate datasets with the same sample size. From top to bottom, the pine plot shows replicates with
sample size 2× 20, 2× 15, 2× 10, 2× 5, and 2× 3. The overlap score ranges from 0 to 1 represented
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Figure B.8: Pine plots for dataset GSE53757 showing reproducibility of the results from ssGSEA
across sample sizes. Reproducibility is quantified by overlap score (Equation 4.2). Each layer of the
pine plot illustrates the overlap score of the results of a method for 10 replicate datasets with the same
sample size. From top to bottom, the pine plot shows replicates with sample size 2×20, 2×15, 2×10,
2 × 5, and 2 × 3. The overlap score ranges from 0 to 1 represented by a gradient from blue to red,
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Figure B.9: Box plots showing the distribution of overlap scores resulting from gene set analysis
using FRY when using the original dataset GSE53757 for generating replicate datasets. The panel on
the left shows the overlap scores from replicate datasets, while that on the right depicts the overlap
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Figure B.10: Box plots showing the distribution of overlap scores resulting from gene set analysis
using Camera when using the original dataset GSE53757 for generating replicate datasets. The panel
on the left shows the overlap scores from replicate datasets, while that on the right depicts the overlap
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Figure B.11: Box plots showing the distribution of overlap scores resulting from gene set analysis
using ssGSEA when using the original dataset GSE53757 for generating replicate datasets. The panel
on the left shows the overlap scores from replicate datasets, while that on the right depicts the overlap
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Figure B.12: Box plots showing the distribution of overlap scores resulting from gene set analysis
using PAGE when using the original dataset GSE53757 for generating replicate datasets. The panel
on the left shows the overlap scores from replicate datasets, while that on the right depicts the overlap
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Figure B.13: Box plots showing the distribution of overlap scores resulting from gene set analysis
using GSVA when using the original dataset GSE53757 for generating replicate datasets. The panel
on the left shows the overlap scores from replicate datasets, while that on the right depicts the overlap
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Figure B.14: Box plots showing the distribution of overlap scores resulting from gene set analysis
using PLAGE when using the original dataset GSE53757 for generating replicate datasets. The panel
on the left shows the overlap scores from replicate datasets, while that on the right depicts the overlap
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Figure B.15: Box plots showing the distribution of overlap scores resulting from gene set analysis
using ROAST when using the original dataset GSE53757 for generating replicate datasets. The panel
on the left shows the overlap scores from replicate datasets, while that on the right depicts the overlap
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Figure B.16: Box plots showing the distribution of overlap scores resulting from gene set analysis
using GlobalTest when using the original dataset GSE53757 for generating replicate datasets. The
panel on the left shows the overlap scores from replicate datasets, while that on the right depicts
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Figure B.17: Box plots showing the distribution of overlap scores resulting from gene set analysis
using PADOG when using the original dataset GSE53757 for generating replicate datasets. The panel
on the left shows the overlap scores from replicate datasets, while that on the right depicts the overlap
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Figure B.18: Box plots showing the distribution of overlap scores resulting from gene set analysis
using GSEA-G when using the original dataset GSE53757 for generating replicate datasets. The panel
on the left shows the overlap scores from replicate datasets, while that on the right depicts the overlap
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Figure B.19: Kendall’s coefficient of concordance for each method under study when using the
original dataset GSE10334 for generating replicate datasets. The x-axis shows the sample size. The
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Figure B.20: Kendall’s coefficient of concordance for each method under study when using the
original dataset GSE13355 for generating replicate datasets. The x-axis shows the sample size. The
y-axis shows concordance coefficients of the results of gene set analysis of 10 replicate datasets of the
same size.
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Figure B.21: The number of gene sets predicted as differentially enriched for each method under
study when using the original dataset GSE10334 for generating replicate datasets. The x-axis shows
the sample size per group. The y-axis shows the average number of gene sets predicted as differentially
enriched across 10 replicate datasets of the same size. The red line parallel to the x-axis shows the
size of the gene set database being used, i.e. the maximum possible number of gene sets that could be
predicted as being differentially enriched.
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Figure B.22: The number of gene sets predicted as differentially enriched for each method under
study when using the original dataset GSE13355 for generating replicate datasets. The x-axis shows
the sample size per group. The y-axis shows the average number of gene sets predicted as differentially
enriched across 10 replicate datasets of the same size. The red line parallel to the x-axis shows the
size of the gene set database being used, i.e. the maximum possible number of gene sets that could be
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GSE53757 32133.2 9 <2.2e-16?
GSE13355 33592.8 9 <2.2e-16?
GSE10334 31661.4 9 <2.2e-16?
GSE26554 29326.9 9 <2.2e-16?
? 2.2e-16 is the smallest p-value reported by cochran.qtest method from RVAideMemoire
Table C.2: The p-values of Wilcoxon sign tests for pairwise comparisons of the results of the methods
using dataset GSE53757.
Camera FRY GAGE GSEA GSVA ORA PAGE PLAGE ROAST
FRY 4.94e-324
GAGE 0.00e+00 2.51e-101
GSEA 4.47e-28 0.00e+00 0.00e+00
GSVA 0.00e+00 2.37e-09 1.46e-57 0.00e+00
ORA 0.00e+00 0.00e+00 0.00e+00 0.00e+00 0.00e+00
PAGE 0.00e+00 0.00e+00 0.00e+00 0.00e+00 0.00e+00 1.62e-44
PLAGE 0.00e+00 5.21e-282 0.00e+00 0.00e+00 0.00e+00 4.94e-324 4.94e-324
ROAST 0.00e+00 4.41e-01 4.69e-103 0.00e+00 2.47e-10 0.00e+00 0.00e+00 9.51e-277
ssGSEA 4.94e-324 5.41e-207 0.00e+00 0.00e+00 1.15e-266 0.00e+00 0.00e+00 2.04e-09 1.57e-202
Note that a p-value of 0.00e+00 is smaller than the representable floating-point precision.
Table C.3: The p-values of Wilcoxon sign tests for pairwise comparisons of the results of the methods
using dataset GSE13355.
Camera FRY GAGE GSEA GSVA ORA PAGE PLAGE ROAST
FRY 0.00e+00
GAGE 0.00e+00 4.08e-104
GSEA 1.25e-09 9.88e-324 0.00e+00
GSVA 0.00e+00 4.66e-159 3.03e-01 0.00e+00
ORA 2.78e-101 9.88e-324 0.00e+00 1.05e-152 0.00e+00
PAGE 0.00e+00 0.00e+00 0.00e+00 0.00e+00 0.00e+00 9.55e-152
PLAGE 9.88e-324 6.49e-233 0.00e+00 9.88e-324 0.00e+00 0.00e+00 0.00e+00
ROAST 0.00e+00 5.33e-15 6.33e-74 0.00e+00 5.39e-134 0.00e+00 0.00e+00 4.37e-272
ssGSEA 0.00e+00 7.62e-253 0.00e+00 0.00e+00 0.00e+00 0.00e+00 0.00e+00 1.02e-03 1.81e-295
Note that a p-value of 0.00e+00 is smaller than the representable floating-point precision.
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Table C.4: The p-values of Wilcoxon sign tests for pairwise comparisons of the results of the methods
using dataset GSE10334.
Camera Camera FRY GAGE GSEA GSVA ORA PAGE PLAGE ROAST
FRY 0.00e+00
GAGE 0.00e+00 1.55e-11
GSEA 2.70e-03 4.94e-324 0.00e+00
GSVA 0.00e+00 2.36e-100 2.04e-01 0.00e+00
ORA 4.41e-37 4.94e-324 0.00e+00 4.44e-23 4.94e-324
PAGE 0.00e+00 4.94e-324 0.00e+00 0.00e+00 0.00e+00 0.00e+00
PLAGE 0.00e+00 9.91e-132 6.79e-212 4.94e-324 3.28e-229 0.00e+00 0.00e+00
ROAST 0.00e+00 5.00e-02 1.93e-12 0.00e+00 1.70e-104 0.00e+00 4.94e-324 7.23e-128
ssGSEA 0.00e+00 0.00e+00 0.00e+00 4.94e-324 0.00e+00 4.94e-324 4.94e-324 6.10e-145 0.00e+00
Note that a p-value of 0.00e+00 is smaller than the representable floating-point precision.
Table C.5: The p-values of Wilcoxon sign tests for pairwise comparisons of the results of the methods
using dataset GSE26554.
Camera FRY GAGE GSEA GSVA ORA PAGE PLAGE ROAST
FRY 0.00e+00
GAGE 0.00e+00 1.05e-128
GSEA 3.920e-67 0.00e+00 0.00e+00
GSVA 0.00e+00 3.78e-60 3.44e-24 0.00e+00
ORA 5.00e-05 0.00e+00 0.00e+00 5.33e-39 0.00e+00
PAGE 9.58e-105 0.00e+00 1.90e-320 9.41e-285 0.00e+00 2.07e-173
PLAGE 4.94e-324 0.00e+00 0.00e+00 0.00e+00 0.00e+00 0.00e+00 0.00e+00
ROAST 0.00e+00 1.76e-12 1.03e-65 0.00e+00 3.86e-65 0.00e+00 0.00e+00 0.00e+00
ssGSEA 0.00e+00 0.00e+00 0.00e+00 4.94e-324 0.00e+00 4.94e-324 0.00e+00 3.06e-19 0.00e+00
Note that a p-value of 0.00e+00 is smaller than the representable floating-point precision.
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Appendix D
Supplementary Material for Chapter 5
Algorithm 1 Calculation of specificity of ORA
Input:
G = {Gj | 1 ≤ j ≤ m}: A gene set database
L = {Li | 1 ≤ i ≤ l}: A set of differentially
expressed gene lists
U : A set of genes used as background set
for ORA
α : The significance level
γ : The threshold value used for identifying
true positives
Output:
Specificity value corresponding to
each Li ∈ L
i = 1
while i ≤ l do
j = 1
while j ≤ m do
pj = ORA(Gj , Li, U)
j = j + 1
end while
Calculate padjustedj as the adjusted p-value corresponding to pj , where (1 ≤ j ≤ m)
G+i ← {Gk | padjustedk < α and 1 ≤ k ≤ m}
G−i = G−G+i
Calculate T+i (γ) and T
−
i (γ) using Equations 5.5 and 5.6
Calculate TPi, FPi, TNi, and FNi using Equations 5.7, 5.8, 5.9, and 5.10
Calculate SPCi using Equation 5.11
i = i+ 1
end while
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Figure D.1: The graph representing the overlap between gene sets in GeneSetDB. In this graph,
each vertex represents a gene set in GeneSetDB, and each edge represents an overlap with Jaccard
coefficient greater than or equal to 0.5 between two gene sets. The “hairball” is the result of a large
number of gene sets with a substantial overlap (≥ 0.5) with each other.
Table D.1: The result of Shapiro-Wilk tests for different values of γ. All p-values are less than
0.0000001.












Figure D.2: The graph representing the overlap between gene sets in GeneSigDB. In this graph,
each vertex represents a gene set in GeneSigDB, and each edge represents an overlap with Jaccard
coefficient greater than or equal to 0.5 between two gene sets. The “hairball” is the result of a large




















Figure D.3: A frequency plot for fi values in GeneSetDB illustrates the prevalence of gene set overlap.
For each gene set Gi in a gene set database G (GeneSetDB here), fi is the number of gene sets Gj















Figure D.4: A frequency plot for fi values in GeneSigDB illustrates the prevalence of gene set overlap.
For each gene set Gi in a gene set database G (GeneSigDB here), fi is the number of gene sets Gj
(j 6= i) in G with a non-zero overlap with Gi.
Figure D.5: The histogram of the specificity values (γ = 0.5). Obvious deviation of the histogram
from a bell-shaped curve suggests that the specificity values are not normally distributed. A similar
pattern was observed for other values of γ.
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Appendix E
Supplementary Material for Chapter 7
Table E.1: List of genes associated with JIA that were extracted from literature.
Gene ID Gene Symbol Gene ID Gene Symbol
7124 TNF 6556 SLC11A1
3569 IL6 51752 ERAP1
3586 IL10 51752 ERAP1
64127 NOD2 79679 VTCN1
3557 IL1RN 7332 UBE2L3
4282 MIF 7297 TYK2
929 CD14 7185 TRAF1
3558 IL2 5771 PTPN2
861 RUNX1 111343 Il1
6352 CCL5 3560 IL2RB
114548 NLRP3 4055 LTBR
26191 PTPN22 4012 LNPEP
3596 IL13 8838 CCN6
4210 MEFV 64167 ERAP2
3559 IL2RA 221895 JAZF1
3593 IL12B 5619 PRM1
864 RUNX3 9051 PSTPIP1
7128 TNFAIP3 677 ZFP36L1
3570 IL6R 57511 COG6
59067 IL21 3899 AFF3
149233 IL23R 116028 RMI2
3659 IRF1 79722 ANKRD55
6775 STAT4 57198 ATP8B2
727 C5 79899 PRR5L
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